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Cancer patient survivorship has increased substantially over the past few decades due to 
advances in anticancer treatments. However, a deleterious effect of these lifesaving treatments 
is premature ovarian insufficiency (POI), as they are gonadotoxic. POI leads to infertility and loss 
of ovarian endocrine function, which is particularly devastating for female cancer survivors who 
experience POI prior to puberty, because puberty is an important developmental in a female’s 
life. Lack of ovarian endocrine function and absence of puberty leads to long-term co-morbidities 
such as poor bone health, diminished metabolic turnover, and high risk of cardiovascular events. 
Current treatment options such as hormone replacement therapy and ovarian auto-
transplantation are associated with non-physiological delivery of hormones and risk of re-
implanting cancerous cells. We hypothesized that allo-transplantation of encapsulated and 
immuno-isolated donor ovarian tissue restores ovarian endocrine function without evoking an 
immune response. This thesis describes how we tested the concept of immuno-isolation to 
protect encapsulated allogeneic ovarian tissue in murine and non-human primate models. First, 
we developed a dual capsule made with poly(ethylene glycol) (PEG) contained a proteolytically 
degradable core which was conducive for the dynamic growth of ovarian tissue and a non-
degradable PEG shell that would serve as the immuno-protective barrier. We demonstrated in 
an ovariectomized syngeneic murine model that ovarian tissue encapsulated in Dual PEG survived 
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and functioned until it was removed 60 days post-implantation. The serum level of follicle-
stimulating hormone significantly decreased from 64 ng/mL in ovariectomized mice to 34 ng/mL 
in mice that received implants. Multiple follicles with healthy morphology were present in the 
grafts retrieved after 60 days of implantation. Next, allogeneic ovarian tissue encapsulated in 
Dual PEG and implanted in recipient mice did not evoke detectable production of allo-specific 
antibodies, while non-encapsulated controls resulted in a 23-fold increase compared to pre-
implantation levels; the capsule proved to be immuno-isolating and protected the encapsulated 
allograft from the outside immune environment and led to ovarian endocrine restoration. We 
demonstrated that the Dual PEG capsule prevented cellular infiltration and also retained cells 
encapsulated within. We then investigated the question whether the immuno-isolating capsule 
could be utilized towards auto-transplantation ovarian tissue from leukemia patients through 
retention of cancerous cells present in the graft and prevent cancer spreading and metastasis. 
Encapsulation of 1,000 4T1 cancer cells prevented proliferation, migration and metastasis to 
other organs through 28 days transplantation, while control mice had to be euthanized because 
of the spread disease.  We then demonstrated encapsulation of ovarian allografts in Dual PEG 
precludes sensitization of the host immune system which confirms the capsule is immuno-
isolating and the host immune system is not exposed to allo-antigens while the graft is 
encapsulated, possibly allowing multiple implantations of the capsule. Lastly, we demonstrated 
that non-human primate (NHP) ovarian tissue can develop in the Dual PEG capsule restoring 
estradiol and progesterone levels to 50 and 70 pg/mg creatine, respectively. Additionally, the 
encapsulated tissue was protected from an immune response as indicated by the lack of active, 
dividing T cells in a syngeneic and allogeneic NHP model. We show the capsule can withstand the 
 xxv 
multi-fold volumetric expansion of NHP follicles, protecting the encapsulated allograft, which 
promotes graft survival and ovarian endocrine restoration. Taken together, this dissertation 
works towards allowing the implantation of allogeneic ovarian tissue to restore ovarian 
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1.2 Life-Saving Cancer Therapies Induce Premature Ovarian Insufficiency 
The development of modern and much-improved anti-cancer treatments contributed to 
significantly increased rates of survival particularly in childhood cancer cases, reaching in most 
cases 85%. The severity and extent of complications has decreased with the introduction of 
newer treatments as well. However, premature ovarian insufficiency (POI) remains one of the 
most persistent and deleterious effects having an impact on survivors far past remission. POI 
results from ovarian susceptibility to gonadotoxic treatments such as pelvic or whole body 
radiotherapy and alkylating agents [1-7]. These treatments affect rapidly dividing cells and 
destroy the interactions between the oocyte and hormone-producing granulosa cells, affecting 
both fertility and ovarian endocrine function. Clinically POI is defined as persistent amenorrhea 
combined with elevated levels of follicle-stimulating hormone (FSH) before age 40 [8]. Cancer 
treatments can lead to POI during or immediately following the completion of cancer treatments 
[2] or years following the completion of treatments [3].   
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Adolescent patients treated for cancer before undergoing puberty experience delayed or absent 
puberty, which is particularly detrimental as puberty is an important physiological milestone in a 
female’s life.  Puberty initiates physical and psychological changes into adulthood that determine 
height, bone health, insulin responsiveness, lipid metabolism, cardiovascular health, and 
cognition [9-11]. This development process is initiated before puberty and orchestrated by a 
pulsatile secretion of gonadotropin releasing hormone (GnRH) and growth hormone (GH) from 
the hypothalamus, which in turn regulates the release of gonadotropins, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) from the pituitary. Further, FSH and LH stimulate the 
ovaries to produce estradiol, androstenedione, progesterone, inhibins A and B, activin and 
follistatin which have systemic effects in many organs and tissues including endocrine glands and 




Figure 1.1: Schematic of hypothalamic-pituitary-gonadal axis and the integration into other 
systems of the body  
 
The intricate and highly connected crosstalk between the ovary and the rest of the body is 
regulated with ovarian hormones that create a negative feedback loop by inhibiting the 
production of GnRH and FSH in the brain, resulting in dynamic pulsatile levels of circulating 
hormones and gonadotropins[12-14]. The pulsatility of the hypothalamic-pituitary-gonadal 
(HPG) axis is crucial to proper development and regulation of a plethora of systems including 
reproductive, fat, musculoskeletal, cardiovascular, and immune systems [15,16]. For female 
childhood cancer survivors who experience POI due to gonadotoxic treatments, the hormonal 
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balance is disrupted which inhibits the normal pubertal development, leading to irreversible co-
morbidities such as unbalanced bone growth, poor bone health, abnormal fat distribution, high 
risk of cardiovascular disease, and metabolic changes [17-21].  
1.3 Fertility Preservation Options for Cancer Survivors 
To combat the ovarian damage caused by chemo and radio therapy, there have been efforts to 
use ferto-protective adjuvant therapies, such as sphingosine-1-phosphate, imatinib, and AS101; 
however, these treatments are still considered experimental and were not tested on adolescents 
[22-24] The only clinically approved ferto-protective intervention is gonadotropin-releasing 
hormone (GnRH) agonist, which shuts down the ovarian function and preserves the follicular pool 
to some extent [25,26]. For female patients, strategies to preserve fertility include embryo 
cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation. For embryo 
cryopreservation, patients undergo in vitro fertilization (IVF), which has a relatively high success 
rate [27,28]; however, this option is limited by the fact that anti- cancer treatments must be 
delayed to complete the ovarian stimulation cycle, which excludes a significant percentage of 
patients [8]. For prepubescent cancer patients, embryo or oocyte cryopreservation are not an 
option, because ovaries are dormant and not responsive to gonadotropin stimulation. A relatively 
new, but still experimental option to preserve fertility and restore ovarian endocrine function is 
ovarian tissue cryopreservation and subsequent auto-transplantation after remission [29]. Tissue 
can be transplanted orthotopically in the pelvis or heterotopically outside the pelvis-abdominal 
wall. Spontaneous pregnancies have been reported after orthotopic ovarian tissue 
transplantation and have resulted in over 100 babies born, mostly in the cases of identical twins 
[30-36]. Stern et al [37] reported a pregnancy from a heterotopic implantation of ovarian tissue 
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into the abdominal wall. While cryopreservation and auto-transplantation of ovarian tissue is the 
only available option to preserve both fertility and endocrine function in prepubertal patients 
experiencing POI, it is associated with the risk of re-introducing cancerous cells harbored in the 
stroma of the ovarian tissue [38-41]. To date, there is no standard universal protocol to ensure 
the absence of malignant cells in ovarian autografts removed from the patient prior to anti-
cancer treatments. Several studies have attempted to identify and quantify cancerous cells 
present in ovarian tissue using histological analysis or PCR [39,41.42]. In some cases histological 
analysis showed no evidence of malignant cells, but cancer-related biological markers were 
elevated in PCR analysis [39,41,42]. It is currently recommended to use of molecular markers for 
detection of malignant cells, but unfortunately not all cancers display specific genetic markers 
that can be detected via PCR complicating tissue characterization [43]. Additionally, there is no 
consensus as to which markers are most sufficient to detect malignant cells present in ovarian 
tissue, dependent on the strain of cancer [42], further complicating the classification of the 
ovarian tissue as safe. As the result, challenges in identifying cancer cells harbored in the tissue 
prevent clinical translation of this approach, especially in the case of hematologic malignancies, 
such as acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin’s lymphoma, 
where ovarian involvement can be high. 
1.4 Restoration of Ovarian Endocrine Function with Hormone Replacement Therapy 
Girls with POI who experience delayed onset of puberty require hormone replacement therapy 
(HRT) to initiate and sustain pubertal development and changes associated with sex 
development. HRT, originally designed to treat postmenopausal symptoms in women, lacks long-
term safety data in children [44]. For puberty induction, the prescribed regimen starts with 
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increasing doses of estrogen, followed by a combination of estrogen and progesterone as a life-
long treatment, until menopause. Unfortunately, HRT only delivers a fraction of ovarian 
hormones, e.g. estrogen and progesterone, at higher doses and at a constant and non-pulsatile 
rate, which does not mimic physiological puberty [45].  As a result, HRT-mediated puberty in girls 
with POI results in premature closure of the bone growth plate, cessation of bone growth and 
long-term metabolic imbalances [44,46-48]. Achieving an optimal pharmaceutical delivery of all 
the ovarian hormones is challenging due to the complexity of the regulation of the HPG axis.  
1.5 Allo-transplantation of Ovarian Tissue to Restore Ovarian Endocrine Function  
In the light of limitations of the current techniques to physiologically restore ovarian endocrine 
function in female cancer survivors with POI, in this thesis I propose a different strategy. I 
hypothesized that encapsulation of ovarian allograft in immuno-isolating hydrogel-based capsule 
will restore the physiological crosstalk of the HPG axis and the hormonal balance. The proposed 
design of the capsule with a biomimetic degradable core and inert non-degradable shell will 
promote survival and function of the encapsulated ovarian tissue and minimize the risk of an 
immune reaction, thus eliminating the need for immunosuppression. 
1.6 Immuno-Isolation to Protect Allogeneic Tissue 
Transplantation of a donor tissue requires systemic immunosuppression to prevent rejection; 
however, systemic immunosuppression in turn carries significant side effects, at times more 
debilitating than the disease treated by the transplant. Immuno-isolation of the graft can 
elegantly solve this problem by providing local protection and avoiding systemic 
immunosuppression. 
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An immuno-isolating construct or device creates a physical barrier around the implanted cells or 
tissues, and precludes contact with immune cells from the host. To ensure graft viability, such a 
device must allow bidirectional diffusion for nutrients and oxygen, as well as endocrine and 
paracrine factors to the implanted cells and exchange soluble factors for an extended period of 
time. To date, most studies have focused on immuno-isolation of allogeneic and xenogeneic 
pancreatic islets in mice and non-human primate (NHP) models for the treatment of diabetes 
[49-55]. 
One of the early attempts to implement immuno-isolation goes back to 1933, when an Italian 
scientist Bisceglie enclosed mice tumor cells in a polymer membrane and transplanted these cells 
into peritoneum in guinea pigs. He observed that the cells survived for 12 days and concluded 
that tumor cells were not attacked by the immune system of the host while receiving the 
nutrients through diffusion [56]. It was not until the 1960–1970s that the idea of using 
encapsulation of cells for immune protection gained traction again [57]. Chick et al. [58] and Lim 
and Sun [59] were the first to successfully use encapsulated pancreas islets in a hydrogel to 
develop a functional pancreatic transplant. Following these early experiments, substantial 
progress has been made in biological and polymer sciences leading to development of 
encapsulation devices for delivery of drugs and peptides for treatment of renal failure, 
hemophilia, and diabetes [60-64].  
Immunoisolation can be achieved through either hydrogels or synthetic devices composed of 
membranes. The advantage of natural and synthetic hydrogels in biomedical applications comes 
from their excellent biocompatibility and high-equilibrium water content. The mechanical 
properties of hydrogels are similar to that of native extracellular matrix [65].  Importantly, these 
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properties can be tuned to mimic the environment that is most compatible with a specific tissue 
requirement in order to optimize graft viability and functionality. Examples of such tuning are 
modification of crosslinking density, molecular weight, and concentration of the polymeric 
material, which in turn defines the mechanical properties of the hydrogel, such as swelling ratio, 
mesh size, and diffusivity [66-69].  
There are a few commercially available membrane-based immunoisolation devices. One of them 
is TheraCyte which is comprised of a 0.4 -µm pore cell-impermeable polytetrafluoroethylene 
(PTFE) membrane, laminated to a 5-mm pore membrane. The outer membranes support 
neovascularization, whereas the inner membrane prevents the encapsulated tissue within it to 
come in contact with the host immune cells [70]. Encaptra created by ViaCyte company is another 
example. This device was tested with pancreatic endoderm cells derived from human embryonic 
cells. After device implantation in mice, pancreatic cells matured and secreted insulin in response 
to rising blood glucose levels [71,72]. The design of both TheraCyte and Encaptra permits their 
retrieval once the implant is exhausted, with a potential follow-up implantation of a new device 
to sustain physiological function. 
1.7 Hydrogels as Immuno-isolators 
Hydrogels used for encapsulation and immune isolation include natural hydrogels, such as 
alginate, chitosan, agarose, fibrin, and synthetic hydrogels, such as poly (ethylene glycol) (PEG) 
[62, 73-76]. The versatility of hydrogels allows them to mimic the natural environment and 
extracellular matrix to provide cues for transplanted cells/tissue and support the desired cellular 
response. Specifically, ovarian follicles undergo significant expansion during active hormone-
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secreting stage, after which they regress and die. For the purpose of this thesis I focused on two 
hydrogels, alginate and PEG that present with desirable physical, mechanical and chemical 
properties.   
In general, factors that influence immunoprotective ability and capsule biocompatibility include 
the size of the capsule, wall thickness, mechanical strength, permeability, and surface 
characteristics [77-81]. Mechanical strength of the capsules is important to avoid physical 
breakage and infiltration of immune cells through the defects. Specifically for alginate, it was 
found that coating of the negatively charged alginate capsules with polycations, such as poly-L-
lysine, poly-D-lysine, and poly-L-ornithine increases the mechanical stability and restricts 
permeability of immune cells [82]. However, coating with poly-L-ornithine and poly-D-lysine 
increased the inflammatory responses towards capsules [83], while coating with poly-L-lysine has 
been shown to improve the biocompatibility and inhibit adhesion of inflammatory cells [78-84]. 
Adherent inflammatory cells secrete cytokines that amplify the local inflammatory reaction and 
lead to formation of a fibrotic capsule around the device. As a result, cells inside the immuno-
isolating alginate-based device cannot receive nutrients and oxygen, which leads to the failure of 
the graft. 
Size and geometry of the capsule affect the function and survival of transplanted cells. Veiseh 
et al. [62] examined the effect of the size and geometry of alginate hydrogels on local immune 
response, resulting in fibrosis, as well as the functionality of the encapsulated cells. When 
comparing hydrogels with diameters ranging from 0.3 mm to 1.5 mm they showed improved 
survival and function in larger capsules. Islets encapsulated in 1.5 mm alginate spheres were able 
to restore blood glucose levels for a period of 180 days, while islets encapsulated in 0.5 mm 
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capsules lasted for only 25 days. The larger size of the hydrogel did not have a negative effect on 
graft functionality. In addition to maintenance of normoglycemia, they found that 1.5 mm 
alginate spheres were largely devoid of cellular deposition, whereas 0.3 mm spheres evoked 
significant deposition of fibrotic tissue. Other materials used in this study, such as stainless steel, 
glass, polycaprolactone and polystyrene, demonstrated a higher degree of fibrosis around the 
material compared to alginate [62].  
PEG is a synthetic polymer also used in biomedical and immuno-isolating applications. Biological 
inertness and easy manipulation of mechanical properties provide a high degree of 
reproducibility [85]. By controlling the PEG concentration in the hydrogel, one can tune the 
mechanical properties (i.e. shear modulus) to elicit the desired cellular response [86,87]. This is 
essential because the stiffness of the hydrogel impacts the severity of the foreign body response 
(FBR). Softer gels cause a less extensive reaction compared to stiffer gels. Additionally, softer gels 
induce secretion of lower levels of inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, 
compared to stiffer gels in vitro [88].  Through the process of mechanotransduction, 
macrophages behave differently based on F-actin localization. On softer gels, macrophages 
experience attenuated force compared to stiffer gels leading to a pronounced effect on 
macrophage spreading and attachment [89]. Furthermore, the crosslinking mechanism and 
density of PEG hydrogels can be manipulated. Although PEG’s molecular structure is conserved 
– PEG diol with two hydroxyl end groups – the structure of the end-groups can be modified and 
functionalized allowing for a high degree of versatility and crosslinking chemistry, such as free 
radical polymerization [90-94] and Michael-type addition [95.96].  
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The molecular weight cut-off (MWCO) of the molecules that can diffuse through the PEG 
hydrogel is a tunable property as well. Tugba et al. [97] compared the diffusion of a 
physiologically active glucagon like peptide-1 (GLP-1) and a relatively inert bovine serum albumin 
(BSA) through PEG diacrylate (PEGDA) hydrogels. Given a PEG concentration of 5% w/v, 100% of 
encapsulated BSA was released from 20 kDa PEG hydrogels in the initial 30 h of the release 
experiment, while only 84% BSA was released over the same period from 10 kDa PEG. Whereas, 
in 10% w/v PEG, BSA release decreased to 73% and 67% for 20 kDa and 10 kDa PEGDA hydrogels, 
respectively. They determined that diffusivity was dependent on PEG concentration and 
molecular weight of the PEG macromer enabling only molecules of a specific size and below to 
diffuse through the PEG hydrogels. When tuning the size exclusion of a polymeric membrane, 
one must be vigilant, as a MWCO of approximately 20 kDa would be needed to exclude secreted 
cytokines, but this may also affect cell viability due to restricted diffusion of large proteins [98]. 
A balance needs to be reached to prevent infiltration of host immune cells while not inhibiting 
the exchange of nutrients and oxygen. 
Several studies proved that encapsulation of pancreatic islets in PEG hydrogels can restore 
glucose to physiological levels in vitro and in vivo [49-52]. Cruise et al [49] showed that PEGDA 
acted as a passive membrane barrier around the encapsulated islets. Additionally, PEGDA did not 
affect islet cell functionality as streptozotocin-induced mice maintained normoglycemia up to 
four months [50]. Although PEGDA has been shown to support islet survival and act as a passive 
barrier to host immune cells, its immunoprotective qualities are limited in time due to its 
hydrolytically degradable structure. To further promote the functionality of the encapsulated 
cells, Weber et al. [51] created a dual PEG hydrogel system. This multilayered hydrogel consists 
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of a PEG-laminin core and an exterior inert PEG layer. The core provides a biologically active 
environment for the islets allowing the islets to survive 28 days in culture, while the outer shell 
provides a protective barrier against a host immune response [51] Headen et al. [52] showed that 
encapsulation of islets in PEG-maleimide did not affect cell viability and provided a tunable 
hydrogel network that supported insulin production in encapsulated human islets similar to the 
non-encapsulated islets in culture.  
Due to PEG’s non-fouling properties, PEGylation of other materials has been investigated as a 
method for immunoprotecting islet cells, and it has been shown that the PEGylated capsules 
reduced IL-2 secretion compared to alginate-poly-L-ornithine capsules [64]. Although PEG 
protects from infiltration of cytotoxic T-cells and reduces host-cell interactions, smaller 
components of the immune system, such as cytokines and antibodies produced by immune cells 
can still potentially diffuse through the passive barrier. This may lead to islet destruction, and 
shorten graft longevity [53]. To address this deficiency, Cheung and Anseth [99] demonstrated 
that conjugating apoptosis-inducing anti-Fas monoclonal antibodies to the surface of PEG 
hydrogels attenuates the immune response to the pancreatic islet cells further by destroying 
auto-reactive T-cells. The inclusion of anti-Fas monoclonal antibodies on the surface of the 
hydrogels induced apoptosis of Fas-sensitive Jurkat T cells.  
TheraCyte, which is a membrane immunoisolator [70], has been used for encapsulation of 
pancreatic tissue to restore glucose levels in different animal models. Itkin-Ansari’s group 
showed that TheraCyte protected pancreatic allograft from immune rejection in Rhesus monkeys 
for 1 year compared to a non-encapsulated allo-graft, which lasted only 14 days [100]. A study 
by Kumagai-Braesch et al. [101] showed that TheraCyte supports islet allografts for six months in 
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rats with normal and sensitized immune system. Bruin et al. [102] showed that human embryonic 
stem cells can differentiate into pancreatic progenitors in TheraCyte and were able to restore 
glucose levels in diabetic mice. Recently, Boettler et al. [63] encapsulated pancreatic tissue in 
TheraCyte and observed that the diabetic mice were able to maintain normoglycemia following 
implantation of TheraCyte. Table 1  illustrates the advantages and limitations of natural and 
synthetic materials as immuno-isolating devices. 
 
Table 1: Advantages and disadvantages of alginate, PEG, and TheraCyte as encapsulating 









1.8 Use of Immuno-isolation to Support Ovarian Tissue Allo-Transplantation and Restore 
Ovarian Endocrine Function 
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The experimental success with allogeneic implantations of pancreatic islets and parathyroid cells 
led to the investigation of the feasibility of treatment of additional endocrine disorders, such as 
ovarian insufficiency in young female patients. Premature ovarian failure is a common side effect 
of anticancer treatments in girls and young women. Allogeneic ovarian tissue implantation has a 
promising potential as a means to restore ovarian endocrine function physiologically and avoid 
the side effects associated with delayed puberty and ovarian insufficiency. 
The application of biomaterials for immuno-isolation of a gonadal tissue has promising potential 
for restoring endocrine function in males and females who suffer from premature gonadal 
insufficiency caused by cytotoxic therapy or autoimmune diseases. Just as islet transplantation is 
used to treat endocrine disruption in Type 1 Diabetes [49-52,62-64] as depicted in Figure 1.2.  
 
 
Figure 1.2: Immunoisolation of islet cells in a hydrogel. The basic principle is encapsulating islets 
in a semipermeable membrane which after a period of implantation results in the release of 
insulin. These hydrogels ideally allow the inflow of nutrients and exchange of hormones while 
minimizing immune cell infiltration. 
 
 15 
Transplantation of ovarian follicles secreting sex hormones in response to endogenous circulating 
gonadotropins, could establish normal physiological endocrine ovarian function. The 
transplantation of ovarian follicles has similarities to islets, yet also presents unique challenges 
as well as opportunities. Follicles have a similar initial size to islets and secrete sex hormones 
(estradiol and progesterone) in response to circulating stimuli. Unlike islets, however, follicles 
expand and contract as they undergo structural and functional changes during the menstrual 
cycle. Furthermore, follicles are avascular and relatively resistant to hypoxia, allowing them to 
survive when implanted as larger structures. Due to these similarities and advantages compared 
to islets, immuno-isolation methods can be utilized towards follicles or ovarian tissue (Figure 1.3). 
 
 
Figure 1.3: Immunoisolation of multiple follicles in a hydrogel. The basic principle is encapsulating 
follicles in a semipermeable membrane which after a period of implantation results in follicular 
development. These hydrogels ideally allow the inflow of nutrients and exchange of hormones 
while minimizing immune cell infiltration. 
 
By protecting ovarian follicles or tissue from the host using PEG, alginate, and TheraCyte, 
successful restoration of ovarian endocrine function can be potentially achieved. This is possible 
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by maintaining the viability and functionality of a sufficient number of follicles secreting gonadal 
hormones in response to the circulating gonadotropic factors. It has been shown that 
proteolytically degradable synthetic PEG-based hydrogels support mice follicle growth and 
maturation [103].  Sittadjody et al. [104] encapsulated rat granulosa and theca cells in 
multilayered alginate to engineer an artificial ovarian tissue in vitro. They observed that sex 
steroids and peptide hormones were released in response to added gonadotropins.  
1.9 Conclusion 
The life-saving chemo and radiotherapies may cause premature ovarian insufficiency (POI), which 
is associated with ovarian damage, loss of fertility and endocrine function. For childhood cancer 
survivors who experience POI prior to puberty, the impact is particularly detrimental as the 
absence of puberty leads to co-morbidities such as poor bone health, altered metabolism, and 
poor cardiovascular health. Current options to restore endocrine function are HRT and ovarian 
tissue cryopreservation and auto-transplantation but are associated with limitations such as non-
physiological delivery of hormones and risk of re-introduction of cancerous cells. This thesis 
details the work to study the hypothesis that allo-transplantation of ovarian tissue can restore 
ovarian endocrine function utilizing the concept of immune-isolation to protect ovarian allografts 
from an immune response. In Chapter 2, we describe the design and development of different 
formulations of PEG-based hydrogel for encapsulation of ovarian tissue. Here we further 
investigated the inflammatory reaction with the PEG-based capsules in the host surrounding 
tissues to determine which formulation attenuates the inflammation and fibrotic capsule 
formation around the implanted graft. In Chapter 3, we describe the development of a Dual PEG 
capsule with a degradable core and non-degradable shell that is conducive for ovarian tissue 
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development and is immuno-isolating. Multiple formulations of PEG-based capsules were tested 
in a syngeneic mouse model of POI to assess ovarian endocrine restoration and graft function. In 
Chapter 4, we tested the ability of the Dual PEG capsule to immuno-isolate the encapsulated 
allogeneic mouse ovarian tissue and assessed restoration of ovarian endocrine function and 
immune response in an allogeneic mouse model. In Chapter 5, we describe the ability for the 
Dual PEG capsule to retain cancer cells when co-encapsulated with syngeneic mouse ovarian 
tissue in application towards ovarian tissue auto-transplantation. In Chapter 6, we tested 
whether allogeneic ovarian tissue sensitizes the immune system when encapsulated in Dual PEG 
using an allogeneic mouse model and subsequent implantations of either encapsulated or non-
encapsulated ovarian allografts. In Chapter 7, we tested whether non-human primate (NHP) 
ovarian tissue encapsulated in Dual PEG survives and develops in a syngeneic and allogeneic NHP 
model of POI. Additionally, we studied whether the encapsulated allografts provoked an immune 
response, testing the immuno-isolating capability of Dual PEG when encapsulating NHP ovarian 
tissue. In Chapter 8, the overarching conclusions of this thesis are made and possible future 
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2.2 Abstract 
Poly(ethylene glycol) (PEG) can be functionalized and modified with various moieties allowing for 
a multitude of cross-linking chemistries. Here, we investigate how vinyl sulfone, acrylate, and 
maleimide functional end groups affect hydrogel formation, physical properties, viability of 
encapsulated cells, post-polymerization modification, and inflammatory response of the host. 
We have shown that PEG-VS hydrogels, in the presence of a co-monomer, N-vinyl-2-pyrrolidone 
(NVP), form more efficiently than PEG-Ac and PEG-Mal hydrogels, resulting in superior physical 
properties after 6 minutes of ultraviolet light exposure. PEG-VS hydrogels exhibited hydrolytic 
stability and non-fouling characteristics, as well as the ability to be modified with biological 
motifs, such as RGD, after polymerization. Additionally, unmodified PEG-VS hydrogels resulted in 
lesser inflammatory response, cellular infiltration, and macrophage recruitment after 
implantation for 28 days in mice. These findings show that altering the end group chemistry of 
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PEG macromer impacts characteristics of the photo-polymerized network. We have developed a 
tunable non-degradable PEG system that is conducive for cell or tissue encapsulation and evokes 
a minimal inflammatory response, which could be utilized for future immuno-isolation 
applications.   
2.3 Introduction 
The use of synthetic hydrogels presents a unique opportunity for tissue engineering 
applications, because the polymer network can be tuned to mimic the microenvironment of the 
native tissue to achieve desired function [85,87, 105]. Poly(ethylene glycol) (PEG) is one of the 
most studied and widely utilized biomaterial for synthetic hydrogels. Due to its high-water 
content and non-fouling properties, PEG based hydrogels are highly biocompatible and tunable 
[85, 106]. Additionally, the viscoelastic properties of PEG hydrogels allow for expansion and 
growth of encapsulated tissue, which is vital for engineering a hydrogel based immuno-oisolating 
construct [107, 108].  
An immuno-isolating construct or device creates a physical barrier around the implanted 
cells or tissues, precludes contact with immune cells from the host and prevents sensitization. 
For the immuno-isolation of implanted allogeneic tissue, it is important for the network to be 
non-degradable yet porous enough to allow effective diffusion of nutrients and metabolites and, 
on the other hand, block transport of allo-antigens and cells out of the device and into the 
surrounding tissues of the recipient. An important design criteria when engineering an immuno-
isolating construct is to create an interface with the host tissues that elicits a minimal 
inflammatory response. Evoking a strong inflammatory response would result in a thick fibrotic 
capsule in addition to immune cell recruitment around the construct, thereby hindering function 
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[109]. Due to its non-fouling properties, PEG coating and encapsulation has been shown to be a 
successful strategy to reduce acute inflammatory responses [110,111]. Additionally, PEG chain 
density, length, and conformation contribute to the ability to resist protein absorption [112-114]. 
Functionalization of the end hydroxyl groups of the otherwise inert PEG macromer with 
reactive end groups allows for a variety of crosslinking chemistries [90, 91, 94-96]. Multiple 
chemistries have been developed to functionalize PEG, such as vinyl sulfone, acrylate, amine, or 
maleimide end groups [115-119]. Presence of acrylate groups promotes the formation of a 
crosslinked network via photo-polymerization in the presence of a photo-initiator [90, 120,121], 
while vinyl sulfone and maleimide end groups are used for Michael-type addition chemistry with 
cysteine containing enzyme sensitive peptides to create a proteolytically degradable network 
[95,96,115]. Additionally, PEG macromers can be modified with biological motifs such as integrin 
binding peptides to create a microenvironment conducive for cell attachment [122].  
 Crosslinking of hydrogels using photo-polymerization is expedient, results in hydrogels 
with superior physical properties for in situ encapsulation, and creates networks that are 
resistant to proteolytic degradation [120]. Furthermore, several groups have shown photo-
polymerized systems are cytocompatible and useful for a multitude of engineering applications 
[90, 123-130]. During the photo-polymerization process, light exposure creates free radicals in 
the presence of photo-initiators, which react as electron donors with the terminal double bonds 
and form crosslinked networks. Free radical mediated crosslinking is dependent on the reactivity 
of the free radical and the electrophilic nature of the available double bonds. Since this reaction 
is dependent on the presence of double bonds, we hypothesize that the chemistry of the 
functional end groups of a multi-arm PEG macromolecule will alter the susceptibility of double 
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bonds to react with free radicals, therefore, affecting the integrity of the crosslinking network 
and physical properties of the hydrogel. To test this hypothesis, we prepared photo-polymerized 
vinyl sulfone (PEG-VS), acrylate (PEG-Ac), and maleimide (PEG-Mal) hydrogels (Figure 2.1) and 
assessed how changing chemistry of the functional end group of the multi-arm PEG backbone 
impacted the crosslinking efficiency, bulk properties, stability, cell compatibility, modification 
efficiency, and the degree of inflammatory response. Our end objective was to develop a tunable 
non-degradable PEG system that is conducive for cell or tissue encapsulation and evokes a 
minimal inflammatory response, which could be utilized for immuno-isolation applications.   
 
Figure 2.1: Chemical schematic of photo-polymerization of PEG-VS, PEG-Ac, and PEG-Mal in the 
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2.4 Results 
2.4.1 The end group chemistry in PEG hydrogels impacts gelation efficiency and physical 
properties 
We hypothesized that altering the functional end group attached to a multi-arm PEG 
backbone would alter the gelation efficiency and physical properties of the resultant photo-
polymerized hydrogel due to a change in the reaction environment and reactivity of the 
respective group. To determine the effect of functional end groups on efficiency of gelation, we 
exposed the respective precursor solutions to 6, 15, and 30 minutes of UV light and measured 
gel fraction. When comparing across the three functional groups, PEG-VS hydrogels formed most 
efficiently, as demonstrated by the largest gel fraction at all exposure times and compositions 
(Figure 2.2A, Table 2).  
 
 
Figure 2.2: Gel fraction of 2-, 4-, and -8-arm 5% w/v (A) PEG-VS, (B) PEG-Ac, and (C) PEG-Mal 
hydrogels with 0.1% v/v NVP exposed to UV light (1090 µW/cm2) for 6, 15, and 30 minutes (n=5 



























































Table 2: Gel fraction of -2, -4, and -8-arm 5% w/v PEG-VS, PEG-Ac, and PEG-Mal hydrogels with 
.1% v/v NVP and without RGD modification (n=15 for 8-arm, n=5 for 2- and 4-arm compositions), 
without NVP and without RGD modification (n=5 for all compositions), and with .1% v/v NVP and 
with .5mM RGD (n=5 for all compositions). All gels were exposed to UV light for 6 minutes. “–” 
indicates the hydrogels did not form. 
 
 
After 6 minutes exposure to UV light (1090 µW/cm2), 8-arm PEG-VS, PEG-Ac, and PEG-
Mal (NVP(+), RGD(-)) hydrogels formed with 99%, 89%, and 63% efficiency, respectively. All 
tested multi-arm PEG-VS hydrogels that included NVP formed completely by 6 minutes of 
exposure, while PEG-Ac and PEG-Mal hydrogels did not form completely up to 30 minutes of UV 
light exposure (Figure 2.2). All multi-armed PEG-VS hydrogels incorporated 99% of solid content 
by 6 minutes, while PEG-Ac and PEG-Mal hydrogels incorporated up to 89% and 70% solid content 
by 30 minutes, respectively (Figure 2.2).  
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Formation of PEG-VS photo-crosslinked hydrogels is the result of the reaction between 
the electron deficient activated vinyl group and free radicals, similar to the nucleophile-catalyzed 
thiol Michael-type addition reaction of PEG hydrogels. The stronger reactivity of the vinyl sulfone 
group is due to the vinyl moiety being more electron deficient than that of the acrylate or 
maleimide[24], which was confirmed by the downfield shifting of the VS protons in the PEG-VS 
1H NMR spectrum (Supplemental Figure 2.1A). The sulfone group of the PEG-VS is a stronger 
electron withdrawing group compared to the neighboring carbonyl group of acrylate and amide, 
attracting more electrons away from the neighboring double bond, causing electron deficiency. 
Thus, the double bond in vinyl sulfone is more susceptible to reacting with free radicals and the 
rate of propagation is increased. During propagation, the electron withdrawing force of the 
sulfone moiety further destabilizes the secondary free radical resulting in an increase in reactivity 
[131]. Interestingly, PEG-Mal did not crosslink as quickly or efficiently as PEG-VS or PEG-Ac, across 
all compositions. One of the proposed explanations could be that the reaction of free radicals 
with the double bond resulted in bond dimerization, thereby, stabilizing the resultant free radical 
via resonance [132]. To further investigate the impact the functional end groups had on the 
network, swelling ratio (Figure 2.3) and storage modulus (Figure 2.4A) of PEG-VS, PEG-Ac, and 





Figure 2.3: Swelling ratio of (A) 5% w/v 2-, 4-, and -8-arm 5% w/v PEG-VS, PEG-Ac, and PEG-Mal 
hydrogels without NVP and without RGD modification (n=5 for all compositions), (B) with NVP 
and without RGD modification (n=15 for 8-arm, n=5 for 2- and 4-arm), and (C) with NVP and with 
.5mM RGD (n=5 for all compositions) after 6 minutes exposure to UV light (1090 μW/cm2). 
Numbers (2,4, or 8) within columns indicate arms around PEG macromer. “X” indicates the 
hydrogel composition did not form. Differing letters (a, b, c) and indicate statistical significance 
(p<0.05). Significance was determined by a Welch two-sample t-test. 
 
Altering the functional end group in a multi-arm PEG macromer impacted the crosslinking 
network as shown by the significant difference between swelling ratio (Figure 2.3B) and storage 
moduli (Figure 2.4A) of 5% w/v 8-arm PEG-VS, PEG-Ac, and PEG-Mal (NVP(+), RGD(-)) hydrogels. 
Photo-crosslinked PEG-Mal exhibited the highest swelling ratio (Qm=22) which corroborated that 
the PEG-Mal network was less dense compared to that of PEG-VS (Qm=19) and PEG-Ac (Qm=15) 
(Figure 2.3B). PEG-VS and PEG-Ac hydrogels exhibited a storage modulus of 4500-5000 Pa, while 
 26 
PEG-Mal hydrogels had a storage modulus of 2400 Pa, indicating a less mechanically strong 
network (Figure 2.4A). 
 
 
Figure 2.4: A) Storage modulus of 5% 8-arm w/v PEG-VS (n=3), PEG-Ac (n=3), and PEG-Mal (n=3) 
with NVP and without RGD modification after 6 minutes exposure to UV light 
and (B) Degradation over 60 days in PBS of 8-arm 5% w/v PEG-VS (n=5), PEG-Ac (n=5), and PEG-
Mal (n=4) hydrogels with NVP and without RGD modification after 6 minutes exposure to UV 
light. “*” indicate statistical significance (p<0.05). Significance was determined by a Welch two-
sample t-test. 
 
 In addition to the functional end group, the number of reactive ends in the multi-arm PEG 
macromer affected the properties of the photo-crosslinked hydrogels. Decreasing the number of 
arms around a PEG macromer from 8 to 4 to 2 arms decreased the efficiency of the photo-
initiated reaction, similar to what we observed when the hydrogels were formed using Michael-
type crosslinking chemistry [133]. The most dramatic effect of decreasing number of arms was 
 8   
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observed in PEG-Mal hydrogels with NVP, because 2 and 4-arm PEG-Mal did not form after 6 
minutes of UV light exposure (Figure 2.2C, Table 2, Figure 2.3B); this finding further confirmed 
that maleimide end functional group does in fact stabilize the double bond and sterically hinder 
free radical attack more than vinyl sulfone or acrylate groups. To further investigate why the 8-
arm PEG-Mal network was not fully formed after 6 minutes of exposure and whether the 
irradiation time was the limiting factor, we increased the UV exposure time to 30 minutes. The 
storage moduli of 8-arm PEG-Mal hydrogel after 30 minutes of exposure reached on average 
9470 Pa (n=3). The volume of the crosslinked hydrogel remained unchanged and we concluded 
that the 3.5-fold increase in the storage modulus compared to shorter irradiation times was due 
to improved network formation and not due to the evaporation of solvent. These results 
indicated incomplete network formation after 6 minutes of UV exposure, as corroborated by the 
gel fraction (Figure 2.2C). When considering 8-arm and 4-arm PEG-VS and acrylate gels, with the 
increase in functionality (number of arms) of the macromer, the fraction of arms that must 
become crosslinked in order to produce a gel decreases, allowing macromer structure to set the 
fractional conversion of end groups that must be achieved to reach the gel point [134]. 
To validate network formation, FTIR analysis was performed (Supplemental Figure 2.2). 
The observed peak at 1420 cm-1 represents C‒H of C=C, which is related to formation of free 
radicals after decomposition of the photo-initiator (Supplemental Figure 2.2A-C) [135,136]. All 
FTIR spectra showed a broad absorption band around 3430 cm-1 due to the –OH stretching 
frequencies [136]. Peaks around 2920 and 2864 cm-1 are related to asymmetric and symmetric 
behavior (stretching) of methyl group (namely =C‒H vibrations) (Supplemental Figure 2.2A-C) 
[137], as complemented by the NMR spectra (Supplemental Figure 2.1). The spectrum of 8-arm 
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PEG-Ac (NVP(+)) gels suggests network formation due to the formation of C‒C bonds between 
PEG polymer backbone chains in the hydrogel (Supplemental Figure 2.2B) that affects the 
mobility of the PEG backbone [138], as observed by the spectrum peak broadening. This 
observation was supported by the finding that PEG-Ac hydrogels have a swelling ratio of 
approximately 15 independent of the number of arms around the macromer (Figure 2.3B). A 
peak around 1720 cm-1 in the spectra of hydrogels indicates double bond conversion 
(Supplemental Figure 2.2B, C) [139]. The FTIR spectra of 8-arm PEG-Ac and 8-arm PEG-Mal 
hydrogel had a stronger peak compared to the spectrum of 8-arm PEG-VS gel (Supplemental 
Figure 2.2A), suggesting that a greater portion of double bonds stay intact, which presents an 
option of post crosslinking modification of the unreacted double bonds.  
 
2.4.2 Inclusion of NVP alters hydrogel physical properties and has a protective effect on cell 
viability during encapsulation 
It has been demonstrated NVP accelerates gelation due to the increase in vinyl group 
concentration and diffusion of free radicals [140]. To investigate this effect on gelation and 
network formation after 6 minutes of UV light exposure, gel fraction and swelling ratio with and 
without NVP was acquired (Table 2, Figure 2.3A,B). The presence of NVP in the precursor solution 
is essential for formation of 2-arm PEG-VS gels in 6 minutes, but had a less pronounced effect on 
gelation of 4- and 8-arm PEG-VS networks (Table 2). Inclusion of NVP impacted the physical 
properties of the network as indicated by the significant decrease in swelling ratio (Figure 2.3A, 
B). NVP demonstrated no impact on PEG-Ac network formation and a minimal impact on the 
physical properties. For all PEG-Mal networks, the inclusion of NVP is essential for gelation (Table 
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2, Figure 2.3A). Furthermore, steric hindrance of the free radicals on the macromer ends would 
explain the improved gelation in the presence of NVP [141]. In radical polymerization, the 
reactivity of a free radical depends upon the electrons’ delocalization, polarity and volume nature 
of the side groups linked to the radical carbon [142]. The effect was more pronounced for vinyl 
sulfone, meaning that the radicals at the end of the chain in PEG-VS are more sterically hindered 
than those of acrylates. We hypothesize the electron deficiency of the vinyl moiety and 
destabilization of the radical in PEG-VS is able to overcome steric hindrance to efficiently form 
hydrogels via free radical reaction (Figure 2.3A, Table 2). In this reaction, NVP acts as a facilitator 
and creates more free radicals that are accessible by larger sterically hindered VS and Mal groups. 
We demonstrated that the degree to which NVP facilitates the reaction was dependent on the 
chemistry and structure around the vinyl groups in a multi-arm PEG macromer.  
Additionally, for any cell/tissue encapsulation, the ability for the cells to survive the 
encapsulation process is vital. To investigate whether cells or tissue can survive the encapsulation 
process, we encapsulated mouse embryonic fibroblasts (MEFs) in PEG-VS, PEG-Ac, and PEG-Mal 
hydrogels with and without NVP and assessed survival after one day in culture. Similar to Hao et 
al. [140], we observed that after the addition of NVP to the precursor solution the encapsulated 
cells exhibited greater viability (Figure 2.5A).  Cells encapsulated in PEG-VS, PEG-Ac, and PEG-Mal  
hydrogels with NVP exhibited a viability of 87%, 89%, and 68%,respectively, which decreased 
significantly to 60% and 40%, when NVP was not included in PEG-VS and PEG-Ac hydrogels(Figure 
2.5A(F)). PEG-Mal hydrogels did not form when NVP was not included. It was hypothesized that 
the protective effect of NVP was due to improved formation kinetics of the network, decreasing 
the time and absolute exposure of the cells to free radicals. Overall, we showed that NVP can be 
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added in the precursor solution to increase the kinetics of the reaction, the physical properties 
of the network, and does not negatively impact cell viability upon encapsulation. When 
comparing cellular response to encapsulation between the end functional groups of PEG 
macromers, cells encapsulated in PEG-VS and PEG-Ac exhibited a significantly higher viability 
(87% and 89%, respectively) than cells encapsulated in PEG-Mal hydrogels  (68% viability) (Figure 
2.5A(F)). We hypothesize that this is due to the kinetics of the reaction and cells being exposed 
to more absolute free radicals during the PEG-Mal encapsulation, as well as toxicity from residual 




Figure 2.5: A)Fluorescent images of MEFs encapsulated in 5% 8-arm PEG-VS and PEG-Ac without 
NVP (A,B), respectively and 5% 8-arm PEG-VS, PEG-Ac, and PEG-Mal with .1% v/v NVP (C,D,E), 
respectively. Cells were stained with calcein AM and ethidium homodimer-1 for 30 minutes. 
Magnification 10×. (F)Quantification of cell viability in PEG-VS, PEG-Ac, and PEG-Mal hydrogels 
(n=3). “*” indicates statistical significance (p<0.05). “X” indicates the hydrogel did not 
form. (B) Brightfield and fluorescent images of MEFS seeded on 5% 8-arm PEG-VS, PEG-Ac, and 
PEG-Mal hydrogels without RGD modification (A,B,E,F,I,J) and 5% 8-arm PEG-VS, PEG-Ac, and 
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PEG-Mal hydrogels incubated in a 5mM RGD solution after polymerization (C,D,G,H,K,L). 
Magnification 20×, inset magnification 10×. 
 
2.4.3 The functional end group of a PEG macromer impacts the efficiency of RGD modification  
We determined the efficiency of RGD conjugation to PEG-VS and PEG-Ac by analyzing 
NMR spectra of the macromers before and after the conjugation reaction. By reacting 5% 8-arm 
PEG monomers, which have 10 mM reaction arms with 5 mM RGD we expected to see a 50% 
depletion of vinyls. Using NMR and assigning a vinyl peak an integration value of 1.0, the ratio 
between the protons in the double bond and in the PEG backbone can be calculated and 
compared between unmodified and RGD modified PEG macromers (Supplemental Figure 2.1). 
For PEG-VS, there was a 53.5% reduction in vinyl protons when comparing modified to 
unmodified, indicating 100% binding efficiency. For 8-arm PEG-Ac, there was a 24.5% reduction 
of vinyls from unmodified to modified. The double bonds in PEG-Mal undergone hydrolysis during 
dialysis and the ratio between the modified and unmodified macromers could not be determined 
(Supplemental Figure 2.1). Based on these results, we concluded that RGD binds with 100% 
efficiency to vinyl sulfone moieties because of the vinyls’ electron deficiency and susceptibility to 
thiol-mediated reactions.  
RGD modification of multi-armed PEG impacted gelation and the physical properties of 
the resultant hydrogel. When 0.5mM RGD was added to PEG-VS, PEG-Ac, and PEG-Mal hydrogels, 
solid content incorporation decreased after 6 minutes of gelation (Table 2) and swelling ratio 
increased compared to unmodified hydrogels (Figure 2.3B,C), indicating a less dense network. 
The most drastic impact was seen in PEG-VS hydrogels as 2- and 4-arm PEG-VS hydrogels 
modified with .5mM RGD did not form after 6 minutes of gelation (Table 2). 
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2.4.4 Available double bonds allow for post-polymerization RGD modification of PEG hydrogel 
networks 
To investigate whether post-polymerization modification of the crosslinked hydrogels 
with RGD was possible we incubated the gels with 5mM RGD solution for 15 min. After a thorough 
washing step, we seeded mouse embryonic fibroblasts (MEFs) on top of the gels. We compared 
cell adhesion to 5% w/v 8-arm PEG-VS, PEG-Ac, and PEG-Mal hydrogels with RGD modification 
(RGD(+)) and without RGD (RGD(-)) added after polymerization (Figure 2.5B). Cells seeded on the 
hydrogels treated with RGD post-polymerization attached to the gel surface and demonstrated 
a spindle-shaped morphology. Without the RGD modification, cells seeded on the gels formed 
clusters and did not spread. Post-polymerization modification with RGD also improved the 
viability of the seeded cells for PEG-VS hydrogels, which was 49% without and 95% with RGD 
modification. Larger clusters and 100% viability was observed when cells were seeded on 
unmodified PEG-Ac and PEG-Mal hydrogels (Figure 2.5B). This can be explained by the fact that 
vinyl sulfone groups are more hydrophilic than acrylate and maleimide groups and hardly 
promote any protein absorption, increasing the non-fouling properties [110]. The possibility of 
modifying a hydrogel with bioactive peptides after polymerization enables the creation of a bio-
responsive surface without drastically impacting the physical properties of the network. 
 
2.4.5  Hydrolytic stability of photo-crosslinked PEG hydrogels for immuno-isolation application 
In immuno-isolation applications, proteolytic or hydrolytic degradation of the hydrogel 
leads to exposure of the recipient immune system to the donor tissue and may result in 
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sensitization of the host and rejection of the implanted tissue causing premature graft failure. 
For this reason, an immuno-isolating hydrogel system must be designed to be non-degradable 
and stable in vivo.  Photo-polymerization of functionalized PEG forms crosslinks between the 
carbon atoms, through the double bonds at the end-groups of the otherwise biologically inert 
macromer. Similar to previous findings demonstrating significant hydrolytic degradation of PEG-
Ac hydrogel [143], we found that in physiological conditions, PEG-VS hydrogels were more stable 
than PEG-Ac hydrogels (Figure 2.4B). PEG-VS hydrogel swelling ratio changed the smallest 
percentage over a span of 60 days in DPBS. The presence of carbonyls in PEG-Ac and PEG-Mal 
hydrogels make them more susceptible to hydrolytic attack of hydroxyl groups. In addition to 
being hydrolytically stable, differential scanning calorimetry (DSC) demonstrated PEG-VS samples 
show good thermal behavior within the application temperature (Supplemental Figure 2.3). 
Within the application temperature, no significant changes are seen, since the two curves, before 
and after gelation, are similar. The Tm of the polymer has been shifted from 51.3 °C to 54.6 °C, as 
a result of UV polymerization. As a consequence of network formation, and hence more complex, 
less flexible structure, the decrease in endothermic peak is evident (Supplemental Figure 2.3). 
 
2.4.6 Inflammatory response of the surrounding host tissues to the implanted PEG hydrogels  
Attenuated inflammatory response at the interface between the immuno-isolating device 
and the host tissues contributes to extended immuno-isolation and survival of the graft. We 
investigated the local interactions at the interface between the hydrogel implant and host 
tissues. We implanted subcutaneously for 28 days PEG-VS, PEG-Ac, and PEG-Mal hydrogels, and 
performed macro- and microscopic characterization. Interestingly, hydrogels at the retrieval 
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showed blood vessel development around the hydrogels, yet the hydrogels were intact and were 
easily removable. PEG-Mal hydrogels with and without RGD induced a strong response from the 
host, compared to other groups showing dense collagen deposition with stratified cells. In 
addition to the presence of multinucleated giant cells, PEG-Mal based hydrogels with and without 
RGD showed clear infiltration of cells into the hydrogel (Figure 2.6Q, R, U and V) with presence 
of macrophages M1 and M2, as was confirmed with CD-68 and CD-163 antibody staining (Figure 
2.6S, T, W and X), which will hinder the immuno-isolating properties of the hydrogel (Figure 2.6Q, 
R, U and V). Similarly, PEG-Ac hydrogels became encapsulated in a pseudostratified cell lining 
with giant cells, with some infiltration into the hydrogel (Figure 2.6I, J, M and N). 
Neovascularization was observed in the surrounding dense collagen with increased macrophage 
infiltration in PEG-Ac gels without RGD compared to those with RGD (Figure 2.6I, J, K, L, M, N, O, 
P). PEG-VS hydrogels showed the least inflammatory response with an attenuated cell lining and 
a thinner but dense collagen deposition with only occasional giant cells. No cellular infiltration in 
PEG-VS hydrogels occurred after 28 days (Figure 2.6A, B) compared to PEG-VS-RGD hydrogels 
(Figure 2.6E, F). This observation corroborated with what was seen in Figure 2.5B, as unmodified 
PEG-VS hydrogels elicited minimal cellular attachment and spreading compared to PEG-Ac and 
PEG-Mal hydrogels (Figure 2.5B), indicating less protein absorption. Interestingly, PEG-VS 
hydrogels with and without RGD showed stronger presence of macrophage M2 (Figure 2.6D, H) 
and lesser presence of M1 (Figure 2.6C, G) compared to PEG-Ac and PEG-Mal hydrogels, possibly 





Figure 2.6: Histological images of 8-arm PEG types after implantation for 28 days. (A, B) PEG-
VS, (E, F) PEG-VS-RGD, (I, J) PEG-Ac, (M, N) PEG-Ac-RGD, (Q, R) PEG-Mal and (U, V) PEG-Mal-
RGD. Host response to implanted PEG types as observed: (B) PEG-VS implant with retraction 
artifact and loosely adherent capsule composed of attenuated epithelioid cells (dashed 
outline). (J) PEG-Ac implant with multilayered cellular capsule overlying granulation tissue with 
prominent angiogenesis and frequent multinucleate giant cells (dashed outline). (R, V) PEG-Mal 
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implant with infiltration into and partial resorption of the hydrogel matrix (dotted outline). (C, 
G) Presence of macrophage M1 (CD-68 staining) were observed in (G, K) PEG-Ac and (S, W) PEG-
Mal hydrogels. Whereas macrophage M2 (CD-163 staining) observed in weak to strong presence 
between PEG hydrogel types (P, T, X, D, H and L). (*) PEG hydrogel. Magnification 10× (A, E, I, M, 
Q, U) scale bar, 500 μm. Magnification 40× (B, C, D, F, G, H, J, K, L, N, O, P, R, S, T, V, W, X), scale 
bar, 50 μm. 
 
2.5 Discussion 
The design of an immuno-isolating hydrogel system has to address cytocompatibility 
upon encapsulation, the physical properties of the network that match the physiological host 
environment, resistance to proteolytic and hydrolytic degradation, and minimal inflammatory 
response. In a previous study, we investigated the ability of TheraCyte and alginate to support 
and protect ovarian tissue in a syngeneic and allogeneic model [144]. We found that alginate was 
not able to withstand the volumetric expansion of ovarian tissue, compromising its immuno-
isolating capability. Immuno-isolating non-degradable PEG hydrogels have been used for 
encapsulating pancreatic cells [49-52] using crosslinking chemistries with non-degradable 
peptides[52, 136, 145], scramble peptides [146-148], and photo-polymerization [120, 140, 149]. 
However, non-degradable and scramble peptides can require longer gelation times compared to 
photo-polymerization[136], and gelation upon monomer-peptide introduction may limit 
advanced patterning opportunities. During photo-crosslinking, expedient polymerization only 
upon light exposure presents the opportunity for advanced patterning and spatiotemporal 
control. To our knowledge, non-degradable PEG-VS hydrogels have not been developed using 
solely photo-polymerization. Photo-polymerized PEG-VS based hydrogels, described here, meet 
the design criteria for an immuno-isolating device and are advantageous towards 
microencapsulation due to the high degree of tunability, biocompatibility, and non-fouling 
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surface [85,106]. We hypothesized that utilizing PEG-VS as the backbone polymer would create 
a hydrolytically stable hydrogel system in a physiological environment without impacting tissue 
viability upon encapsulation. In this study, we investigated how changing the end functional 
group around a PEG macromer impacts gelation, physical properties, and compatibility, with the 
objective of designing a hydrogel system that could be used towards immuno-isolating 
applications.  
We first compared how vinyl sulfone, acrylate, and maleimide impacted gelation 
efficiency and physical properties of the resultant PEG hydrogels. PEG-VS hydrogels form most 
efficiently across the functional groups given the same exposure time, because double bonds in 
the vinyl sulfone moiety are more electron deficient [121], leading to faster free radical reaction 
and propagation. The physical properties of PEG-VS hydrogels were also superior to that of PEG-
Ac and PEG-Mal given the same crosslinking time, which would be vital for tissue encapsulation 
and tuning the mesh size for immuno-isolation applications. A shorter crosslinking time to 
complete the encapsulation minimizes the impact on cell viability. Additionally, including NVP, a 
co-monomer, at a low concentration demonstrated a protective effect on cell viability upon 
encapsulation. We hypothesized that in the presence of NVP the cells were exposed to a 
decreased absolute number of free radicals for a shorter time due to the improved gelation 
kinetics. Overall, we have demonstrated that addition of NVP improves gelation, physical 
properties, and cell cytocompatibility. 
Unmodified PEG hydrogels are inert to protein absorption and cell interactions. We 
showed the efficiency of RGD binding was impacted by the functional end group that was present 
during the thiol-mediated reaction. In this reaction the thiol present in the side chains of RGD 
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reacts with vinyl groups present in the functional group on the PEG arms. PEG-VS incorporated 
RGD most efficiently due to the electron deficiency of the double bond and availability to react 
with thiol groups. We have been able to demonstrate that RGD can be incorporated into PEG-VS 
and PEG-Ac hydrogel networks after photo-polymerization due to the presence of unreacted 
double bonds. Post-crosslinking modification could be important for tissue engineering 
applications as one can create a hydrogel system with the desired physical properties and then 
modify the network with bioactive motifs post-polymerization.  
Resistance to hydrolytic degradation is an important design criterion for an immuno-
isolating device. Photo-polymerization was used as the crosslinking chemistry to minimize the 
extent of proteolytic degradation. However, hydrolytic degradation of ester and maleimide 
bonds may lead to premature graft rejection. PEG-Ac and PEG-Mal hydrogels are susceptible to 
hydrolytic degradation due to the presence of carbonyls and/or ring opening, while PEG-VS 
hydrogels are more stable in physiological conditions. We confirmed that PEG-VS was the most 
hydrolytically stable over a span of 60 days. Additionally, biocompatibility of an implanted device 
with the surrounding tissues of the host and a minimal inflammatory response contribute to the 
graft longevity. Macrophages play a key role in inflammatory response after implantation of 
biomaterials [150]. Upon implantation, PEG-VS hydrogels had the least amount of cellular 
infiltration compared to PEG-Ac and PEG-Mal hydrogels. RGD incorporation in all PEG hydrogel 
types further facilitated cell infiltration. Interestingly, PEG-Ac-RGD hydrogels attracted less 
macrophage reaction when compared to the non-modified PEG-Ac, which corroborates with 
Blakney et al. who used PEG-DA hydrogels [151]. Overall, we demonstrated that PEG-VS 
hydrogels can form efficiently via photo-polymerization, are hydrolytically stable, maintain cell 
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viability upon encapsulation, and elicit a lesser inflammatory response compared to PEG-Ac and 
PEG-Mal hydrogels.  
This study has demonstrated that reactive functional end groups of the multi-arm PEG 
macromers impact free radical mediated network formation. The PEG-VS network formed more 
efficiently via photo-polymerization, impacting bulk properties, was most stable in physiological 
conditions, and elicited an attenuated inflammatory response compared to PEG-Ac and PEG-Mal 
hydrogels. Further, NVP can be added to the precursor solution to expedite the cross-linking 
process without impacting cellular response upon encapsulation. One of the potential 
applications of these hydrogels would be their use for immuno-isolation methods. A shorter 
crosslinking time would improve the biocompatibility of a hydrogel when used with live cells or 
in proximity to live tissues and should have the least effect on the viability of cell or tissue 
encapsulated within the photo-polymerized hydrogel. These attributes are crucial for efficient 
encapsulation of tissue or cells, including those of allogeneic origin, for long-term immuno-
isolating applications.  
 
2.6 Materials and Methods 
 
2.6.1 Hydrogel Preparation 
To form the hydrogel network, 2, 4, or 8-arm PEG-VS, PEG-Ac and PEG-Mal (JenKem 
Technology, Beijing, China) macromer powder was dissolved in sterile Dulbecco’s Phosphate 
Buffered Saline(DPBS) (pH 7.4, Gibco, USA) solution and 0.4 mg/100µL of photo-initiator Irgacure 
2959 (Ciba, Basel, Switzerland, MW=224.3) to create a solid concentration of 5% w/v. 
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Furthermore, a co-monomer, N-vinyl-2-pyrrolidone (NVP) (Sigma-Aldrich, USA), was added in 
some compositions at a final concentration of 0.1%, as NVP has been shown to enhance the 
gelation mechanism without impacting the cell compatibility [140]. To form the gels, the 
precursor solution (PEG, Irgacure 2959 and NVP (in some compositions)) was exposed to UV light 
at a constant intensity (1090 µW/cm2 at a distance of 4 cm) for a designated duration. 
 
2.6.2 Gel Fractions of PEG- Hydrogels 
5% w/v 2, 4, and 8-arm PEG-VS, PEG-Ac, and PEG-Mal hydrogels were tested with no NVP 
and no RGD (NVP(-), RGD(-)), with 0.1% v/v NVP and no RGD (NVP(+), RGD(-)), and with 0.1% v/v 
NVP and modified with 0.5 mM RGD (NVP(+), RGD(+)). PEG precursor solution of constructs 
containing 0.5 mM RGD was incubated with 0.5 mM RGD for 15 minutes in isotonic HEPES buffer 
prior to UV exposure. All precursor solutions were exposed to UV light (365 nm, 1090 µW/cm2 at 
a constant height of 4 cm) for 6 minutes and precursor solution containing NVP and no RGD were 
exposed for 6, 15, and 30 minutes. Gels were swelled overnight at room temperature to remove 
soluble monomers and lyophilized to remove water content. Dry mass was obtained and divided 
by theoretical solid content to quantify gel fraction (n=5 for all compositions). 
 
2.6.3 NMR Analysis to Characterize RGD Conjugation 
We evaluated the effect of the end-group chemistries on the efficiency of Michael-type 
addition of RGD to 8-arm 5% PEG-VS, PEG-Ac, and PEG-Mal. 5% w/v PEG precursor solution was 
incubated with 5 mM RGD for 15 minutes in HEPES buffer. A 5% w/v 8-arm PEG solution contains 
10 mM reactive arms; so theoretically, half of the arms should be reacted when 5 mM RGD is 
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added. After incubation, 1 mL of the respective precursor solutions were transferred to a dialysis 
tubing (3.5-5 kDa MWCO, Spectrum Laboratories, California, USA). Dialysis against Milli-Q water 
was performed overnight to remove unreacted RGD molecules. The solutions were then 
lyophilized and the solid content was dissolved in 600 µL of deuterium oxide and transferred to 
a respective NMR tube. The NMR data was acquired on a 500 MHz Varian VNMR spectrometer 
equipped with two high band and one low band radio frequency channels. All spectra were 
acquired at 25 °C.  
 
2.6.4 Fourier Transform Infrared Spectroscopy (FTIR) Analysis 
Samples of pure chemicals and powdered dry hydrogels (xerogels) were submitted to FTIR 
analysis and the spectra were obtained using a Bomem MB 100 FTIR Spectrophotometer applying 
the Potassium Bromide (KBr) disc method. 1.5 mg of the powdered dry hydrogels were mixed 
and grinded (sample/KBr ratio was kept at 1/50 constant) and then compressed into a pellet at a 
pressure of 11 t for about a minute, using the Graseby Specac Model: 15.011. Spectra were 
obtained in the 4000–400 cm-1 wave number range at 25 °C and at 4 cm-1 spectral resolution. 
 
2.6.5 Swelling Ratio 
The swelling ratios of PEG hydrogels with varying compositions were determined. The 
hydrogels were formed as described above and submerged in DPBS for 24 hours. After 24 hours, 
excess DPBS was removed and the swollen mass of the hydrogels was obtained. These hydrogels 
were then air dried at room temperature and lyophilized to remove any moisture. Larger volumes 
(100 µL) of hydrogels were used to minimize error from weighing. The mass swelling ratio (Qm) 
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was determined by dividing the mass of the swollen gels (Ms) by the mass of the dry gels (Md). 
Results shown are mean ± SD. 
 
2.6.6 Rheology 
The storage moduli of PEG hydrogels with varying compositions were investigated. After 
formation, the hydrogels were swollen in DPBS overnight. A TA HR-2 rheometer (TA Instruments) 
equipped with a 20 mm parallel plates and a Peltier stage was used for this study. To ensure the 
hydrogel was the same size as the geometry, 1 mm thick hydrogel slabs were made and a 20 mm 
diameter disc was punched out (n=3). A constant strain rate of 5% was maintained for all tested 
hydrogels and the storage modulus was obtained by performing an angular frequency sweep 
from 0.1 to 10 rad/s. Results shown are mean ± SD. 
 
2.6.7 In Vitro Hydrolytic Degradation of PEG-VS, PEG-Ac and PEG-Mal Hydrogels 
The sensitivity of PEG hydrogels with varying end groups to hydrolytic degradation was 
investigated by incubating the gels in DPBS (pH: 7.4) at 37 °C for a period of 60 days (n=5 for PEG-
VS and PEG-Ac, n=4 for PEG-Mal). Fresh DPBS was added every other day. Degradation was 
measured by determining the swelling ratio which was calculated every fifth day relative to the 
average initial dry (polymer) mass. All swelling ratio measurements were normalized to the initial 
swelling ratio (Day 1) [143]. Results shown are mean ± SD. 
 
2.6.8 Differential Scanning Calorimetry (DSC) Analysis 
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The DSC experiments were performed using a DSC 1 instrument (Mettler–Toledo, 
Switzerland). Dried hydrogel samples were crimped in standard 40 µl aluminum pans and tracings 
were performed between 0.0 and 350.0 °C, at a heating rate of 10 °C/min under constant 
nitrogen purge of 50 cm3/min. 
 
2.6.9 Assessment of the Protective Effect of NVP during Photo-polymerization on Cell Viability 
Mouse embryonic fibroblasts (MEFs) were encapsulated in 5% w/v 8-arm PEG-VS, PEG-Ac 
and PEG-Mal with, NVP(+), and without, NVP(-), 0.1% v/v NVP. Cells were encapsulated at a 
density of 250,000 cells/mL in a 10 µl gel. All cell containing precursor solutions were exposed to 
UV light for 6 minutes (n=3 for each condition). To assess cell viability, a Live/Dead assay 
(Thermofischer Scientific, Waltham, MA), based on membrane integrity was utilized. Briefly, 20 
µl of 2 mM ethidium homodimer-1 and 5 µl of 4 mM calcein-AM were added to 10 mL of sterile 
PBS to make the stock solution. After 24 hours of culture, media was removed and 500 µl of 
Live/Dead stock solution was added to each sample and allowed to incubate for 30 minutes at 
37 °C before imaging. Cell viability was quantified via Image J software. 
 
2.6.10 Post-polymerization RGD Modification 
We investigated whether photo-polymerized PEG hydrogels contained unreacted end 
group that allow post-polymerization modification with the RGD peptide. 100 μL precursor 
solution of 5% w/v 8-arm PEG-VS, PEG-Ac, and PEG-Mal with 0.1% v/v NVP was laid on the bottom 
of a 96 well plate and exposed to UV light for 6 minutes. Gels receiving post-polymerization RGD 
modification (RGD(+)) were incubated in a 5 mM RGD solution for 15 minutes. All gels were 
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washed with sterile PBS and allowed to swell overnight. Mouse embryonic fibroblasts were then 
seeded onto the PEG layers at a density of 25,000 cells/mL and cultured for a period of 6 days to 
evaluate cell spreading. As previously described, cells were stained with a Live/Dead 
cytocompatibility kit to assess viability at day 6 of culture.  Viability was quantified via Image J 
software. 
 
2.6.11 Inflammatory Response to Implanted PEG- Hydrogels 
To investigate the inflammatory response, we subcutaneously implanted PEG hydrogels 
with varying end-group chemistries with and without RGD modification. The Institutional Animal 
Care and Use Committee (IACUC) guidelines for survival surgery in rodents and Policy on 
Analgesic Use in Animals Undergoing Surgery were followed for all the procedures. Animal 
experiments for this work were performed in accordance with the protocol approved by the 
IACUC at the University of Michigan (PRO00005750). A small incision was made on the dorsal side 
of the anesthetized adult female B6CBAF1 mice and the PEG (-VS, -Ac and -Mal) hydrogels were 
implanted subcutaneously in the first group (n=3 mice/group). The second group of mice were 
implanted with PEG hydrogels modified with 0.5 mM RGD (n=3 mice/group). The skin was then 
closed using 5/0 absorbable sutures. The mice were placed in a clean warmed cage for recovery 
and monitored post-operatively for 10 days. The mice received Carprofen (RIMADYL, Zoetis, USA) 
(5 mg/kg body weight) for analgesia before the incision was made. The mice were euthanized 
after a period of 28 days following implantation and the PEG hydrogels were retrieved. 
 
2.6.12 Histological Analysis 
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Retrieved PEG-VS, PEG-Ac and PEG-Mal hydrogels were fixed in Bouin’s fixative solution 
(Sigma-Aldrich) at 4 °C overnight and then transferred to 70% ethanol at 4°C until processing. 
After fixation, the samples were processed at the Histology Core in Microscopy & Image 
Analysis Laboratory at the University of Michigan. Samples were embedded in paraffin and 
serially sectioned at 5 μm thickness and were stained with hematoxylin and eosin. Stained 




2.6.13 Immunohistochemistry for Macrophages  
To analyze the macrophage infiltration following implantation with PEG hydrogels, 
paraffin-sectioned slides were stained for mouse CD-68 and CD-163. First, sections were 
deparaffinized with Xylene and rehydrated. Slides were incubated in peroxide blocking 
reagent (BUF017B, BioRad, USA) for 30 min at room temperature to block any endogenous 
peroxidase activity. The slides were then incubated in antigen retrieval buffer, pH8.0 
(BUF025A, BioRad) for 20 min at 96 °C and additional 20 min at room temperature for antigen 
retrieval. Following which the slides were incubated with normal goat serum (ab156046, 
abcam, USA) to block non-specific binding sites for 30 minutes at room temperature. The 
sections were incubated overnight at 4 °C with primary antibodies: rat anti-mouse CD-68 
antibody (1:100 dilution, MCA1957; BioRad), rabbit anti-mouse CD-163 antibody (1:100 
dilution, ab182422, abcam). The slides were subsequently incubated for 60 minutes at room 
temperature with secondary antibodies: goat anti-rat (1:100 dilution, STAR72, BioRad) for CD-
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68 and goat anti-rabbit (1:500 dilution, ab97051, abcam) for CD-163. Diaminobenzidine 
(ab94665, abcam) was used as a chromogen and hematoxylin as a counterstain. For negative-
controls, paraffin sections were incubated without the primary antibody. 
 
2.6.14 Statistical Methods 
Statistical analysis was performed using R software. A Welch two-sample T-test was used to 
evaluate differences in swelling ratio, storage modulus, and cell viability. The results were 
considered statistically significant when p<0.05. 
 
 









Supplemental Figure 2.1: NMR spectra of (A)unmodified and modified PEG-VS, (B) unmodified 
and modified PEG-Ac, (C) unmodified and modified PEG-Mal. a and a’ indicate vinyl protons, b 
indicates methylene protons in the PEG backbone, and c indicates aromatic proteins from RGD. 
 
 
Supplemental Figure 2.2: FT-IR spectra of 8-arm (A) PEG-VS, (B) PEG-Ac, and (C) PEG-Mal before 






















Immuno-isolating poly(ethylene glycol) based capsules support ovarian tissue 




James R. Day, Anu David, Alexa L. Cichon, Tanay Kulkarni, Marilia Cascalho, Ariella Shikanov 
 
3.2 Abstract 
A common irreversible adverse effect of life-saving anticancer treatments is loss of gonadal 
endocrine function and fertility, calling for a need to focus on post-treatment quality of life. Here, 
we investigated the use of poly(ethylene glycol)-vinyl sulfone based capsules to support 
syngeneic donor ovarian tissue for restoration of endocrine function in mice. We designed a dual 
immuno-isolating capsule (PEG-Dual) by tuning the physical properties of the PEG hydrogels and 
combining proteolytically degradable (PEG-PD) and non-degradable (PEG-NPD) layers to meet 
the numerous requirements for encapsulation and immuno-isolation of ovarian tissue, such as 
nutrient diffusion and tissue expansion. Tuning the components of the PEG-Dual capsule to have 
similar physical properties allowed for concentric encapsulation. Upon implantation, the PEG-
based capsules supported ovarian tissue survival and led to a significant decrease in FSH levels 
60 days post-implantation. Mice that received the implants resumed regular estrous cycle activity 
and follicle development in the implanted grafts. The PEG-Dual capsule provided an environment 
conducive for tissue survival, while providing a barrier to the host environment.  This study 
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demonstrated for the first time that immuno-isolating PEG-VS capsules can support ovarian 
follicular development resulting in the restoration of ovarian endocrine function and can be 




Loss of gonadal endocrine function and fertility in cancer patients undergoing chemo- and 
radiotherapy is a common irreversible consequence of these lifesaving therapies [46,152-156]. 
With improved survival rates of up to 80%, survivors of childhood cancer are a rapidly growing 
population, necessitating a shift in focus from simply survival to quality of life post-treatment. 
Abnormal puberty, osteopenia, muscle wasting, cardiovascular disease, frailty, sterility and risk 
of premature death all stem from impaired gonadal function[157-160. The restoration of 
reproductive and endocrine function is uniquely challenging due to the limited and non-
renewable ovarian reserve. Cryopreservation of ovarian or testicular tissue obtained prior to 
exposure to gonadotoxic treatments, with subsequent implantation in survivors can restore both 
fertility and endocrine function, but the risk of re-introducing malignant cells present in the 
ovarian tissue limits its translation to the clinic[39,40, 161.  To avoid this risk, implantation of the 
donor ovarian tissue encapsulated in an immuno-isolating capsule has the potential to restore 
ovarian endocrine function by secreting the gonadal hormones, while eliminating the risk of 
reseeding cancer cells and the need for immunosuppressant therapy.  
Implantation of hormone secreting cells, such as pancreatic islets, in immuno-isolating 
capsules has been investigated for treating Type I diabetes[50,51,63,64]. For this purpose, 
hormone secreting cells are encapsulated in a semi-permeable membrane that prevents or 
attenuates the interaction between the encapsulated allogeneic cells or tissue and the host 
immune system, while allowing diffusion of nutrients and waste[162]. Ovarian follicles, which are 
the functional hormone secreting units of the ovary, are similar to islets in that they synthesize 
and secrete hormones in response to circulating stimuli, in this case follicle stimulating hormone 
(FSH); however, unlike islets, ovarian follicles are dynamic in growth. At the beginning of each 
cycle only a small portion of follicles activates and enters the growing pool. The growing follicles 
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undergo a multiple fold volumetric expansion, which when encapsulated in an immuno-isolating 
capsule must be accommodated by a degradable matrix that mirrors and allows the follicle 
expansion. Furthermore, follicles are avascular and relatively resistant to hypoxia, allowing them 
to survive and function with diffusion through the encapsulating matrix being the only 
mechanism to supply oxygen and nutrients. 
We have reported earlier that hydrogels prepared with poly(ethylene glycol) vinyl sulfone 
(PEG-VS) and crosslinked with proteolytically sensitive peptides supported follicle development 
in vitro and in vivo[133,146]. For the purposes of immuno-isolation, we investigated whether the 
tunable properties of PEG hydrogels and inert non-immunogenic interface with the host[85,106] 
can match the requirements to allow follicle expansion while preventing infiltration of the cells 
from the host and immune reaction. We encapsulated syngeneic ovarian tissue in three different 
PEG-VS constructs: a non-degradable photo-polymerized PEG-VS hydrogel (PEG-NPD), a 
proteolytically degradable PEG-VS hydrogel (PEG-PD), and a dual PEG-VS hydrogel (PEG-Dual) 
construct containing a proteolytically degradable PEG-VS core with a non-degradable PEG-VS 
shell (Figure 3.1).  
 
 
Figure 3.1: Schematic of encapsulating ovarian tissue in Dual PEG. 
 
The objectives of this study were to: 1) answer the question whether the viscoelastic properties 
of a non-degradable PEG-VS hydrogel are sufficient to allow follicle expansion; 2) create a dual 
construct with a degradable core and non-degradable shell with controlled physical properties 
to match follicle expansion; and 3) to identify the PEG-VS-based hydrogel construct that supports 




3.4.1 Visco-elastic properties of PEG-VS hydrogels 
To determine the physical properties of the PEG hydrogels encapsulating the ovarian tissue, we 
measured the equilibrium mass swelling ratio and storage modulus of 5% PEG-NPD and PEG-PD. 
We found that PEG-NPD, prepared via free radical photo-polymerization chemistry, and PEG-PD, 
prepared with thiol-ene Michael type addition chemistry, had comparable swelling ratios (Figure 
3.2A). The Qm of PEG-PD hydrogels was 32.2, and the Qm of PEG-NPD hydrogels was 30.2. 
Similarly to the swelling ratio, the storage modulus for PEG-PD hydrogels was 2403 Pa and 2876 
Pa for PEG-NPD (Figure 3.2B,C). Specifically important for the PEG-Dual capsule, similar swelling 
ratios and visco-elastic properties of the two types of the hydrogels allow concentric 





Figure 3.2: Swelling ratio (n=5 for all compositions ) and (B) storage modulus of 5% PEG-PD (n=3)  
and PEG-NPD (n=4). (C) Illustration of storage modulus and loss modulus of 5% PEG-PD and 5% 
PEG-NPD. All data reported A,B is mean ±SD.  
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3.4.2 Encapsulation and subcutaneous implantation of ovarian tissue 
The ovarian tissue encapsulated in PEG-NPD, PEG-PD, or PEG-Dual hydrogel was completely 
surrounded in the respective hydrogel network (Figure 3.3A,D,G). For the PEG-Dual hydrogel, the 
ovarian tissue was encapsulated in PEG-PD core, which was surrounded by a PEG-NPD shell 
(Figure 3.3G). At the time of sacrifice, the hydrogels were easily identified and retrieved from the 
subcutaneous space. No difference in the appearance of the different capsules was noted. 
Because of the inert and non-fouling properties of PEG hydrogels, we observed minimal 
interaction with the host tissue at the area around the implanted capsules (Fig 3.3B,E,H). At the 
macroscopic evaluation of the capsules, which were easily removed from the host, the ovarian 
tissue was visible and fully encapsulated in the center of the capsules. No signs of 
revascularization or cell infiltration were observed, which was the anticipated result to ensure 




Figure 3.3: Macroscopic images of PEG-VS hydrogels before and after implantation. (A) Ovarian 
tissue encapsulated in PEG-PD, (B) PEG-PD at the time of sacrifice, (C) PEG-PD after removal, (D) 
Ovarian tissue encapsulated in PEG-NPD, (E) PEG-NPD at the time of sacrifice, (F) PEG-NPD after 
removal, (G) Ovarian tissue encapsulated in PEG-Dual, (H) PEG-Dual at the time of sacrifice, (I) 
PEG-Dual after removal. White dotted circle indicates the localization of the hydrogel on the mice. 
Solid black arrows indicate encapsulated ovarian tissue. Dashed black arrows indicate the border 
of PEG-PD and solid white arrows indicate the border of PEG-NPD. Magnification 5X (A, D, G)  
 
 
3.4.3 Follicle development and growth in the immuno-isolation capsules  
We performed histological analysis of the retrieved ovarian tissue in immuno-isolating capsules 
to investigate the growth and development of the follicles, up to 60 days post implantation. After 
7 days of implantation in the immuno-isolating capsule small primordial and primary follicles 
were found in all the capsules (Figure 3.4A,D,G). After 30 days of implantation multiple large 
antral follicles developed in the ovarian tissue implanted in PEG-PD and PEG-Dual, supporting our 
initial hypothesis that proteolytic degradation was essential to promote follicular growth (Figure 
3.4B,H). We identified multiple follicles in the PEG-NPD capsule after 30 and 60 days, yet the 
antral follicles failed to develop an antral cavity, as demonstrated in Figure 3F. Similar to the 
findings at 30 days post implantation, multiple growing and fully developed antral follicles were 
observed in the ovarian tissue implanted in PEG-PD and PEG-Dual, but not in PEG-NPD. In 
agreement with our macroscopic findings, we did not find evidence of blood vessel infiltrating 












Figure 3.4: Histological image of ovarian tissue encapsulated: in PEG-PD (A) showing primordial 
(*) and primary follicles (**) in 7 day implants (n=3 mice), (B), (C) showing secondary (***) and 
antral follicles (****) in 30 (n=4 mice) and 60 day (n=7 mice) implants respectively, PEG-NPD 
implants showing primordial and secondary follicles (D, E, F) after 7 (n=8 mice), 30 (n=4 mice) 
and 60 (n=6 mice) days respectively and PEG-Dual implants showing secondary (G) and antral 
(H,I) follicles in 7 (n=3 mice), 30 (n=4 mice) and 60 (n=11 mice) day implants respectively. (P) 







3.4.4 Restoration of ovarian endocrine function 
In adult mice with healthy functioning ovaries the levels of circulating FSH is below 20 ng/mL. 
After ovariectomy the lack of negative feedback of estradiol, normally produced in the ovarian 
follicles, results in increased levels of FSH that can reach 100 ng/mL. Mice in all groups had the 
average FSH level of 4-8 ng/mL before ovariectomy (n=16 for PEG-NPD, n=11 for PEG-PD, n=18 
for PEG-Dual).  After a bilateral ovariectomy, FSH levels rose significantly (p<<0.05) to an average 
of 55-71 ng/mL (n=15 for PEG-NPD, n=12 for PEG-PD, and n=16 for PEG-Dual). The rise in FSH 
levels is the result of low levels of circulating estradiol, confirming that the ovaries were removed 
and the hypothalamus-pituitary-gonad axis was disrupted. 60 days after mice received ovarian 
tissue encapsulated in PEG-NPD (n=6), PEG-PD (n=7), or PEG-Dual hydrogel (n=11), FSH levels 
decreased significantly from an average of 64 ng/mL to an average of 34.8 (p=0.0004), 30.5 
(p=0.028), and 34.3 ng/mL (p=0.01), respectively (Figure 3.5A), indicating the HPG axis was 
restored upon implantation in all the groups. 
 
3.4.5 Estrous Cycle Restoration 
Estrous cycle correlates with ovulation and lasts 4-5 days in rodents. After ovariectomy the 
estrous cyclicity ceases, which is determined by the absence of cornified cells in the vaginal 
secretions. Implantation of ovarian tissue in PEG-PD restored cyclicity in 90% of the mice one 
week post implantation, and in 100% by the second week (Figure 3.5B). Restoration of cyclicity 
was delayed in mice that received the implants in PEG-NPD and PEG-Dual with 60% of the mice 
cycling 1 week after implantation, and reaching 100% cyclicity by week 4. However, while 90% of 
the mice that received ovarian implant in PEG-Dual capsule continued cycling for 9 weeks, only 
67% of the mice that received the PEG-NPD capsule continued cycling after 7 weeks, which 
correlates with the histological analysis and suggests that the follicle growth was restricted in the 






Figure 3.5: A) FSH levels of mice receiving ovarian tissue encapsulated in PEG-NPD, PEG-PD, and 
PEG-Dual before ovariectomy, after ovariectomy, four weeks post-implantation, and sixty days 
post-implantation. An asterisk (*) denotes a significant difference (p<0.05) between pre-
ovariectomy levels and the designated group. Significance was determined by a two-sample T-
test. (B) Cyclicity observed in mice implanted with D-PEG, ND-PEG and PEG-Dual in the syngeneic 
model. Presence of a change between leukocytes and cornified cells at least once per week was 








3.4.6 Collagen Deposition 
After implantation for 30 and 60 days, PEG-PD, PEG-NPD, and PEG-Dual exhibited a thin fibrotic 
capsule around the respective hydrogel (Figure 3.6A-F). There was no significant difference in 
the fibrotic capsule thickness around the immuno-isolating capsules (Figure 3.6G).  When 
comparing fibrotic capsule thickness from 30 to 60 days post-implantation, there was no 
significant difference in collagen deposition (p<0.05), indicating the absence of a chronic 
inflammatory response. Cell infiltration from the host or cell migration from the encapsulated 
ovarian follicles was not observed in the implants. Interestingly, cells were present throughout 
the fibrotic capsule around the degradable hydrogel (PEG-PD) (Figure 3.6A), but in the case of 
non-degradable PEG, cells were concentrated in the narrow space between the gel and the 
fibrotic capsule. This finding may indicate that a degradable gel induced a different reaction with 
the innate immune cells compared to a non-degradable gel.  
 
 
Figure 3.6: Trichrome staining of fibrotic capsule around PEG-NPD, PEG-PD, and PEG-Dual after 
30 days (A, B, C) and 60 days (D, E, F) subcutaneous implantation in mice. An asterisk (*) indicates 
the PEG hydrogel. Magnification 40X. (G) Quantification of fibrotic capsule thickness around 






This study investigated whether the PEG-based immuno-isolating capsules support the viability 
and function of encapsulated and implanted ovarian tissue for the purpose of restoration of 
ovarian endocrine function in ovariectomized mice. The results show for the first time the 
development and characterization of novel photo-polymerized and dual PEG based hydrogel 
systems.  We found that PEG-VS based hydrogels support ovarian tissue and restore endocrine 
function for at least 60 days. Future allogeneic studies in mice and higher species will confirm 
whether PEG-PD and PEG-Dual constructs protect the tissue from being recognized and/or 
destroyed by allo-immunity. 
We designed the immuno-isolating capsule by tuning the physical properties of the PEG 
hydrogels and combining degradable and non-degradable layers to meet the numerous 
requirements for immuno-isolation of ovarian tissue. For example, the diffusion of nutrients was 
achieved with low solid concentration and efficient crosslinking density of the network. The non-
degradable layer of the PEG hydrogel created a physical barrier between the host and the 
implant. The proteolytic degradation in response to the cell-secreted proteases from the 
encapsulated follicles allowed the volumetric expansion of ovarian tissue. Lastly, the 
intermediate stiffness and inertness of the PEG hydrogel caused minimal inflammatory response 
at the interface of the capsule and the host.  
 The strategy of encapsulating the tissue grafts in encapsulating devices allows oxygen and 
nutrients delivery via diffusion through the hydrogel without the risk of exposure to the immune 
cells. These properties may be useful to prevent rejection of tissue allografts which inevitably 
occur when the tissue is directly transplanted. The tunability of PEG hydrogels allows excellent 
control over pore size of the network formed around the encapsulated tissue. Ovarian tissue 
encapsulated in PEG-PD, PEG-NPD and the PEG-Dual capsule survived the encapsulation and the 
implantation for 60 days. The histological sections of the retrieved tissue demonstrated no 
evidence of necrosis and appeared normal with phenotypically healthy follicles. Further, in the 
dual capsule we matched the swelling ratio and storage moduli of each layer, which allowed us 
to co-encapsulate several layers of hydrogels having similar properties. The degradable core 
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around the encapsulated ovarian tissue surrounded by a non-degradable shell interfacing with 
the host isolated the tissue from the host environment, while still allowing diffusion and 
promoting survival of the tissue.  
Ovarian follicles exhibit dynamic growth during the hormonal phases, necessitating a 
need for a material with viscoelastic properties that either degrades in response to follicle 
secreted proteases or can mechanically withstand the follicle expansion. Our previous study 
using alginate as an immuno-isolator for ovarian tissue demonstrated that the viscous properties 
of alginate were insufficient to support the follicle expansion, and either excessively compressed 
the tissue or failed to maintain the protective layer [144]. Shikanov et al. demonstrated that a 
proteolytically degradable PEG-VS hydrogel system was conducive for the development of 
ovarian follicles as they can grow, mature, and respond to circulating gonadotropins in culture 
[146]. Here, we proposed to encapsulate the ovarian tissue in viscoelastic PEG hydrogel and 
determine whether the proteolytic degradation of the matrix was essential for ovarian tissue 
survival and function. When implanted in mice for 7, 30, and 60 days, all PEG constructs 
supported ovarian tissue survival and secondary and antral follicles were present in the retrieved 
implants. FSH levels in mice with ovarian tissue encapsulated in PEG-NPD, PEG-PD, and PEG-Dual 
significantly decreased 60 days post-implantation compared to pre-implantation levels (p<0.05), 
indicating the reversal of the ovariectomized phenotype and restoration of the ovarian endocrine 
function. The restoration of the estrous cycle and the decrease in FSH levels proved that the 
tissue encapsulated in the construct responded to the circulating gonadotropins and the 
encapsulated follicles secreted estradiol creating a negative feedback loop in the HPG axis. The 
histological evaluation of the encapsulated tissue indicated that PEG-PD was superior in terms of 
supporting tissue viability and function compared to PEG-NPD. PEG-PD degraded in response to 
the secreted proteases from cells, providing a supporting network without exerting a 
compressive force back on the tissue in a way PEG-NPD does. However, PEG-PD cannot solely 
serve as an efficient immunoisolator and eventually would degrade exposing the tissue to the 
host immune system. Co-encapsulation of a degradable PEG-PD core in a non-degradable PEG-
NPD shell demonstrated successful restoration of ovarian endocrine function similar to PEG-PD 
alone with the possibility for no risk of rejection. As PEG-PD degrades over time, the outer layer 
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of PEG-NPD is crucial to protect the implanted tissue for allogeneic implantations. The inclusion 
of a degradable core provides the biomimetic microenvironment for the encapsulated ovarian 
tissue while the PEG-NPD outer shell provides protection from the immune cells in the host. In 
the current study, we demonstrated that the ovarian tissue encapsulated in PEG-Dual hydrogel 
remains healthy long-term and restoration of endocrine function occurs as indicated by the 
continuation of the estrous cycle. Corresponding to this observation we observed a significant 
decrease in FSH levels compared to the pre-implantation levels. 
 Synthetic biomaterials, such as PEG hydrogels, are an attractive platform for protein and 
cell delivery because of their low inflammatory index [85,106]. PEG hydrogels are one of the most 
commonly used synthetic materials for islet immuno-isolation, for example. Multiple reports 
demonstrated that islets encapsulated in PEG remained viable and maintained 
normoglycemia[50-52,162]. PEGylated membranes also protected islets from cytokine induced 
inflammation and destruction in vitro [64]. Similarly, the implanted PEG-based capsules with 
encapsulated ovarian tissue described here did not cause an excessive inflammatory reaction. 
Our in vivo studies demonstrated a thin collagen capsule formation, which correlates with a 
minimal inflammatory response characteristic to the inert properties of PEG hydrogels. 
Importantly, we did not observe infiltration of cells or blood vessels from the host, which further 
confirmed the efficiency of the tested hydrogels as establishing a barrier between the tissue and 





3.6 Materials and Methods 
3.6.1 Hydrogel Preparation 
To form the PEG-NPD hydrogel network, 4-arm poly (ethylene glycol) vinyl sulfone (PEG-VS, 
20kDa, JenKem Technology, Beijing, China) is dissolved in a solution containing sterile D-PBS (pH 
7.4) and 0.4 mg/100 µL Irgacure 2959 (Ciba, Switzerland, MW=224.3) to create a concentration 
of 5% w/v. Irgacure 2959 is the photo-initiator of choice as it has been demonstrated to be 
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biocompatible across multiple cell lines [130]. Further, N-vinyl-2-pyrrolidone (NVP) (Sigma-
Aldrich, St. Louis, USA) is added at a final concentration of 0.1%, as NVP has been demonstrated 
to enhance gelation without impacting cytocompatibility [140]. To induce cross-linking, the 
precursor solution is exposed to UV light at a constant intensity (1090 µW/cm2 at a distance of 4 
cm). 
The PEG-PD hydrogels are formed via Michael-type addition through the inclusion of a plasmin 
sensitive tri-functional peptide sequence (Ac-GCYK↓NSGCYK↓NSCG, MW 1525.69 g/mol, >90% 
Purity, CelTek, ↓ indicates the cleavage site).  Briefly, to prepare the gels, 8-arm PEG-VS (40kDa, 
JenKem Technology, Beijing, China) is dissolved in an isotonic HEPES buffer (HEPES 0.05M, 
pH=7.4) to create a final concentration of 5 or 10% w/v and YKNS was added, such that the molar 
ratio of –SH and –VS groups was 1:1.   
The PEG-Dual hydrogel construct contains a proteolytically degradable core with a non-
degradable outer shell. To manufacture the dual PEG hydrogel, a 4 µL degradable core (5% w/v 
PEG-VS) is formed via the aforementioned technique for the degradable 8-arm PEG-VS hydrogel. 
Immediately after 5 minutes of gelation, the degradable hydrogel bead is transferred over and 
placed in the center of a 10 µL bead of the non-degradable precursor solution. The PEG-Dual 
construct is then exposed to a constant intensity (1090 µW/cm2 at a distance of 4 cm) for 6 
minutes creating the non-degradable outer shell of the hydrogel (Figure 3.1).   
3.6.2 Swelling Ratio  
5% w/v PEG-NPD and PEG-PD hydrogels were tested. The PEG-NPD gels were exposed to UV light 
for 6 minutes and were submerged in DPBS for 24 hours. Similarly, the PEG-PD gels formed for 5 
minutes after the introduction of YKNS; thereafter the reaction was quenched by submerging the 
gels in DPBS and remained there for 24 hours. After 24 hours, excess DPBS was removed and the 
swollen mass of the hydrogels was obtained.  Gels were then removed from solution and allowed 
to dry at room temperature. Larger volumes were used to minimize error from weighing.  The 
mass swelling ratio (Qm) was determined by dividing the mass of the swollen gels (Ms) by the 
mass of the dry gels (Md) [120]. 
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3.6.3 Rheology  
The storage modulus (G’) and loss modulus (G”) was investigated for two PEG constructs—5% 
PEG-NPD and 5% PEG-PD. The gels were prepared and swollen in DPBS overnight. A TA HR-2 
rheometer (TA Instruments, USA) equipped with 20 mm parallel plates and a Peltier stage was 
used for this purpose. To ensure the hydrogel was the same size as the geometry, 1 mm thick 
hydrogel slabs were made and a 20mm diameter disc was punched out. A constant strain rate of 
5% was kept for all samples and the storage modulus was obtained by performing an angular 
frequency sweep from 0.1 to 10 rad/s.  
 
3.6.4 Ovariectomies in recipient mice 
Before any surgical procedure, preemptive analgesics were administered. To induce infertility, 
bilateral ovariectomies were performed on 12-16 week old adult female mice (B6CBAF1). All 
procedures (PRO00005750) followed the IACUC guidelines for survival surgery in rodents and the 
IACUC Policy on Analgesic Use in Animals Undergoing Surgery. Briefly, the female was 
anesthetized by isoflurane, Carprofen (Rimadyl, Zoetis, USA) was administered, and a midline 
incision was made in the abdominal wall. Using an abdomen retractor, the intraperitoneal space 
was exposed, and the ovaries were removed, leaving the remainder of the reproductive tract. 
The muscle and skin layer of the abdominal wall were closed with 5/0 absorbable sutures (AD 
Surgical, USA). The animal recovered in a clean warmed cage. Post-surgery, animals received 
analgesia for at least 24 hours or as needed.  
 
3.6.5 Ovarian tissue encapsulation in PEG hydrogels 
Ovaries were collected from 6-8 days old B6CBAF1 female pups. These pups are genetically 
matched to the receiving host. The collected ovaries were transferred to Leibovitz L-15 media 
(Sigma-Aldrich, USA) and dissected into 2 pieces. The ovarian tissue pieces were then transferred 
into maintenance media (a-MEM) and placed into incubator set to 5% CO2. For encapsulation in 
PEG-NPD, the ovarian tissue was transferred into a 10uL droplet of the precursor solution (5% 
w/v PEG-VS, .4% Irgacure 2959, .1% NVP) and exposed to UV light. For encapsulation in the PEG-
PD, the ovarian tissue was transferred into a 10 μL droplet of the plasmin sensitive tri-functional 
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peptide and PEG-VS precursors’ solution. The droplet was allowed to crosslink for 5 minutes and 
then was quenched in maintenance media. For the PEG-Dual hydrogel encapsulation, the tissue 
was first encapsulated in a 4 μL PEG-PD gel and was then placed in the center of a 10 μL bead of 
PEG-NPD and exposed to UV light.  All constructs were imaged immediately after encapsulation 
of the tissue.  
 
3.6.6 Implantation of immuno-isolating capsules in mice 
To investigate the survival and function of the ovarian tissue encapsulated in immuno-isolation 
capsules we implanted subcutaneously immuno-isolating capsules in the ovariectomized mice. 
Briefly, a small incision was made on the dorsal side of the anesthetized mice and two constructs 
(PEG-NPD, PEG-PD, or PEG-Dual) with encapsulated ovarian tissue were implanted 
subcutaneously and the skin was closed using 5/0 absorbable sutures. The mice received 
analgesia for at least 24 hours after surgery or as needed. Mice were euthanized at pre-
determined end time points (7, 30, and 60 days post-operation).  
 
3.6.7 Serum Hormone analysis 
Blood was collected from the lateral tail vein at designated time points with a 5 3/4” glass Pasteur 
pipette up to the time of sacrifice. After collection, all samples were stored at 4°C overnight, then 
centrifuged for 10 minutes at 10,000 rpm and the collected serum was stored at -20°C. The 
samples were analyzed for mouse FSH using a radio-immunoassay (Ligand Assay and Analysis 
Core Facility, University of Virginia Center for Research in Reproduction). The core at the 
University of Virginia used mouse FSH reference preparation AFP5308D for assay standards and 
mouse FSH antiserum (guinea pig; AFP-1760191) diluted to a final concentration of 1:400,000 as 
primary antibody. The secondary antibody is from Equitech-Bio, Inc. and was diluted to a final 
concentration of 1:25.  The radio-immunoassay has a sensitivity of 2.0 ng/ml and less than 0.5% 
cross-reactivity with other pituitary hormones.  When needed, the samples were diluted 5-10 
fold.  
 
3.6.8 Evaluation of the regularity of estrous cycle  
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To assess estrous cycle cessation, vaginal cytology was performed seven days after ovariectomy. 
After transplantation, vaginal cytology was resumed seven days post-operation and was 
performed daily until sacrifice. The transition from leukocytes to cornified cells at least once a 
week was counted as a resumed or continued cycle.  
 
3.6.9 Histological analysis of the retrieved capsules and the encapsulated tissue 
Immediately after retrieval of the immunoisolating capsules from mice, the capsules were fixed 
in Bouin’s fixative at 4°C overnight and transferred and stored in 70% ethanol at 4°C. Constructs 
encapsulating ovarian tissue were then processed, embedded in paraffin, serially sectioned at a 
5 μm thickness, and stained with hematoxylin and eosin. To determine the stage of follicular 
development, follicles were classified as follows:  follicles with one layer of squamous granulosa 
cells around the oocyte were classified as primordial follicles, a single layer of cuboidal granulosa 
cells - primary follicles, two or more layers of granulosa cells - a secondary follicle, and follicles 
with an antral cavity were classified as antral follicles.  
 
3.6.10 Trichrome Staining 
After retrieval of the PEG constructs from the mice, the capsules were fixed in Bouin’s fixative at 
4°C overnight and transferred and stored in 70% ethanol at 4°C. Hydrogels were then processed, 
embedded in paraffin, serially sectioned at a 5 μm thickness, and stained with Masson’s Trichome 




Statistical analysis was performed using the R software. Two-sample t-tests were used to 
evaluate changes in hormone levels and differences in swelling ratio and storage modulus 
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4.2 Abstract 
Premature ovarian insufficiency (POI) is a significant complication of cytotoxic treatments due to 
extreme ovarian sensitivity to chemotherapy and radiation. POI is particularly devastating for 
young girls reaching puberty, because it irreversibly affects their physical and cognitive 
development. Changes occurring during puberty determine their height, bone health, insulin 
responsiveness, lipid metabolism, cardiovascular health and cognition. The only available 
treatment for POI during puberty is hormone replacement therapy (HRT), which delivers non-
physiological levels of estrogen, lacks other ovarian hormones and pulsatility, and is not 
responsive to feedback regulation. Here we report that ovarian allografts encapsulated in a 
hydrogel-based capsule and implanted in ovariectomized mice restore ovarian endocrine 
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function in immune competent mice. Ovarian tissue from BALB/c mice was encapsulated in 
poly(ethylene-glycol) (PEG) hydrogels, with a proteolytically degradable core and a non-
degradable shell. The dual capsules were implanted subcutaneously in immune competent 
ovariectomized C57BL/6 mice for a period of 60 days. Non-encapsulated ovarian allografts 
implanted in a control group sensitized the recipients as confirmed with donor-specific IgG in the 
serum, which increased 26-fold in the 3 weeks following transplantation (p=0.02) and infiltration 
of the graft with CD8 T cells consistent with allo-immunity. In contrast, encapsulation in the Dual 
PEG capsules prevented sensitization to the allograft in all the recipients with no evidence of 
lymphocytic infiltration. In summary, the approach of hydrogel-based immuno-isolation presents 
a minimally invasive and a robust cell-therapy to restore hormonal balance in ovarian 
insufficiency. This report is the first to demonstrate the application of a tunable PEG-based 
hydrogel as an immuno-isolator of allogeneic ovarian tissue to restore endocrine function in 
ovariectomized mice and prevent cell-mediated immune rejection in immune competent mice. 
 
4.3 Introduction 
Childhood cancer survival rates have significantly increased reaching over 80% in 2017 due to 
improved cancer therapies; however, the same life-saving anticancer treatments have led to 
profound health complications in the young survivors [8, 46,47 163-165. One of the most 
significant side effects of the anticancer therapy is ovarian toxicity, leading to impaired gonadal 
function and premature ovarian insufficiency (POI) [19,166]. POI is particularly devastating for 
young girls reaching puberty, because it irreversibly affects their physical and cognitive 
development. Changes occurring during puberty promote the physical and psychologic 
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development into adulthood determining height, bone health, insulin responsiveness, lipid 
metabolism, cardiovascular health and cognition[9-11]. These changes are initiated before 
puberty and orchestrated by the pulsatile secretion of gonadotropin releasing hormone (GnRH) 
and growth hormone (GH) from the hypothalamus, which in turn regulate the release of 
gonadotropins, luteinizing (LH) and follicle-stimulating (FSH) hormones from the pituitary. FSH 
and LH stimulate the ovaries to produce estradiol, androstenedione, progesterone, inhibins A 
and B, activin and follistatin which have systemic effects in many organs and tissues including 
endocrine glands and the regulation of reproductive functions.  
Hormones secreted from the ovary create a negative feedback loop by inhibiting the production 
of GnRH and FSH in the brain, resulting in dynamic oscillating levels of circulating hormones and 
gonadotropins [12-14]. The pulsatility and the circadian rhythm of the hypothalamic-pituitary-
gonadal (HPG) axis are crucial for the development and regulation of a multitude of systems 
including the reproductive, fat, musculoskeletal, cardiovascular, and immune systems [15,16] 
(Figure 1.1). Deficiency of gonadal hormones, as occurs in POI, leads to irreversible imbalance in 
bone development and metabolic abnormalities. Thus, POI inhibits normal puberty causing 
stunted bone growth, abnormal fat distribution and deposition and metabolic changes [19-21]. 
The only available treatment to initiate puberty in girls with POI is hormone replacement therapy 
(HRT). HRT was originally designed to treat postmenopausal symptoms in women and long-term 
safety data in children are scant [44]. For puberty induction HRT is usually initiated with low levels 
of estrogen, followed by increasing doses of estrogen and progesterone combination as a life-
long treatment, until menopause [167]. Unfortunately, HRT delivers only a fraction of ovarian 
hormones, e.g. estrogen and progesterone, at higher doses and at a constant and non-pulsatile 
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rate, which is inadequate to reproduce physiological puberty [45]. Achieving an optimal 
pharmaceutical delivery of all the ovarian hormones is challenging due to the complexity of the 
regulation of the HPG axis. As a result, HRT-mediated puberty in girls with POI results in 
premature closure of the bone growth plate, cessation of bone growth and long-term metabolic 
imbalances [44,46-48].  
On the other hand, cryopreservation of ovarian tissue prior to gonadotoxic treatments followed 
by auto-transplantation is a promising novel experimental approach, which restores fertility and 
ovarian endocrine function. This practice has already resulted in more than 70 babies born to 
identical twin sisters and cancer survivors who cryopreserved their ovaries [31-36]. However, in 
patients with hematological malignancies, this procedure cannot be performed because of the 
risk of introducing malignant cells present in the ovarian tissue, nor would it be helpful for 
patients who did not cryopreserve their tissue before the anti-cancer treatments, which by far is 
the most common case [39,40].  
To mitigate the limitations of HRT and to avoid the risk of cancer recurrence associated with auto-
transplantation of ovarian tissue from subjects with hematologic cancers, we have developed a 
novel strategy to restore ovarian endocrine function. In this study we investigated whether a 
synthetic viscoelastic poly(ethylene glycol vinyl sulfone) (PEG-VS) hydrogel sustains survival and 
function of allogeneic ovarian tissue while preventing rejection.  The capsule provides a 
supportive environment for the encapsulated and implanted tissue, allows diffusion of oxygen 
and nutrients, and physically prevents cell migration. Our earlier studies demonstrated that 
ovarian follicles encapsulated in proteolytically degradable PEG-VS hydrogels developed to the 
antral stages in vitro [146] and in vivo [168]. By keeping the follicular structure intact we 
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attempted to mimic the physiological interactions between the follicular cells and to maintain 
the follicle symphony [169-171]. Additionally, non-degradable PEG-VS matrices conducive for 
tissue encapsulation evoked minimal inflammatory response after implantation in a syngeneic 
mouse model [172-173]. The objective of this study was to investigate whether PEG-VS-based 
capsules support the survival and function of ovarian allografts and protect them from rejection, 
in absence of immune-suppression, in immune competent mice with POI.  
 
4.4 Results 
4.4.1 Macroscopic Evaluation of the Ovarian Implants 
To determine physical integrity, all the encapsulating devices were macroscopically inspected at 
the time of retrieval after 60-day implantation period. The PEG-VS hydrogel-based capsules were 
easily identified and removed from the subcutaneous space. The ovarian tissue was visible at the 
center of the hydrogels. The PEG-based hydrogel capsules with ovarian allografts demonstrated 
minimal interaction with the host tissues at the implantation site (Figures 4.1C, D, G, and H). 
Similar to our findings from the syngeneic implantation44, macroscopically the capsules appeared 
intact and transparent, with no or minimal tissue attached and with no visible blood vessels or 









Figure 4.1: A) Schematic of ovarian tissue encapsulation in PEG-PD.  (B) Ovarian tissue 
encapsulated in PEG-PD before implantation, (C) at time of sacrifice, and (D) after removal. (E) 
Schematic of ovarian tissue encapsulation in Dual PEG.  (F) Ovarian tissue encapsulated in Dual 
PEG before implantation, (G) at time of sacrifice, and (H) after removal. Black arrow indicates 
ovarian tissue, dotted black arrow points to PEG-PD core, white arrow points to the non-
degradable PEG-based shell of the Dual PEG, and white dotted circle in C and G indicates area of 
gel. Drawings used to depict the encapsulation process were created using Adobe Illustrator 
(23.0.3 2019). 
 
In contrast, the TheraCyte device, although intact, was firmly embedded in the subcutaneous 
space of the host. Multiple visible blood vessels surrounded the TheraCyte capsule. These 
findings are consistent with known properties of the PTFE surface promoting protein adsorption, 
interactions with cells and inflammatory changes in the surrounding tissues [101]. Ovarian 
allografts implanted without a device lasted less than 3 weeks after implantation and were 
completely destroyed leaving only intense vascularization due perhaps to immunity and 
inflammation (Supplemental Figure 4.1).  
 
4.4.2 Restoration of Ovarian Endocrine function  
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We evaluated restoration of ovarian endocrine function by measuring the regularity of estrous 
cycles and circulating levels of FSH. In mice of reproductive age (starting at 4 weeks old) regular 
estrous cyclicity corresponds with normal ovarian function and ovulation. Each estrous cycle lasts 
4-5 days and is easily identified by the type of cells present in the vaginal cytology sample.  The 
estrous cycle corresponds to four stages: metestrus, estrus, proestrus and diestrus.  After 
bilateral ovariectomy mice experience persistent diestrus and consistent with absence of ovarian 
function we found no cornified cells in the samples of vaginal cytology for a 2-week period.  
After implantation of allogeneic ovarian tissue encapsulated in PEG-PD, TheraCyte, and Dual PEG 
mice demonstrated an average of 8, 11, and 12 cycles, respectively, over the 60-day implantation 
period (Figure 4.2). All the mice (n=9/9) implanted with non-encapsulated ovarian allograft 
(control group), resumed cyclicity one week after implantation. However, four weeks after the 
implantation all the control mice stopped cycling and returned to the continuous diestrus 
phenotype characteristic of POI, averaging at 5.75 cycles over a 60-day implantation period 
(Figures 4.2A and B). In the PEG-PD group 90% of mice resumed cyclicity in the first week, 
however the rate of cyclicity continuously decreased and at the end of the experiment (60 days), 
only 50% of the mice were still cycling. Implantation of ovarian allograft encapsulated in 
TheraCyte restored cyclicity in 80% of the mice by the first week of implantation. The percentage 
of cycling mice steadily increased and and reached 100% after 4 weeks and remained steady up 
to day 60. Mice that received ovarian allograft encapsulated in Dual PEG experienced a delay in 
resumption of cyclicity compared to other mice, with only 50% of the mice cycling in the first 
week of implantation, 80% by the second and 100% by week 4. By the end of the implantation 
period, 80% of the mice receiving the Dual PEG implants were still cycling (Figures 4.2B, C, D, and 
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E). Mice receiving allogeneic tissue encapsulated in Dual PEG exhibited the highest degree of 
estrous cycle resumption indicated by an average of 12 cycles over the 60 day implantation 
period (Figure 4.2A), which is the expected amount of cycles for a non-menopausal mouse over 
that time span given the observed delay to resume estrous activity. 
 
 
Figure 4.2: Restoration of estrous cycle in mice receiving encapsulated ovarian tissue. (A) Average 
number of cycles over the 60-day implantation period in mice receiving encapsulated ovarian 
tissue in PEG-PD, TheraCyte, and Dual PEG.  Dashed line indicates the expected average number 
of cycles over 60 days, and “a” and “b” indicate significant differences, p<0.05. Representative 
cycles of mice receiving (B) non-encapsulated ovarian tissue, (C) ovarian tissue encapsulated in 




Circulating FSH and estradiol levels in healthy mice are inversely proportional and fluctuate 
during the estrous cycle because estradiol inhibits the production and secretion of FSH via 
negative feedback loop. Circulating FSH levels, serve as reliable surrogates for ovarian endocrine 
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function. Before ovariectomies, mice in all the groups had an average FSH level of 9 ng/mL (n=9 
for the controls, n=10 for the TheraCyte, n=10 for the PEG-PD and n=10 for Dual PEG). Following 
ovariectomies, FSH levels rose significantly to an average of 53 ng/mL, confirming the disruption 
of the HPG axis in all these mice (Figure 4.3). In the control group, where mice received the non-
encapsulated allogeneic ovarian tissue, FSH levels remained elevated during the 60-day 
implantation period, confirming insufficient production and secretion of ovarian hormones 
(Figure 4.3B). In the PEG-PD group, five out of ten mice exhibited a significant decrease of FSH 
levels from 53 ng/mL to 23 ng/mL (p=0.003) by day 60 and were deemed the “functional group” 
(Figures 4.3A and D). The remaining five mice had an average FSH level of 56 ng/mL at day 60 
similar to the levels before implantation (54 ng/mL) indicating absence of ovarian endocrine 
function, e.g. the “non-functional group” (Figures 4.3A and E).  In the TheraCyte implant group, 
seven out of ten mice were “functional” and had an average FSH level of 34 ng/mL after 
implantation compared to 50 ng/mL before implantation, (p=0.02) (Figures 4.3A and H). In three 
mice with TheraCyte implants, however, FSH levels did not decrease and reached an average of 
63 ng/mL at 60 days indicating tissue failure. (Figures 4.3A and I). The Dual PEG group had the 
greatest number of mice demonstrating estrous cyclicity and decreased levels of FSH. Based on 
estrous activity, the encapsulated tissue in Dual PEG was functional in eight of ten mice after 60 
days of implantation. In these eight mice, we observed a significant decrease of FSH levels from 
48 ng/mL to 28 ng/mL (p=0.002) (Figures 4.3A and L). The remaining two mice with the Dual PEG 
implants that stopped cycling by day-60 had an average FSH level of 68 ng/mL at day 60 indicating 





Figure 4.3: Percentage of non-encapsulated ovarian tissue and encapsulated ovarian tissue in 
PEG-PD, TheraCyte, and Dual PEG that remained functional throughout the time course of the 
implantation or became non-functional. Consistent estrous cyclicity and decrease in circulating 
FSH levels qualified as "functional grafts", while absence of cycles and/or FSH levels similar to 
levels in ovariectomized deemed as "non-functional". (B) FSH levels of mice receiving non-
encapsulated allogeneic ovarian tissue. (C) Histological image of non-encapsulated allogeneic 
ovarian tissue after 28 days post implantation. Serum FSH levels of (D, H, L) encapsulated ovarian 
tissue that remained functional or (E, I, M) became non-functional during the time course of the 
implantation in PEG-PD, TheraCyte, and Dual PEG, respectively. * indicates statistical significance, 
p<0.05, and n.s. represents not significant. Histological images of “functional” (F,J, N) or (G, K, O) 
“non-functional” encapsulated ovarian allografts in PEG-PD, TheraCyte, and Dual PEG, 
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respectively, and retrieved 60 days after implantation. ‘-14’ corresponds to one day before 
ovariectomy and 2 weeks prior to implantation. ‘-1’ corresponds to two weeks after ovariectomy 
and 1 day prior to implantation. (N inset) Ovarian allografts containing healthy ovarian follicles 
were completely encapsulated in PEG through 60 days implantation. (P) indicates PEG, and (T) 
represents TheraCyte. Scale bars: 500μm(F), 200μm  (C, O), 100μm (G, N inset),  50μm (J,K, N). 
 
 
To evaluate the follicular development of the implanted ovarian tissue we analyzed tissue 
sections explanted at 60 days after implantation by histological analysis. In controls transplanted 
with non-encapsulated ovarian allografts we observed no ovarian follicles at the site of 
implantation, consistent with graft rejection (Figure 4.3C). In contrast, we observed all stages of 
ovarian follicle development (up to the antral stage) in sections obtained from the functional 
PEG-PD, TheraCyte and Dual PEG encapsulated allografts (Figures 4.3F, J, and N) indicating that 
those devices support follicle development. Multiple antral follicles were not observed in any of 
the groups. As expected, there were no structurally healthy-looking ovarian follicles in sections 
from non-functional PEG-PD, TheraCyte and Dual PEG implants (Figures 4.3G, K, and O).   
 
4.4.3 Ovarian Allograft Immunity  
Efficacy of encapsulation to sustain ovarian allograft function depends on preventing host 
sensitization and/or destruction by allo-immunity effectors. Allo-specific immunity is manifested 
by the production of specific-antibodies and by infiltration of grafts by lymphocytes. To 
determine if encapsulated ovarian allografts evoked immunity we measured circulating allo-
specific IgM and IgG by flow cytometry.  Figures 4.4A and 4.4B demonstrate that donor-specific 
IgG increased 26 fold in the 3 weeks following transplantation (p=0.02) of non-encapsulated 
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ovarian allografts. As hypothesized, all of the ovarian allografts evoked allo-specific immunity 
(n=9/9) (Figures 4.4A and B). Immuno-pathology examination of the grafts revealed infiltration 
with CD8 T cells consistent with allo-immunity (Figure 4.4C). In contrast, encapsulation of the 
ovarian tissue in Dual PEG hydrogels blocked sensitization in all the recipient mice. None of the 
mice receiving ovarian allograft encapsulated in Dual PEG devices (n=10/10 immunoisolating) 
produced allo-specific IgG up to 60 days after transplantation, at explant(Figures 4.4D and E). 
Consistent with the absence of allo-immunity, immunopathology analysis of the ovarian 
allografts encapsulated in the Dual PEG device showed no evidence of lymphocytic infiltration. 
(Figure 4.4F). These results indicate that the Dual PEG device has immune-isolating properties 
and suggests non-immunologic reasons, such as primary tissue-driven failure, for the absence of 
ovarian function in two Dual PEG device encapsulated allografts.   
 
Figure 4.4: A) Representative flow cytometry plots reflecting binding of serum allo-specific 
antibodies from recipients of non-encapsulated grafts, to donor cells. Y-axis, donor-specific IgG; 
X-Axis, donor-specific IgM.  The mean fluorescence intensity (MFI) for donor specific IgG reflects 
the average of values read on the Y-Axis; the MFI for donor specific IgM reflects the average of 
values read on the X-Axis  (B)  Graph depicts the average MFI±SD of allo-specific IgG in mice 
receiving non-encapsulated allogeneic ovarian tissue. * indicates statistical significance (p<0.05) 
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(C) Immunohistochemical staining of CD8+ cells present in the non-encapsulated allograft. (D) 
Representative flow cytometry plots reflecting binding of serum allospecific antibodies, obtained 
from recipients of dual PEG-encapsulated grafts, to donor cells;  and (E) Average MFI±SD of allo-
specific IgG in mice receiving allogeneic ovarian tissue encapsulated in Dual PEG.  (F) 
Immunohistochemical staining of CD8+ cells in the dual PEG-encapsulated allograft. Scale bars: 
100 μm(C), 200 μm(F). Inability to detect circulating allo antibodies and absence of CD8+ T cells 
in the allografts were deemed the capsules "immunoisolating”. 
 
 
Ovarian allografts encapsulated in degradable capsules, PEG-PD, and Theracyte produced mixed 
results in terms of ovarian function and allo-immunity (Figure 4.5). Encapsulation in PEG-PD 
hydrogels was less effective at preventing sensitization than encapsulation with in Dual PEG 
hydrogels. Three out of 10 mice with allografts encapsulated in PEG-PD hydrogels had allo-
specific IgG and CD8 T lymphocytes were detected in the excised graft. (Figures 4.5D, E and F). In 
these mice, follicles were not observed and little viable tissue remained after 60 days, 
corroborating the tissue was not functional. Of the 10 mice implanted with ovarian allografts 
encapsulated in TheraCyte, three mice developed a an allo-specific IgM-IgG response and had 
CD8 lymphocytes in the graft (Figures 4.5J, K and L). In summary we show that Dual PEG devices 
allow long-lived function of ovarian allographs while blocking sensitization of the host. Dual PEG 
devices were superior to TheraCyte or PEG-PD at maintaining function of the enclosed tissue 





Figure 4.5: Representative flow cytometry plots reflecting binding of serum allo-specific 
antibodies from recipients of allogeneic ovary tissue encapsulated in PEG-PD or TheraCyte where 
the tissue (A,G) remained functional or (D,J) failed during the implantation period. Average 
MFI±SD of allo-specific IgG levels in mice receiving PEG-PD and TheraCyte where the tissue (B,H) 
remained functional or (E,K)  failed during the implantation period. Immunohistochemical 
staining of CD8+ cells present in mice receiving PEG-PD and TheraCyte where the tissue (C,I) 



























In this study, we used PEG based hydrogel capsules to enclose and implant ovarian allografts in 
immune competent ovariectomized mice to restore the ovarian endocrine function in the hosts. 
We had demonstrated earlier that the proteolytically degradable synthetic PEG hydrogels (PEG-
PD) cross-linked with protease sensitive peptides promote the survival and growth of 
encapsulated murine primordial ovarian follicles in a syngeneic mouse model of POI [146, 168]. 
Our results show that encapsulation with PEG-PD and Dual PEG hydrogel sustain physiological 
development of ovarian allograft tissue in vivo. Dual PEG implants proved to be superior at 
maintaining function in the long run because they maintain structural integrity for longer that 
PEG-PD.   
While the degradable PEG-PD hydrogels sustain ovarian follicle growth in a syngeneic model, we 
hypothesized that degradation of these hydrogels cannot support long-term survival and 
function of ovarian allografts because the immune cells from the host would eventually reach 
the allograft causing rejection. In fact, 60 days post implantation, 50% of PEG-PD ovarian 
allografts were “non-functional” similar to non-encapsulated allografts with elevated levels of 
circulating allo-specific IgG. We hypothesize the degradable matrix of PEG-PD resulted in larger 
pores over time, which allowed sensitization to occur and allowed host immune cells to infiltrate 
the hydrogel and cause further damage to the encapsulated tissue. Interestingly, only 50% of the 
hydrogels degraded enough to allow infiltration of the immune cells while the other 50% 
remained functioning with no detectable sensitization. These findings suggest that the kinetics 
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of degradation of the PEG-PD hydrogels determines variable host responses and may introduce 
variability.  
To combine the benefits of hydrogels at sustaining ovarian function and a more robust shell to 
avoid sensitization and early graft demise, we developed a Dual PEG hydrogel encapsulating 
system with a proteolytically degradable core to allow follicular development and a non-
degradable outer shell to act as a barrier against the host immune system. In a syngeneic study, 
Dual PEG hydrogels implanted with ovarian tissue caused minimal inflammatory response and 
supported ovarian follicle survival and development, and promoted restoration of endocrine 
function in ovariectomized mice for at least 60 days [172]. In the current study, we investigated 
whether Dual PEG hydrogels protected the encapsulated ovarian allograft from the host immune 
system and restored ovarian endocrine function. The dual capsule was compared to TheraCyte, 
a commercially available immunoisolator experimentally used for allogeneic islet 
transplantation. Encapsulated islets have been shown to survive in TheraCyte in allogeneic 
models, however in human clinical trials, insulin independence was not achieved [174]. Recently, 
we showed that TheraCyte supports implantation of ovarian allograft for 21 days and protects 
the tissue from rejection [144]. TheraCyte immuno-isolating properties depend on a specialized 
construction involving two membranes: the outer membrane promotes vascularization and the 
inner membrane prevents infiltration of immune cells. In accord, we found the retrieved 
TheraCyte devices to be significantly more vascularized compared to Dual PEG hydrogels that 
presented with minimal interactions with the host. However, the design of the TheraCyte device 
and the augmented vascularization did not improve the survival or function of ovarian allograft 
compared to Dual PEG hydrogels, suggesting that vascularization of the device plays a less 
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significant role for ovarian follicles compared to other tissues, such as islets, which are more 
sensitive to hypoxia. Importantly, the modular design of the Dual PEG capsule can support 
significantly greater number of tissue constructs, compared to the TheraCyte’s rigid pouch. 
Lastly, Dual PEG capsules shielded the allogeneic ovarian tissue against sensitization. Inclusion of 
the non-degradable shell adds immune-protection, which is not observed with the PEG-PD alone.   
Of those mice that did not experience rejection, a significant decrease in the levels of FSH 
compared to the preimplantation FSH levels was observed. This decrease in FSH levels is due to 
the implants’ ability to produce estrogen thereby restoring the HPG axis in the ovariectomized 
mice. We used ovaries from 6-8 days old BALB/c mice due to the presence of a higher proportion 
of primordial/primary follicles, which could withstand the initial hypoxic environment post-
transplantation. Following transplantation, a restoration of estrous activity could be due to the 
activation of the implanted follicles and recruitment into the growing pool with every estrous 
cycle. Growing follicles were consistently present in the histological analysis of the encapsulated 
ovarian implants in mice showing decreased FSH levels.    
Sittadjody et al [175, 176] reported that multilayered constructs prepared with cells isolated from 
ovarian tissues and encapsulated in alginate secreted sex hormones in vitro and restored HPG 
axis in syngeneic studies in rats. Importantly, this study demonstrated superior short- and long-
term outcomes from delivery of ovarian cells compared to pharmacological HRT (pHRT) in 
ovariectomized rats, which may have important clinical implications. In the current study we 
investigated whether the allogeneic ovarian tissue was immune-protected by measuring allo-
specific antibodies and T-cell infiltration of grafts. In contrast to the non-encapsulated or failed 
ovarian allografts that presented with elevated levels of allo-specific IgG and CD8+ lymphocyte 
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graft infiltration, allo-specific IgG in the sera of mice receiving the dual encapsulated ovarian 
tissue were undetectable and there was no lymphocyte infiltration of the implants. Mice with 
elevated allo-specific IgG and CD8 T cells corresponded with the failure to restore HPG axis. These 
mice had elevated FSH levels indicating that the implanted allogeneic ovarian tissue was rejected 
by the host immune system.  
In summary, the approach of hydrogel-based immuno-isolation presents a minimally invasive and 
a robust way to restore hormonal balance in mice. The basic biology and the factors regulating 
folliculogenesis are similar in mouse and humans, however further comprehensive and 
mechanistic studies in large animals will establish the importance of vascularization and the 
advantages over pharmacological regimens currently available.  Because, this cell-based therapy 
delivers hormones in a pulsatile self-regulating manner, adverse side effects observed with 
pharmacological treatments can be avoided. This report is the first to demonstrate the feasibility 
and application of a tunable PEG-based hydrogel to encapsulate allogeneic ovarian tissue and to 
restore endocrine function in ovariectomized mice preventing rejection. Future non-human 
primate studies will be conducted to assess the ability of the Dual PEG capsule to support corpus 
luteum formation; capsule modification may be required to promote vasculature formation and 
greater diffusion of necessary metabolites and nutrients without the risk of immune rejection. 
 
4.6 Materials and Methods 
4.6.1 Experimental Design 
Adult cycling female mice (C57BL/6) underwent bilateral ovariectomies to induce POI. Ovaries 
from BALB/c 6-8 days old mice were encapsulated in (i) a proteolytically degradable PEG-VS 
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hydrogel (PEG-PD) (Figure 4.1A), (ii) a dual PEG-VS hydrogel (Dual PEG) containing a 
proteolytically degradable PEG-VS core with a non-degradable shell and subcutaneously 
implanted for 60 days (n=10 recipient mice) (Figure 4.1E) and (iii) TheraCyte, a commercially 
available poly-terephthalate-ethylene (PTFE) pouch. TheraCyte was used as a control for 
immune-protective capabilities as it has been used towards islet transplantation. All the 
encapsulated ovarian allografts were implanted subcutaneously for 60 days (n=10 recipient 
mice). In the control group, non-encapsulated allogeneic ovaries from 6-8 days old BALB/c mice 
were subcutaneously implanted in C57BL/6 mice (n=9) for 28 or 60 days. The number of donor 
mice matched the number of recipient mice with each recipient mouse receiving 2 BALB/c 
ovaries.  
 
4.6.2 Ovariectomies in Recipient Mice 
The IACUC guidelines for survival surgery in rodents and the IACUC Policy on Analgesic Use in 
Animals Undergoing Surgery were followed for all the procedures. Animal experiments for this 
work were performed in accordance with the protocol approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University of Michigan (PRO00007716). 
Bilateral ovariectomies were performed on adult female mice (C57BL/6) aged 12–16 weeks. The 
mice were anesthetized by isoflurane. Carprofen (5mg/kg. body weight, Rimadyl, Zoetis) was 
administered subcutaneously for analgesia. The intraperitoneal space was exposed through a 
midline incision in the abdominal wall secured using an abdominal retractor. The ovaries were 
removed, and the muscle and skin layer of the abdominal wall were closed with 5/0 absorbable 
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sutures (AD Surgical). The mice recovered in a clean warmed cage and received another dose of 
Carprofen 12 hours post recovery or as needed.   
 
4.6.3 Collection of Donor Ovaries 
Ovaries from 6 to 8 days old BALB/c mice were collected and transferred to Leibovitz L-15 media 
(Sigma-Aldrich, USA). The ovaries were dissected into 2–4 pieces and transferred in the 
maintenance media (α-MEM, Gibco, USA) and placed in the CO2 incubator for further 
manipulation.  
 
4.6.4 Hydrogel Preparation and Ovarian Tissue Encapsulation 
To prepare PEG-PD hydrogels, 8-arm PEG-VS (40kDa, Jenkem Technology, Beijing, China) was 
cross-linked with a plasmin sensitive tri-functional peptide sequence (Ac-GCYK↓NSGCYK↓NSCG, 
MW 1525.69 g/mol, >90% Purity, CelTek, ↓ indicates the cleavage site of the peptide). Dual PEG 
hydrogels were prepared using 4-arm PEG-VS 20kDa, Jenkem Technology) with Irgacure 2959 
(Ciba, Switzerland, MW=224.3) and 0.1% N-vinyl-2-pyrrolidone (Sigma-Aldrich, St. Louis, USA). 
The detailed protocol is described in Day et al. [172] donor ovaries were collected from 6-8 days 
old BALB/c mice. The collected ovaries were transferred to Leibovitz L-15 media (Sigma-Aldrich, 
USA) and dissected open. The ovarian tissue was then transferred into maintenance media (a-
MEM; Gibco, USA), kept at 37˚C and 5% CO2. For encapsulation in the PEG-PD, the ovarian tissue 
was transferred into a 10 µL droplet of the plasmin sensitive tri-functional peptide and PEG-VS 
precursors’ solution. The droplet was allowed to crosslink for 5 minutes and then was quenched 
in maintenance media (Figure 4.1A). For Dual PEG hydrogel encapsulation, the tissue was first 
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encapsulated in a 4 µL PEG-PD hydrogel and was then placed in the center of a 10 µL bead of 
PEG-VS precursor solution (5% w/v PEG-VS, .4% Irgacure 2959, 0.1% NVP) and exposed to UV 
light for 6 minutes(Figure 4.1E).  All constructs were imaged immediately after encapsulation of 
the tissue (Figures 4.1B and F).  
 
4.6.5 Ovary Encapsulation in TheraCyte 
The port of the TheraCyte was widened using a Hamilton syringe without compromising the 
integrity of the TheraCyte wall. Using a mouth pipette, the ovarian pieces were aspirated into the 
pipette and inserted into the TheraCyte. To verify whether all the ovarian pieces were in the 
TheraCyte, the transparent plastic port and the pipette were inspected under the stereo 
microscope. The long port tube was shortened and sealed by melting the plastic to prevent 
leakage of the ovarian pieces and invasion of the host cells. Each TheraCyte contained ovarian 
tissue from two ovaries, and each recipient (C57BL/6) was implanted with one TheraCyte. 
 
4.6.6 Subcutaneous Implantation  
A small incision was made on the dorsal side of the anesthetized mice (C57BL/6) and the 
immunoisolators (PEG-PD, Dual PEG and TheraCyte) with the ovarian tissue were implanted 
subcutaneously. The skin was closed using 5/0 absorbable sutures. The mice received Carprofen 
for analgesia for at least 24 hours after surgery or as needed. Mice were monitored for two 
months and euthanized at the end of the experiment. Control mice received empty PEG-VS 
hydrogels or non-encapsulated ovarian tissue (BALB/c, without a capsule) that were implanted 
subcutaneously for 28 days. 
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4.6.7 Serum Hormone analysis 
Every two weeks blood was collected from the lateral tail vein at set time points, up to 1% of the 
total volume of the blood with a 5 3/4” glass Pasteur pipette. At the time of sacrifice, blood was 
collected via cardiac puncture. Following blood collection, samples were stored at 4°C overnight, 
then centrifuged for 10 minutes at 10,000 rpm and the separated serum was stored at -20°C. The 
samples were analyzed for mouse FSH using a radio-immunoassay (Ligand Assay and Analysis 
Core Facility, University of Virginia Center for Research in Reproduction).  
 
4.6.8 Vaginal Cytology 
Daily vaginal cytology was used to establish presence of estrous cycle following ovariectomies 
and restoration of ovarian endocrine function after implantation of ovarian allografts. The loss of 
estrous cycle as a result of ovariectomies was confirmed by a persistence of leukocytes, which 
also correlated with elevated levels of circulating follicle stimulating hormone (FSH). The cyclical 
transition of cells from leukocytes to cornified and then to nucleated cells signaled resumption 
of normal estrous cyclicity and restoration of ovarian endocrine function.  
 
4.6.9 Histological analysis of the retrieved devices and the encapsulated ovarian tissue 
Following sacrifice, the immunoisolating devices were retrieved from mice, fixed in Bouin’s 
fixative at 4°C overnight, transferred and stored in 70% ethanol at 4°C. After processing, samples 
were embedded in paraffin, serially sectioned at 5 μm thickness, and stained with hematoxylin 
and eosin.  
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4.6.10 Flow Cytometry 
Serum allo-antibody titer measurements were performed using flow cytometry before and after 
implantation and reported as mean fluorescence intensities (MFI) for the highest dilution 
showing fluorescence detectable above background (non-immune serum from a non-implanted 
mouse) in immunized mice (positive controls implanted with allogeneic ovaries without a device). 
Thymocytes were isolated from BALB/c mice and incubated with serially diluted recipient serum 
for 30 minutes at 4˚C. Antibodies bound to the thymocytes were detected by Cy5-conjugated 
goat anti-mouse IgG (1:250 dilution, 1030-15, Southern Biotech) and Alexa Fluor 488-conjugated 
goat anti-mouse IgM (1:250 dilution, 1020-30, Southern Biotech) for 30 minutes at 4˚C and 
analyzed in a BD FACSCanto II (BD Biosciences, Franklin Lakes, NJ). The mean fluorescence 
intensities (MFI) in the APC-channel (measuring bound IgG) and FITC channel (measuring bound 
IgM) were determined with FlowJo 10 software (FlowJo, LLC, Ashland, OR). 
 
4.6.11 Immunohistochemistry for T cells 
To analyze T cell infiltration following subcutaneous implantation with PEG-PD, Dual PEG, and 
TheraCyte, paraffin-sectioned slides were stained to identify CD4 and CD8+ cells. First, sections 
were deparaffinized with Xylene and rehydrated. The slides were incubated in antigen retrieval 
buffer, pH9.0 (ab94681, Abcam) for 20 minutes at 97°C and additional 20 minutes at room 
temperature to cool down. Next, the slides were incubated with KPL Universal Block (5560-0009, 
Sera-Care) to block non-specific binding sites for 30 minutes at room temperature. The sections 
were incubated at room temperature for 1 hour with primary antibodies: rabbit monoclonal anti-
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mouse CD4 antibody (1:1000 dilution, ab183685, Abcam), rabbit polyclonal anti-mouse CD8 
antibody (1:500 dilution, ab203035, Abcam). The slides were subsequently incubated at room 
temperature with secondary antibodies: goat anti-rabbit Ig (1:100 dilution for 15 minutes, 4010-
05, Southern Biotech) for CD4 and goat anti-rabbit (1:50 dilution for 30 minutes, 4010-05, 
Southern Biotech) for CD8. Diaminobenzidine (BDB2004L, Betazoid DAB Chromogen kit, BioCare 
Medical) was used as a chromogen for 10 minutes at room temperature. Hematoxylin (220-102, 
Fischer Scientific) was used as a counterstain. For negative-controls, paraffin sections were 
incubated without the primary antibody. To assess presence or absence of CD8+ cells, 12 sections 
from the front, middle, and end of each specimen were examined, to represent the full thickness 
of the implant. 
 
4.6.12 Statistics 
Statistical analysis was performed using the R software. R version 3.1.2 (2014) was utilized. 
Significance was determined by Welch’s two-sample t-test. To determine whether there was a 
significant difference between the ability of capsule to prevent rejection or not compared to 
controls, Pearson’s Chi-squared test was used. The two main outcomes of the test were 1) 
functionality of the tissue and 2) the ability of the capsule to minimize the exposure of the 
allograft to the recipient’s immune system and minimize infiltration of the immune cells into the 
capsule. 1) Consistent estrous cyclicity and decrease in circulating FSH levels qualified as 
“functional grafts”, while absence of cycles and/or FSH levels similar to levels in ovariectomized 
deemed as “non-functional”. 2) Inability to detect circulating allo-antibodies and absence of CD8+ 
T cells in the allografts were deemed the capsules “immunoisolating”. Mice that presented with 
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elevated levels of FSH, yet had undetectable levels of circulating allo-antibodies were classified 
as having a primary failure of the ovarian tissue for non-immunological reasons. 
 
 











Supplemental Figure 4.1: (A) Non-encapsulated allogeneic ovarian tissue and (B) TheraCyte 





















Immuno-isolating Dual Poly(ethylene glycol) Capsule Prevents Cancer Cells from 
Spreading Following Mouse Ovarian Tissue Auto-transplantation 
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5.2 Abstract 
For female cancer survivors, premature ovarian insufficiency (POI) is a common complication of 
anticancer treatments. Ovarian tissue cryopreservation before treatment, followed by auto-
transplantation after remission is a promising option to restore fertility and ovarian endocrine 
function. However, auto-transplantation is associated with the risk of re-introducing malignant 
cells harbored in the stroma of the ovarian autograft. To mitigate this risk, we investigated in this 
pilot study whether an immuno-isolating dual-layered poly(ethylene glycol) (PEG) capsule can 
retain cancer cells, while supporting folliculogenesis. The dual PEG capsule loaded with 1,000 4T1 
cancer cells retained 100% of the encapsulated cells in vitro for 21 days of culture. However, a 
greater cell load of 10,000 cells/capsule led to capsule failure and cells’ release. To assess the 
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ability of the capsule to retain cancer cells, prevent metastasis, and support folliculogenesis in 
vivo we co-encapsulated cancer cells with ovarian tissue in the dual PEG capsule and implanted 
subcutaneously in mice. Control mice implanted with 2,000 non-encapsulated cancer cells had 
tumors formed within 14 days and metastasis to the lungs. In contrast, no tumor mass formation 
or metastasis to the lungs was observed in mice with the same number of cancer cells 
encapsulated in the capsule. Our findings suggest that the immuno-isolating capsule may prevent 
the escape of the malignant cells potentially harbored in ovarian allografts and, in the future, 
improve the safety of ovarian tissue autho-transplantation in female cancer survivors. 
 
5.3 Introduction 
Premature ovarian insufficiency (POI) is a common complication of anticancer treatments, such 
as chemo- and radio therapy, due to ovarian sensitivity to these treatments [164, 166]. In recent 
years, the survival rate of children with cancer has increased to over 85% due to the development 
of modern anticancer therapies; however, these patients experience long-term health problems 
far after they’re cancer-free [177,178]. Female cancer survivors with POI suffer from sterility and 
a myriad of problems associated with ovarian hormone deficiencies, such as premature 
osteopenia, muscle wasting, and cardiovascular disease [179]. Fertility preservation options, such 
as oocyte and embryo cryopreservation, are available for post-pubertal adolescent girls and 
young women. However, these options are not available for prepubertal patients [180].  
For prepubertal patients, an experimental option of cryopreservation of ovarian tissue before 
exposure to toxic treatments, and subsequent auto-implantation after remission would restore 
both fertility and ovarian endocrine function [38,161,181-189]. Ovarian tissue auto-
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transplantation has resulted in close to 100 births to date [190]. Importantly, ovarian tissue auto-
transplantation is associated with a significant risk of re-introducing malignant cells harbored in 
the autologous transplant, particularly in the case of hematologic malignancies, which is common 
in children [39-41, 161]. A few patient cases of ovarian auto-transplantation in Europe resulted 
in relapse and multiple experiments in mice further confirmed the risks associated with this 
approach [39-43]. A potential option for these patients that would provide minimize the risk of 
cancer re-introduction is allotransplantation of donor ovarian tissue [144,172,173], however this 
option would solely provide ovarian endocrine function restoration and not provide an option 
for biologic fertility preservation. 
To date, there is no standard universal protocol to ensure the absence of malignant cells in 
ovarian autografts removed from the patient prior to anti-cancer treatments. Several groups 
attempted to identify and quantify cancerous cells present in ovarian tissue using histology or 
PCR [19,21-22]. However, challenges in identifying cancer cells harbored in the tissue prevent 
clinical translation of this approach, especially in the case of hematologic malignancies, such as 
acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin’s lymphoma, where 
ovarian involvement can be high. For example, even when histological analysis showed no 
evidence of malignant cells, an increase in cancer biological markers was shown through PCR 
analysis [39,41,42]. It’s recommended that the use of molecular markers be used to detect 
malignant cells, because solely histology is not sufficient; however, not all cancers display specific 
genetic markers that can be detected via PCR making tissue characterization very difficult [43]. 
Additionally, there is no consensus as to which markers are most sufficient to detect malignant 
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cells present in ovarian tissue, dependent on the strain of cancer [42], further complicating the 
classification of the ovarian tissue as safe.  
We hypothesized that immuno-isolation may mitigate the risk of re-introducing malignant cells 
during ovarian tissue auto-transplantation. Immuno-isolation uses a semi-permeable membrane 
to encapsulate foreign allogeneic tissue and allow free diffusion of nutrients and metabolites, 
while preventing the infiltration of immune cells attenuating the immune response. Previously, 
we have shown that an immuno-isolating multilayered poly(ethylene glycol) (PEG) capsule 
supports ovarian tissue in vivo and did not elicit a measurable inflammatory response [172,173]. 
The immuno-isolating capsule contains a degradable core that is conducive for ovarian tissue 
survival and a non-degradable shell, which acts as the immuno-protective barrier. We have 
demonstrated that allogeneic ovarian tissue does not elicit a host immune response when 
encapsulated in the Dual PEG capsule, and the capsule prevents lymphocytic infiltration, allowing 
for allogeneic transplantation of ovarian tissue. Because the immuno-isolating capsule prevents 
infiltration of immune cells from the host towards the allograft through the barrier, we 
hypothesized that the capsule will contain cancer cells harbored in the ovarian tissue and will 
prevent their escape. Thus, encapsulating ovarian autografts in the immuno-isolating capsule 
mitigates the risk of cancer relapse or metastasis. Here we investigated the ability of the immuno-
isolating capsule to prevent spreading of the cancer cells in vitro and in vivo, preventing tumor 
mass formation and metastasis, while maintaining the function of ovarian tissue. BALB/c derived 
4T1 breast cancer cells originate from an invasive cancer line and were chosen to investigate the 
effectiveness of the capsule to retain cancerous cells and detect metastasis in a scenario when 
cancer cells escape the capsule and invade the host. This work aims to mitigate the risk of ovarian 
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tissue auto-transplantation and provide female cancer survivors experiencing POI with safer 
options to restore fertility and hormonal balance. 
 
5.4 Results 
5.4.1 Encapsulation of cancer cells in Dual PEG prevents cancer cell escape in culture 
First, we evaluated the ability of the immuno-isolating capsule to retain cancer cells and prevent 
their migration and/or proliferation in the respective capsule. To determine whether cancer cells 
escaped from the gels, the cell-containing capsules were placed in non-tissue treated well plates 
and imaged every other day. One thousand and 10,000 cells per gel were encapsulated in both 
PEG-MT, a degradable capsule, and Dual PEG, a capsule containing a degradable core and non-
degradable shell. For Dual PEG, cells were only encapsulated in the degradable core component 
of the capsule, which would mimic the clinical scenario where only the ovarian tissue surrounded 
by a degradable hydrogel contains cancer cells. Cells encapsulated in PEG-MT escaped the 
capsule by Day 6 in 100% of the gels for both the 1,000 and 10,000 cell/gel groups (n=5) (Figure 
5.1 A-C,H).  
With the inclusion of the non-degradable shell in the case of Dual PEG, cell escape out of the 
capsule significantly decreased (p<0.05). Dual PEG gels with 1000 cells encapsulated in its core 
showed 0% escape through 21 days culture (Figure 5.1 D-H). When the cell concentration was 
increased and 10,000 cells were encapsulated in PEG-Dual, cells did escape with 80% of gels 
showing some extent of cell escape by day 21. However, the kinetics of cell escape was 
attenuated compared to PEG-MT, as at day 2, 100% of Dual PEG gels containing 10,000 retained 
the cells in the core and at day 6, 80% showed complete retention (Figure 5.1H). This 
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demonstrated that the inclusion of the non-degradable shell greatly hinders cell migration and 





Figure 5.1: in vitro encapsulation of 1000 4T1 cells in (A–C) PEG-MT and (D–G) Dual PEG. (H) 
Percentage of hydrogels (n = 5) for each group that retained encapsulated cancer cells through 
21 days of culture. White arrow indicates border of PEG-MT hydrogel, red arrow indicates 
escaped cancer cells, and black arrow indicates border of non-degradable shell in Dual PEG. * 
indicates statistical significance (p < 0.05). 
 
 
5.4.2 Encapsulation of cancer cells in Dual PEG prevents spreading and metastasis in vivo 
To evaluate the Dual PEG capsule’s ability to retain cancerous cells in vivo, cells were co-
encapsulated with mouse ovarian tissue and implanted subcutaneously in a BALB/c mouse 
model. The cancer cell line, mouse ovarian tissue, and recipient mouse strain were all the same 
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to negate any possible immune response. Either, 1,000 or 10,000 cells, were encapsulated in Dual 
PEG with 6-8 day old ovarian tissue (Figure 5.2A,B). Each mouse (n=5 per group) received two 
identical capsules. For positive controls, a cell suspension containing either 2,000 or 20,000 4T1 
cells was injected subcutaneously. When 2,000 cells were injected, proliferation was exhibited in 
5/5 mice with radiance increasing from 3.56E4 to 6.02E9 photons/sec from day 0 to 14 (Figure 
5.2C-E,O). By Day 14, all mice had to be sacrificed as a tumor mass had formed on the dorsal side 
and ulceration started to occur (Figure 5.3A). In the mice receiving 20,000 non-encapsulated 
cancer cells, proliferation and tumor mass formation was observed in 4/5 mice (Figure 5.2F-H, 
O). Similar to the 2,000 cell group, the mice exhibited ulceration by day 14 and had to be 
sacrificed. The cells proliferated as shown by the significant increase of radiance from day 0 to 
day 14 (Figure 5.2O). To confirm the extracted tumor masses were in fact the labeled 4T1 
cells, bioluminescence imaging was used. All tumors exhibited bioluminescence indicating 
the mass was cancerous and derived from the injected 4T1 cells (Figure 5.3B).  
When 1,000 cells were encapsulated in Dual PEG and two capsules were implanted per mouse 
(total of 2,000 cells per mouse), 0 out of 5 mice exhibited a tumor mass formation through 28 
days as shown through a non-significant change in radiance from day 0 to day 28 (Figure 5.2I-K, 
O). From IVIS imaging, it appeared that all cancer cells were retained within the capsule. To 
confirm, when hydrogels were extracted, the capsules as well as the surrounding tissue were 
imaged via bioluminescence and only the inner core of the hydrogels showed luminescent signal 
(Figure 5.3E). Additionally, upon macroscopic evaluation, the hydrogels containing cancer cells 
and ovarian tissue looked exactly as they did when implanted on day 0 and no tumor mass was 
present (Figure 5.3D). For the mice receiving 10,000 cancer cells co-encapsulated with ovarian 
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tissue in Dual PEG ( 2 devices, 20,000 cancer cells total per mouse), 4/5 mice demonstrated tumor 
formation as shown through a significant increase in radiance over the 28 day implantation 
period (Figure 5.2 L-O). Upon extraction, a tumor mass localized to the hydrogels was evident as 
the hydrogel appeared cloudy in appearance (Supplemental Figure 5.1). However, although the 
10,000 cancer cells proliferated over the 28 day implantation period, the cells remained localized 
to the hydrogel, as the hydrogel showed a high level of radiance, indicating the cancer cells were 
present within the capsule, itself (Supplemental Figure 5.1).  
 
 
Figure 5.2: Microscopic image of (A) 1000 and (B) 10,000 4T1 cells co-encapsulated with BALB/c 
ovarian tissue in Dual PEG. Magnification 5×. Bioluminescent imaging of mice receiving (C–E) 
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2000 non-encapsulated 4T1 cells, (F–H) 20,000 non-encapsulated 4T1 cells, (I–K) 2 Dual PEG 
capsules both encapsulating 1000 4T1 cells and ovarian tissue and (L–N) 2 Dual PEG capsules both 
encapsulating 10,000 4T1 cells and ovarian tissue. (O) Average radiance of mice receiving control 
non-encapsulated cells or cells encapsulated in Dual PEG (n = 5 per group). White arrow indicates 
border of degradable PEG-PD core, black arrow indicates border of non-degradable shell in Dual 
PEG, and blue arrow indicates ovarian tissue. * indicates statistical significance (p < 0.05). 
 
 
To assess metastasis, organs such as the brain, ovaries, lungs, spleen, blood, and liver were 
explanted and examined for the presence of cancerous cells through bioluminescent imaging. In 
the 2,000 and 20,000 cell control groups, radiance was exhibited in all the lungs, indicating 
cancerous cells metastasize to the lungs, which is expected for this cell line (Figure 5.3C). When 
4T1 cells were encapsulated in Dual PEG, none of the extracted organs in any animal exhibited 
bioluminescence indicating the encapsulation prevented metastasis of cancerous cells to the 
lungs (Figure 5.3F) contrary to the non-encapsulated control.  
 
 
Figure 5.3: A) Macroscopic image of mice receiving non-encapsulated 4T1 cells and ovarian 
tissue. Bioluminescent imaging of (B) resected tumors and (C) organs following sacrifice 14 days 
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image of mice receiving Dual PEG containing 1000 4T1 cells and ovarian tissue. Bioluminescent 
imaging of (E) resected capsules and (F) organs following sacrifice 28 days after implantation. 
White circle indicates location of hydrogels. 
 
Lastly, to assess the ability of ovarian tissue to survive and develop in the presence of cancer 
cells, histological analysis was performed after explantation of the Dual PEG capsules to 
investigate the degree of folliculogenesis. Healthy, developing primary and secondary follicles 
were seen in ovarian tissue co-encapsulated with 1,000 and 10,000 cancerous cells (Figure 5.4) 
demonstrated folliculogenesis was supported. Interestingly, a higher number of follicles were 
observed in the ovarian tissue encapsulated with 1,000 cancer cells compared to 10,000 cells, 
which could be due to damage to ovarian tissue by the cancerous cells [191]. Multiple primordial 
follicles are present in capsule with 1,000 and 10,000 cancer cells (Figure 5.4B and D). 
 
Figure 5.4: Histological image of ovarian tissue encapsulated in Dual PEG with (A,B) 1000 4T1 
cells and (C,D) 10,000 4T1 cells. Scale bars: 200 μm (A,C) and 50 μm (B,D). * indicates primordial 














Cryopreservation and subsequent auto-transplantation of a patient’s own tissue would be an 
optimal option for young female cancer survivors, as it gives patients the option to have biological 
children long after treatment and restores their natural hormone function [179-184]. However, 
auto-transplantation presents the patients with a risk of re-introducing malignant cells, as the 
ovarian tissue was resected before treatment leading to the possibility of malignant cells being 
stored in the stroma of the tissue. In hematological cases, which is a high percentage of childhood 
cancers, this risk and ovarian involvement is very high [38-42]. Previous studies have been 
conducted to identify cancerous cells present in resected ovarian tissue from cancer patients. 
Due to discrepancies in characterization methodology, molecular marker criteria, and tissue 
heterogeneity, no universal protocol has been established to characterize ovarian tissue as safe 
[39-42]] creating a risk of re-seeding malignant cells for female cancer survivors following ovarian 
tissue auto-transplantation.  
This work describes a method to mitigate this risk by retaining cancerous cells in a capsule which 
is also conducive for ovarian tissue survival and development. Previously, we developed a 
multilayered immuno-isolating capsule, Dual PEG, which contains a degradable core that is 
conducive for ovarian tissue development and a non-degradable shell that acts as an 
immunoprotective barrier [172]. We demonstrated that when encapsulating allogeneic ovarian 
tissue and using an allogeneic mouse model, larger immune cells such as cytotoxic T cells are 
unable to penetrate the capsule. If cells are unable to penetrate the capsule from the outside 
immune environment, we hypothesized the Dual PEG capsule could retain encapsulated 
cancerous cells present in ovarian tissue and not let cells escape.  
 104 
First, we tested Dual PEG’s ability to retain cancerous cells in vitro in comparison to a degradable 
PEG-MT capsule. We demonstrated that by adding the non-degradable photopolymerized PEG 
layer, the ability of the capsule to retain cancer cells significantly increases. Through 21 days of 
culture, we showed 100% effectiveness of cancer cell retention when 1,000 cells were 
encapsulated in Dual PEG, compared to 0% cancer cell retention through 2 days when 
encapsulated in PEG-MT. This difference is due to the nature of the crosslinks in the respective 
capsules. In PEG-MT, the crosslinks are formed via a protease-sensitive peptide, so when the 
cancer cells grow and proliferate, they secrete proteases, which break down the bonds of the 
hydrogel. This opens up the pores and network of the hydrogel, allowing the cells to escape from 
the gel. The photopolymerized layer is not susceptible to proteolytic or hydrolytic degradation as 
the crosslinks are formed via free radicals reacting with double bonds. We observed that when 
the amount of cancer cells was increased to 10,000 per Dual PEG capsule, cancer cells did escape 
in a portion of the gels. This may be due to incomplete encapsulation of the cancer cell-containing 
core or the core being broken down and swelling past the outer shell’s capabilities. However, this 
cell concentration of 2.5 million cells/mL is far above what would be present in a clinical situation 
and was used to test the upper limits of Dual PEG. 
Next, we tested the ability of Dual PEG to retain cancer cells and prevent tumor mass formation 
and metastasis in vivo in a syngeneic mouse model. Previous studies have suspended 100-200 
cancerous cells in a fibrin or alginate matrix, and when implanted into mice, did not reintroduce 
leukemic cell contamination [192,193]. Here, we encapsulated BALB/c mouse ovarian tissue with 
BALB/c derived 4T1 cancer cells (1,000 or 10,000 cells per capsule) in Dual PEG and implanted 
two devices subcutaneously in BALB/c mice. A syngeneic model was used to mimic auto-
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transplantation of cancer cell-containing ovarian tissue. We compared the controls of injections 
containing cell suspensions of 2,000 or 20,000 4T1 cells to match the total amount of 
encapsulated cells in the mice receiving Dual PEG. When non-encapsulated cancer cells were 
injected subcutaneously, we observed rapid cell proliferation via luminescent imaging as well as 
tumor mass formation. By Day 14, we had to sacrifice all control mice as the tumors resulted in 
ulceration. Additionally, luminescent signal was observed in the lungs, indicating the 4T1 cells 
metastasized to the lungs, which is expected for this cancer cell line. When encapsulating 1,000 
cancer cells (250,000 cells/mL) in Dual PEG, we observed no change in luminescent signal in all 
mice through 28 days indicating the absence of tumor mass formation. Additionally, there were 
no cancer cells present in any of the surrounding tissue or organs of interest, indicating cancer 
cells were retained within the capsule and metastasis had not occurred. All observed luminescent 
signal was concentrated in the capsule, further confirming that all cancer cells present were 
retained in the capsule throughout the whole implantation period. When the amount of cell in 
each capsule was increased in 10,000 (2.5 million cells/mL), an increase in luminescent signal was 
observed over the 28 day implantation period indicating cell proliferation and tumor mass 
formation was taking place; however, all the cells were maintained in the gel as indicated by the 
lack of cells in surrounding tissues and susceptible organs. Macroscopically, we were able to see 
the tumor mass within the gel itself and upon IVIS imaging, the hydrogel was shown to be the 
only entity that contained cancer cells. At a high cell density of 10,000 cells/capsule, the Dual PEG 
gel is able to retain those cells and prevent metastasis, unlike the non-encapsulated control. 
When the capsules were explanted and histological analysis was performed, we observed the 
presence of healthy primary and secondary follicles. This is vital to a successful encapsulation 
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strategy for auto-transplantation, as this shows the tissue is capable of surviving within the 
capsule, potentially restoring fertility and ovarian endocrine function.  
This work demonstrated the capability of using an immuno-isolating capsule to retain cancer cells 
that may be present in an ovarian tissue autograft. Previously, we have shown that Dual PEG can 
support ovarian tissue survival and development, leading to the restoration of ovarian endocrine 
function. We have also demonstrated the capsule’s ability to protect encapsulated ovarian tissue 
from an immune response. By using this capsule to encapsulate a patient’s ovarian autograft, the 
risk of re-introducing malignant cells present in that tissue is mitigated. Given there is no protocol 
by which clinical investigators can be absolutely certain ovarian autografts do not contain 
cancerous cells, girls that had hematologic malignancies, and showed zero to a low concentration 
(250,000 cells/mL) of cancerous cells in their ovarian biopsy, could potentially use of an immuno-
isolating capsule to decrease the risk of cancer re-introduction.  Through this work, the option of 
auto-transplantation is potentially safer, which, although experimental, is the only option for pre-
pubescent female cancer survivors to retain, both, future fertility and ovarian endocrine function. 
Future work will be done to assess the ability of encapsulated mouse ovarian tissue to produce 
viable eggs once encapsulated in the dual PEG capsule. To this end, developing new methods to 
create a capsule using alternatives to photopolymerization may be necessary. Limitations of this 
study include the use of mouse ovarian tissue and a short in vivo transplantation period. For this 
reason, future studies encapsulating human ovarian tissue will be conducted to investigate the 
ability of the PEG capsules and other biocompatible materials to accommodate the large 
volumetric expansion of human follicles during development and the ability for capsule to 
support ovulation and corpus luteum formation. 
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5.6 Materials and Methods 
5.6.1 Gel Preparation 
Degradable poly(ethylene glycol) hydrogels (PEG-MT) were formed via Michael-type addition. To 
prepare degradable PEG-MT hydrogels for the core, 8-arm PEG-VS (40kDa, Jenkem Technology, 
Beijing, China) was cross-linked with a plasmin sensitive tri-functional peptide sequence (Ac-
GCYK↓NSGCYK↓NSCG, MW 1525.69 g/mol, >90% Purity, CelTek, ↓ indicates the cleavage site 
of the peptide). The non-degradable shell for Dual PEG hydrogels were prepared using 4-arm 
PEG-VS 20kDa, Jenkem Technology) with Irgacure 2959 (Ciba, Switzerland, MW=224.3) and 0.1% 
N-vinyl-2-pyrrolidone (Sigma-Aldrich, St. Louis, USA). The detailed protocol is described in Day et 
al [172].  
 
 
5.6.2 Collection of murine donor ovaries 
Donor ovaries were collected from 6-8 days old BALB/c mice. The collected ovaries were 
transferred to Leibovitz L-15 media (Sigma-Aldrich, USA) and dissected open. The ovarian tissue 




5.6.3 4T1 cell and ovarian tissue encapsulation 
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BALB/c derived 4T1 cancer cells were encapsulated at a concentration of 250,000 cells/mL (1,000 
cells/gel) or 2.5 million cell/mL (10,000 cells/gel). For encapsulation in the PEG-MT, the cancer 
cells and/or ovarian tissue were transferred into a 4 µL droplet of the plasmin sensitive tri-
functional peptide and PEG-VS precursors’ solution. The droplet was allowed to crosslink for 5 
minutes and then was quenched in maintenance media. For Dual PEG hydrogel encapsulation, 
the tissue was first encapsulated in a 4 µL PEG-MT hydrogel and was then placed in the center of 
a 10 µL bead of PEG-VS precursor solution (5% w/v PEG-VS, .4% Irgacure 2959, 0.1% NVP) and 
exposed to UV light.  All constructs were imaged immediately after encapsulation of the cells and 
tissue to verify complete encapsulation. 
 
5.6.4 Subcutaneous injection and implantation 
For controls, a cell suspension containing 2,000 or 20,000 cancer cells was injected 
subcutaneously on the dorsal side of the anesthetized mice (BALB/c). For animals receiving the 
cancer cells/ovarian tissue encapsulated in Dual PEG, a small incision was made on the dorsal 
side of the anesthetized mice (BALB/c) and 2 capsules per mouse were placed subcutaneously 
containing either 1,000 or 10,000 cancer cells in each capsule making each mouse receive a total 
of 2,000 or 20,000 cancer cells to compare to controls. The skin was closed using 5/0 absorbable 
sutures. The mice received Carprofen for analgesia for at least 24 hours after surgery or as 
needed. Mice were monitored for two weeks to one month and euthanized at the end of the 
experiment. Control mice were sacrificed at 14 days and mice receiving Dual PEG were sacrificed 
after one month. N=5 for each group. 
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The IACUC guidelines for survival surgery in rodents and the IACUC Policy on Analgesic Use in 
Animals Undergoing Surgery were followed for all the procedures. Animal experiments for this 
work were performed in accordance with the protocol approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University of Michigan (PRO00007716). 
 
5.6.5 IVIS imaging 
Bioluminescent imaging via the IVIS (In vivo Imaging System) was utilized to  
to track cell growth during the implantation period. Implanted 4T1 cells were labeled with firefly 
luciferin. Briefly, on the day of implantation and every 7 days during the time course of the study, 
150 µL of 63mM substrate (Xenolight D-Luciferin-K+ Salt Bioluminscent substrate, PerkinElmer) 
was injected intraperitoneally. After 10 minutes of incubation, mice were imaged. Similarly, to 
assess metastasis, collected organs and tumors on day of sacrifice were imaged by adding 28uL 
of 63mM substrate per mL of culture media. Images were processed and analyzed using 
LivingImage software. 
 
5.6.6 Tumor, gel, and organ collection 
At the time of sacrifice, tumors or gels were collected, imaged via IVIS, and fixed in Bouin’s 
fixative. Additionally, the brain, liver, lungs, spleen, blood, and ovaries were collected, imaged 
via IVIS, and fixed in Bouin’s fixative.  
 
5.6.7 Histological analysis of retrieved capsules and the encapsulated ovarian tissue 
Following sacrifice, the immuno-isolating devices were retrieved from mice, fixed in Bouin’s 
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fixative at 4°C overnight, transferred and stored in 70% ethanol at 4°C. After processing, samples 
were embedded in paraffin, serially sectioned at 5 μm thickness, and stained with hematoxylin 
and eosin.  
 
5.6.8 Statistics 
A Pearson’s (N-1) Chi-squared test was performed. Calculated values were performed using R, 
and all p-values were evaluated against a significance level (α) of 0.05. To test significance in 
change in radiance over time, a Welch’s t-test was used with p<0.05 determined as significant. 
 















Supplemental Figure 5.1: (A) Macroscopic image of mice receiving Dual PEG containing 10,000 
4T1 cells and ovarian tissue. (B) Bioluminescent imaging of resected capsules containing 10,000 
4T1 cells following sacrifice 28 days after implantation. White circle indicates the location of the 


















Encapsulation of ovarian allograft precludes sensitization of host immune response 
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Sensitization is an immune memory response in which circulating HLA antibodies in the blood 
hold the potential for accelerated antibody production. Memory T cells mediate this reaction in 
the case of allo-transplantation of organs where allo-antigens on the surface are recognized as 
foreign and presented to T cells for destruction. Immunosuppressive therapies are the only 
clinically available treatment to prevent graft failure in sensitized recipients. Here we utilized an 
immuno-isolating hydrogel-based capsule to protect transplanted ovarian allografts without the 
need for immunosuppressant. For female cancer survivors, allo-transplantation of donor ovarian 
tissue holds great potential as these patients often experience premature ovarian insufficiency 
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(POI) due to ovarian cytotoxity to chemo- and radio-therapy. Implantation of encapsulated 
CBAXC57Bl/6 (F1) ovarian allografts in a Dual PEG capsule, with a degradable core and non-
degradable shell, did not sensitize the BALB/c host immune system. When ovarian allografts were 
implanted in a Dual PEG capsule for 60 days followed by another Dual PEG capsule for another 
60 days, allo-antibody levels were significantly lower compared to non-encapsulated controls. 
We observed the presence of healthy developed antral follicles in the encapsulated graft, 
indicating folliculogenesis was supported and endocrine function was restored. This is the first 
report to demonstrate that ovarian tissue encapsulated in Dual PEG does not sensitize the host 
as shown through subsequent allogeneic implantations. 
 
6.3 Introduction 
Sensitization is an immune memory response in which circulating HLA antibodies in the blood are 
present and the immune system holds the potential for accelerated production of HLA 
antibodies. Memory T cells mediate this reaction when they interact with antigen-presenting 
cells, become active lymphoblasts and eliminate allo-antigens at a rapid rate [194]. In the case of 
allo-transplantation of organs, allo-antigens on the surface are recognized as foreign and 
presented to T cells for destruction. Clinically, sensitization can result in graft failure and remains 
a major challenge in organ transplantation as it limits the available donor pool and increases the 
risk of mortality and morbidity if immunosuppressive therapies are not administered [194-196].  
Immunoisolation is a promising approach to allow transplantation of allogeneic tissues without 
immunosuppression, but it is limited to small tissue fragments that do not require direct 
vascularization and can be sustained by diffusion. One example of such application is allo- 
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implantation of ovarian donor tissue to restore ovarian endocrine health in adolescent childhood 
cancer survivors reaching the age of pubertal development. Over the past few decades the rates 
of childhood cancer survival have increased significantly, rising to over 85% in some cases, due 
to advances in anti-cancer therapies. Unfortunately, these therapies exhibit ovarian toxicity, 
leading to premature ovarian insufficiency (POI). Adolescent patients with POI experience 
hormonal imbalances which in turn lead to long-term co-morbidities such as decreased height, 
diminished bone health, muscle wasting, insulin irresponsiveness, poor lipid metabolism, and 
poor cardiovascular health and cognition [9-11]. The only clinically available option to treat POI 
is hormone replacement therapy (HRT). However, HRT delivers only a fraction of ovarian 
hormones—estrogen and progesterone—at higher doses and in a non-pulsatile manner which is 
essential for proper regulation and does not mimic the physiological hormonal milieu [44,46-48].  
Alternatively, another experimental option for these patients is cryopreservation of ovarian 
tissue prior to gonadotoxic treatments followed by subsequent auto-transplantation. However, 
there is an associated risk of re-implanting malignant cells present in the ovarian tissue, 
particularly in patients with hematological malignancies [39-41, 161]. There is no accepted 
protocol to deem ovarian tissue free of cancerous cells and safe [19,21-22]. Additionally, patients 
often have to undergo treatments immediately after diagnosis and do not have a chance to 
cryopreserve their tissue before treatment [146,180,197].  
Transplantation of donor ovarian tissue to restore ovarian endocrine function for patients 
experiencing POI is an experimental option to avoid the risk of cancer recurrence associated with 
auto-transplantation. Previously, we have developed a novel poly(ethylene glycol)-based (PEG) 
capsule to support ovarian development and function, while preventing an immune-mediated 
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rejection in mouse model of allogeneic transplantation. We demonstrated that the capsule 
prevents infiltration of immune cells and the encapsulated tissue restores ovarian endocrine 
function and does not elicit the production of allo-specific antibodies. The question remains as 
to whether the allo-antigens are possibly diffusing from the encapsulated ovarian allograft, even 
in the absence of rejection, sensitizing the host and as a result preventing future successful 
implantations. In this study, we investigated whether recipients are sensitized to ovarian 
allografts encapsulated in a Dual PEG capsule after sequential allogeneic implantations.  Mice 
were implanted with non-encapsulated or Dual PEG encapsulated ovarian allografts and were 
subsequently implanted with another non-encapsulated or Dual PEG encapsulated ovarian 
allograft. The two-phased implantation schedule mimics the reality in which a recipient is already 
sensitized to antigens prior to implantation. The objective of this study was to show that 
encapsulation of allogeneic ovarian tissue in a Dual PEG capsule, prevents sensitization of the 
recipient even in the cases when the immune system was primed to allo-antigens present in the 
encapsulated graft; this would prolong graft survival, and clinically, allow for multiple 
implantations of encapsulated allogeneic ovarian tissue to restore ovarian endocrine function in 





6.4.1 Non-encapsulated ovarian allograft sensitize the recipient mice 
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Implantation of non-encapsulated ovarian allografts elicited an immune response when 
implanted subcutaneously resulting in a 23-fold increase in allo-specific antibody production 
(Figure 6.2 A,B). The number of circulating allo-specific antibodies gradually increased from 
undetectable 14 days post transplantation to 750 MFI on day 28 and 500  MFI on day 42. On the 
contrary, after implantation of ovarian allograft encapsulated in Dual PEG the levels of circulating 
allo-specific antibodies remained consistently low, ranging between 100 to 250 MFI for 60 days 
after implantation (Figure 6.2 C,D). Negative results of immunohistochemical staining of the 
retrieved grafts confirmed that the graft was isolated and protected from cellular infiltration.  
The endocrine activity of the implanted ovarian allografts was consistent with the levels of 
circulating antibodies and cellular infiltration into the grafts. Ovariectomized mice implanted with 
non-encapsulated ovarian allografts briefly resumed estrous activity after 1 week, and stopped 
in all mice after 4 weeks, correlating with the increasing levels of circulating allo-antigens. The 
estrous activity in ovariectomized mice implanted with encapsulated ovarian allo-grafts resumed 




Figure 6.2: Representative flow cytometry plots of binding of serum allo-specific antibodies from 
recipients of (A) non-encapsulated allogeneic ovary tissue for 42 days and (C) tissue encapsulated 
in Dual PEG for 60 days. Y-axis, donor-specific IgG; X-Axis, donor-specific IgM. Graph depicts the 
average MFI±SD of allo-specific IgG in mice receiving (B) non-encapsulated allogeneic ovarian 
tissue and (D) tissue encapsulated in Dual PEG capsules. (E) Resumption of estrous cycle of mice 
receiving non-encapsulated and Dual PEG encapsulated allogeneic ovarian tissue. Representation 
of estrous activity in mice receiving (F) non-encapsulated and (G) Dual PEG encapsulated 
allogeneic ovarian tissue 
 
6.4.2 Encapsulated ovarian tissue functions in sensitized and naïve mice  
We demonstrated that encapsulated ovarian allografts implanted in naïve mice are protected 
from immune rejection. However, the question remained whether the encapsulated ovarian 
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allografts remained protected in the host that had been previously sufficiently exposed to allo-
antigens resulting in sensitized immune system for subsequent implantations. We tested 
whether encapsulation of ovarian allo-tissue in Dual PEG prevents rejection in a sensitized 
environment where mice were already sensitized with non-encapsulated ovarian tissue for 60 
days and then implanted with ovarian tissue encapsulated in Dual PEG. When we implanted 
ovarian tissue encapsulated with Dual PEG in mice with elevated levels of circulating allo-specific 
antibodies after the sensitization period (Figure 6.3 A,B) the antibody production in the hosts 
plateaued and leveled off through 60 days of the second implantation, indicating a memory 
response was not present. No presence of CD8+ cells was evident in the graft indicating the 
capsule prevented cellular infiltration (Figure 6.3 C). Graft survival was confirmed by the presence 
of multiple healthy developing follicles in the encapsulated graft (Figure 6.3 D-F) and resumption 
of estrous activity following the implantation of the encapsulated graft (Figure 6.3 J,K). By 3 
weeks after the initial non-encapsulated implantation, all mice stopped cycling indicating the 
graft was no longer functional and the mice were sensitized. Once the encapsulated allograft was 
implanted in the sensitized mice at 60 days, all mice resumed cycling by 2 weeks post-
implantation and continued cycling through the entire of the implantation period (Figure 6.3 J,K). 
The presence of healthy developed follicles in the graft once removed from a sensitized host 
(Figure 6.3 D-F) was similar to that observed in a naïve mouse that received Dual PEG 
encapsulated allograft for a primary implantation (Figure 6.3 G-I), confirmed the ovarian allograft 





Figure 6.3: A)Representative flow cytometry plots of binding of serum allo-specific antibodies 
from recipients of Dual PEG encapsulated allogeneic ovary tissue in an already sensitized 
recipient, implanted with non-encapsulated ovarian tissue 60 days prior. Y-axis, donor-specific 
IgG; X-Axis, donor-specific IgM.  The mean fluorescence intensity (MFI) for donor specific IgG 
reflects the average of values read on the Y-Axis.(B) Graph depicts the average MFI±SD of allo-
specific IgG in mice receiving non-encapsulated ovarian tissue for 60 days followed by Dual PEG 
encapsulated ovarian tissue for 60 days. The mean fluorescence intensity (MFI) for donor specific 
IgG reflects the average of values read on the Y-Axis. (C) Immunohistochemical staining of CD8+ 
cells in Dual PEG-encapsulated ovarian allograft. Histological images of allogeneic ovarian tissue 
encapsulated in Dual PEG in a (D-F) sensitized host and  (G-I) primary implantation in a naïve host. 
Representative plot of estrous activity of mice receiving a (J) non-encapsulated ovarian tissue 
and then Dual PEG encapsulated tissue. (K) Resumption of estrous activity in mice receiving a 
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non-encapsulated ovarian tissue and then Dual PEG encapsulated tissue. * indicates the PEG 
hydrogel. Black arrows mark supporting primordial and primary follicles. Scale bars: 50 μm 
(E,F,H,I), 100 μm (C,D,G). 
 
 
6.4.3 Dual PEG precludes sensitization compared to non-encapsulated controls 
We wanted to mimic the clinic and test allogeneic reaction in a sensitized environment. To 
confirm that F1 ovaries sensitize the BALB/c host, we implanted non-encapsulated ovarian 
allografts in naïve BALB/c mice. The first implantation period lasted 42 days, and was followed 
with another implantation of a non-encapsulated allograft for 14 days. Allo-specific immunity 
and subsequent sensitization is manifested by the production of allo-specific antibodies and 
cellular infiltration. Figure 6.4A demonstrates that donor-specific IgG increased significantly in 
recipient mice from undetectable to 742 MFI by 28 days after implantation of non-encapsulated 
ovaries. When these mice received a subsequent implantation of non-encapsulated allogeneic 
ovarian tissue, an increase in IgG was observed 7 days after implantation indicating a memory 
response took place. A memory response is when HLA antibodies are already present and when 
exposed to the same allo-antigen that the host had previously been exposed to, a rapid 
production of antibodies occurs resulting in faster kinetics of immune rejection (Figure 6.4B).   In 
most cases (n=5 of 7), the graft could not be found in the mouse as rejection had occurred and 
eliminated the allograft. In a couple cases (n=2) where the grafts were retrieved histological 
analysis showed necrosis with no evidence of surviving healthy follicles (Figure 6.4J). The 
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presence of CD8+ T cells were present in the graft indicating cellular infiltration and subsequent 
immune rejection had taken place (Figure 6.4C).  
To test whether ovarian allografts encapsulated in Dual PEG led to sensitization, we implanted 
mice with Dual PEG encapsulated ovarian allografts for 60 days followed by another ovarian 
allograft encapsulated in Dual PEG for an additional 60 days. Similar to our previous results, 
encapsulation of ovarian tissue in Dual PEG elicited minimal donor-specific antibodies as through 
60 days IgG increased to 65 MFI, which is significantly lower than what is observed when the 
allogeneic ovarian tissue is not encapsulated (Figure 6.4G,H). When mice were implanted with 
ovarian tissue encapsulated in Dual PEG after an initial implantation of 60 days with Dual PEG, 
minimal allo-specific IgG was produced indicating the mice were not sensitized from the initial 
implantation and the ovarian tissue was immuno-isolated. When the encapsulated grafts were 
removed, we observed the presence of healthy developing follicles up to the antral stage (Figure 
6.3 G-I, Figure 6.4 L-M), indicating the graft was protected against a host response and 
folliculogenesis was supported. Secondary and antral follicles are capable of producing estradiol 
in response to circulating gonadotropins, restoring ovarian endocrine function. All mice resumed 
estrous activity by 2 weeks following the initial implantation and continued cycling through the 
120 day implantation period (Figure 6.40,P) 
Additionally, no presence of CD4+ and CD8+ cells were present within the graft and capsule, 
indicating the Dual PEG capsule did not allow for cellular infiltration during both implantation 
periods (Figure 6.4I). 
To confirm the lack of sensitization after implantation of ovarian tissue encapsulated in Dual PEG, 
mice were implanted with Dual PEG for 60 days and followed by an implantation of non-
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encapsulated ovarian tissue. Non- sensitized mice by the ovarian tissue encapsulated in Dual PEG  
should respond similarly to the first implantation of the ovary-ovary group, as if it is the first time 
the host is the allo-antigens. As expected, during the 60 days of implantation period of 
encapsulated allograft, the production of IgG was minimal and remained below 100 MFI. Once 
the mice received non-encapsulated tissue following the 60 day Dual PEG implantation, allo-
specific IgG rose to 666.6 MFI (Figure 6.4 D,E). Importantly, the kinetics and levels of the allo-
specific IgG was very similar to the first implantation of the ovary-ovary group (Figure 6.4A,B) 
indicating the mice were not sensitized to the F1 ovarian tissue that had been in present in the 
mice in Dual PEG for 60 days.  Interestingly, while the dual PEG immunoisolating capsule 
protected the ovarian allograft the host did not develop tolerance towards the allogeneic tissue, 
which was rejected when implanted without the immunoisolating capsule. No presence of CD8+ 
cells were observed (Figure 6.4F) and healthy developing follicles were found in the encapsulated 
tissue retrieved from the Dual PEG graft after 120 days indicating long-term graft survival was 





Figure 6.4: Representative flow cytometry plots of binding of serum allo-specific antibodies from 
recipients of (A) non-encapsulated allogeneic ovary tissue first for 42 days and then again 
received non-encapsulated ovarian tissue , (D) Dual PEG encapsulated ovarian tissue and then 
non-encapsulated ovarian tissue, and (G) consecutive Dual PEG encapsulated ovarian tissue, to 
donor cells. Y-axis, donor-specific IgG; X-Axis, donor-specific IgM.  The mean fluorescence 
intensity (MFI) for donor specific IgG reflects the average of values read on the Y-Axis; the MFI 
for donor specific IgM reflects the average of values read on the X-Axis Graph depicts the average 
MFI±SD of allo-specific IgG in mice receiving (B) non-encapsulated allogeneic ovarian tissue 
followed by another non-encapsulated tissue implantation, (E) Dual PEG encapsulated ovarian 
tissue followed by non-encapsulated ovarian tissue, and (H) two consecutive Dual PEG 
encapsulated ovarian allografts. Immunohistochemical images of CD8+ cells in (C) non-
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encapsulated ovarian tissue, (F) Dual PEG encapsulated tissue, and (I) Dual PEG encapsulated 
tissue following an initial Dual PEG implantation. Histological images of (J) non-encapsulated 
ovarian tissue and (K) Dual PEG encapsulated ovarian tissue in mice receiving both encapsulated 
and non-encapsulated tissue, and (L-N) Dual PEG encapsulated ovarian tissue following a primary 
Dual PEG implantation. Representative plot of estrous activity of mice receiving a (O) Dual PEG 
encapsulated tissue and then another Dual PEG encapsulated tissue. (P) Resumption of estrous 
activity in mice receiving consecutive Dual PEG encapsulated tissue implantations. * indicates the 
PEG hydrogel. Black arrows mark supporting primordial and primary follicles. Scale bars: 50 μm 
(J,M,N), 100 μm (C,F,I,K,L). 
 
6.5 Discussion 
In this study, we investigated whether encapsulating ovarian allografts in PEG based capsules 
protects against sensitization of the host immune system in an immune competent 
ovariectomized murine model. If encapsulation precludes sensitization, ovarian graft survival is 
prolonged and ovarian endocrine function is restored. Previously, we have demonstrated that 
the Dual PEG capsule containing a degradable core with a non-degradable shell supports ovarian 
survival and development leading to restoration of ovarian endocrine function [172]. 
Additionally, we’ve shown that in an immune competent model, encapsulation of allogeneic 
ovarian tissue in Dual PEG did not result in elevated allo-antibodies or allow cellular infiltration, 
resulting in the graft surviving and restoring endocrine function. While we have shown that 
allogeneic tissue encapsulated in Dual PEG survives in an immune competent mouse, the 
question remained whether the host is exposed to allo-antigens during the implantation period 
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resulting in sensitization and the host immune system being primed to reject any subsequent 
implantations that may follow. This would be crucial to answer in the application of ovarian tissue 
allotransplantation as we hypothesize patients would receive numerous implantations through 
their treatment to maintain ovarian endocrine function. 
We tested whether consecutive implantations of non-encapsulated allogeneic ovarian tissue 
resulted in sensitization of the host, measured by allo-specific antibody levels in the recipient’s 
serum.  As hypothesized, the introduction of an ovarian allograft, followed by another ovarian 
allograft resulted in sensitization of the host and rapid rejection of the secondary implantation. 
This was indicative by the increase in IgG by 7 days after the second implantation, which is much 
more rapid than the kinetics of antibody production if the host’s B cells had never seen the F1 
allo-antigens before. Rejection was confirmed by no presence of follicles in the grafts. 
Conversely, we compared these results to encapsulated allogeneic ovarian tissue. When 
implanting mice with ovarian allografts encapsulated in Dual PEG, followed by another ovarian 
allograft encapsulated in Dual PEG, we observed no levels of elevated allo-specific antibodies in 
the first or second implantation, indicating encapsulation precludes sensitization. We 
hypothesize that this is based on size exclusion and the inability for antigen presenting cells to 
come in contact with allo-antigens and propagate a subsequent humoral and cellular response. 
Precluding sensitization is vital for ovarian tissue survival in allotransplantation as patients will 
receive multiple grafts throughout their treatment. The fact that the encapsulated ovarian tissue 
was not rejected was confirmed by the presence of healthy developing follicles present in the 
graft, up to the antral stage. The presence of secondary and antral confirms the graft was 
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immuno-isolated from the outside immune environment, leading to the restoration of endocrine 
function. 
Previous studies have studied sensitization in transplantation through skin or kidney transplants 
[198. 199], where tissue/organs is transplanted in the recipient and the immune system is 
exposed to allo-antigens resulting in sensitization to that strain of animal. For the application of 
ovarian tissue allo-transplantation, we used a similar concept to test whether the Dual PEG 
capsule precludes sensitization utilizing allogeneic ovarian tissue. To confirm encapsulation of 
ovarian allografts in Dual PEG precludes sensitization, we implanted mice with encapsulated 
ovarian allografts and either followed that with a subsequent non-encapsulated ovarian allograft 
or implanted the capsule in previously sensitized mice. As hypothesized, when implanting 
encapsulated ovarian tissue, elevated IgG levels were not observed through 60 days. The tissue 
was functional as healthy follicles were observed via histological analysis. When following that 
implantation with a non-encapsulated ovarian allograft, interestingly, allo-antibody levels did rise 
significantly, indicating an immune response, but at the kinetics similar to that of the first 
implantation in the mice receiving two ovarian allografts consecutively. This indicates that the 
host immune system had not been exposed to the allo-antigens present in the non-encapsulated 
ovarian allografts even though encapsulated allogeneic ovarian tissue was present in the Dual 
PEG capsule for 60 days. When encapsulated ovarian allografts were implanted in previously 
sensitized mice, we demonstrated that allo-antibody levels did not rise following that 
implantation and in fact, plateaued; indicating the sensitized mice were not further being 
exposed to allo-antigens and a memory response was not mounted. 
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Previously, we have shown changing the degradability of the capsule impacts the ability to 
protect allogeneic ovarian tissue against an immune response.  Day et al demonstrated ovarian 
tissue encapsulated in a proteolytically degradable PEG matrix crosslinked via Michael-type 
addition (MT PEG) resulted in some grafts being rejected, resulting in elevated IgG, cellular 
infiltration and failure to restore endocrine function; while some grafts were protected and 
rejection was not observed similar to Dual PEG. We hypothesize that this is due to the degradable 
nature of the capsule and as the cells secrete proteases, the pores of the network become larger 
leading to the encapsulated allogeneic tissue being more susceptible to interaction with the host 
immune system. This led us to hypothesize that antigen presentation may also be impacted and 
the interaction with the immune system may be completely different than in Dual PEG. To test 
this, we implanted mice with ovarian allografts encapsulated in MT PEG for 60 days followed by 
a subsequent non-encapsulated ovarian allograft. Following the initial implantation of MT PEG, 
we did not observe a significant increase in IgG production. Healthy follicles were present in the 
graft following explantation indicating the encapsulated tissue was functional. Interestingly, 
when we followed the initial 60-day implantation with non-encapsulated allografts, we 
demonstrated elevated IgG production, but it was slightly lower than when a non-encapsulated 
allograft followed a Dual PEG implantation. Previous, studies have shown that a slow delivery of 
antigens may induce a tolerogenic effect on the host immune system. Further studies must be 
conducted to test whether encapsulating ovarian allografts in MT PEG induces tolerance by 
manipulating the kinetics of exposure to allo-antigens. This however demonstrates that antigen 
presentation may be different based on nature of the network the tissue is encapsulated in as 
the accessibility of the antigens is altered.  
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In summary, encapsulating allogeneic ovarian tissue in an immune-isolating capsule precludes 
sensitization of the host immune system, protecting the tissue and resulting in ovarian endocrine 
function restoration. For patients experiencing POI, this allogeneic cell-based therapy delivers 
hormones in a pulsatile self-regulating manner, potentially avoiding adverse side effects 
observed with pharmacological treatments and the risk of re-introducing cancerous cells. The 
ability for Dual PEG to preclude sensitization is vital as we envision patients receiving multiple 
grafts as some patients who experience POI as a child or adolescent have a treatment period 
spanning decades. This is the first report to demonstrate that the Dual PEG capsule completely 
hides the ovarian tissue from the host immune response and the encapsulated tissue does not 
sensitize the host. Future non-human primate and xenogeneic models using human tissue must 
be conducted as the genetic makeup of these animals is much more diverse than inbred mice 
and the kinetics of growth of ovarian tissue is different, which may impact the ability to immuno-
isolate tissue and preclude sensitization. 
 
6.6 Materials and Methods 
6.6.1 Experimental Design 
Adult cycling female mice (BALB/c) underwent bilateral ovariectomies to induce POI. As a positive 
control for sensitization, BALB/c mice were implanted subcutaneously with a non-encapsulated 
ovary from 6-8 day old CBAXC57Bl/6 (F1) mice for 42 days and followed by a subsequent 
implantation of another non-encapsulated F1 ovary for 14 days. For experimental groups, BALB/c 
mice were (i) implanted with non-encapsulated F1 ovarian tissue for 60 days followed by an 
implantation of ovarian tissue encapsulated in Dual PEG for 60 days (ii) implanted with 
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encapsulated ovarian tissue in Dual PEG for Dual PEG for 60 days followed by ovarian tissue 
encapsulated in Dual PEG for another 60 days (iii) implanted with F1 ovarian tissue encapsulated 
in Dual PEG for 60 days followed by an implantation of non-encapsulated F1 ovarian tissue for 
another 60 days (Figure 6.1).  
 
 
Figure 6.1: Experimental design to test sensitization in mice.  
 
6.6.2 Ovariectomies in Recipient Mice 
The IACUC guidelines for survival surgery in rodents and the IACUC Policy on Analgesic Use in 
Animals Undergoing Surgery were followed for all the procedures. Animal experiments for this 
work were performed in accordance with the protocol approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University of Michigan (PRO00007716). 
Bilateral ovariectomies were performed on adult female mice (BALB/c) aged 12–16 weeks. The 
mice were anesthetized by isoflurane. Carprofen (5mg/kg. body weight, Rimadyl, Zoetis) was 
administered subcutaneously for analgesia. The intraperitoneal space was exposed through a 
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midline incision in the abdominal wall secured using an abdominal retractor. The ovaries were 
removed, and the muscle and skin layer of the abdominal wall were closed with 5/0 absorbable 
sutures (AD Surgical). The mice recovered in a clean warmed cage and received another dose of 
Carprofen 12 hours post recovery or as needed.   
 
6.6.3 Collection of Donor Ovaries 
Ovaries from 6 to 8 days old CBAXC57Bl/6 (F!) or BALB/c mice were collected and transferred to 
Leibovitz L-15 media (Sigma-Aldrich, USA). The ovaries were dissected into 2–4 pieces and 
transferred in the maintenance media (α-MEM, Gibco, USA) and placed in the CO2 incubator for 
further manipulation.  
 
6.6.4 Hydrogel Preparation and Ovarian Tissue Encapsulation 
To prepare MT PEG hydrogels, 8-arm PEG-VS (40kDa, Jenkem Technology, Beijing, China) was 
cross-linked with a plasmin sensitive tri-functional peptide sequence (Ac-GCYK↓NSGCYK↓NSCG, 
MW 1525.69 g/mol, >90% Purity, CelTek, ↓ indicates the cleavage site of the peptide). Dual PEG 
hydrogels were prepared using 4-arm PEG-VS 20kDa, Jenkem Technology) with Irgacure 2959 
(Ciba, Switzerland, MW=224.3) and 0.1% N-vinyl-2-pyrrolidone (Sigma-Aldrich, St. Louis, USA). 
The detailed protocol is described in Day et al. [172] donor ovaries were collected from 6-8 days 
old BALB/c mice. The collected ovaries were transferred to Leibovitz L-15 media (Sigma-Aldrich, 
USA) and dissected open. The ovarian tissue was then transferred into maintenance media (a-
MEM; Gibco, USA), kept at 37˚C and 5% CO2. For encapsulation in the MT PEG, the ovarian tissue 
was transferred into a 10 µL droplet of the plasmin sensitive tri-functional peptide and PEG-VS 
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precursors’ solution. The droplet was allowed to crosslink for 5 minutes and then was quenched 
in maintenance media (Figure 4.1A). For Dual PEG hydrogel encapsulation, the tissue was first 
encapsulated in a 4 µL MT PEGhydrogel and was then placed in the center of a 10 µL bead of 
PEG-VS precursor solution (5% w/v PEG-VS, .4% Irgacure 2959, 0.1% NVP) and exposed to UV 
light for 6 minutes(Figure 4.1E).  All constructs were imaged immediately after encapsulation of 
the tissue. 
 
6.6.5 Subcutaneous Implantation  
A small incision was made on the dorsal side of the anesthetized mice (BALB/c) and the 
immunoisolators (MT PEG, Dual PEG) with the ovarian tissue or non-encapsulated ovarian tissue 
were implanted subcutaneously. The skin was closed using 5/0 absorbable sutures. The mice 
received Carprofen for analgesia for at least 24 hours after surgery or as needed.  
 
6.6.6 Histological analysis of the retrieved devices and the encapsulated ovarian tissue 
Following sacrifice, the immuno-isolating devices were retrieved from mice, fixed in Bouin’s 
fixative at 4°C overnight, transferred and stored in 70% ethanol at 4°C. After processing, samples 
were embedded in paraffin, serially sectioned at 5 μm thickness, and stained with hematoxylin 
and eosin.  
 
6.6.7 Vaginal Cytology 
To assess for resumption of estrus activity, daily vaginal cytology was performed. To assess 
estrous cycle cessation after ovariectomy, vaginal cytology was performed seven days post-
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surgery. After transplantation, vaginal cytology was resumed seven days post-operation and was 
performed daily until sacrifice. The transition from leukocytes to cornified cells at least once a 
week was counted as a resumed or continued cycle.  
 
6.6.8  Flow Cytometry 
Serum allo-antibody titer measurements were performed using flow cytometry before and after 
implantation and reported as mean fluorescence intensities (MFI) for the highest dilution 
showing fluorescence detectable above background (non-immune serum from a non-implanted 
mouse) in immunized mice (positive controls implanted with allogeneic ovaries without a device). 
Thymocytes were isolated from CBAXC57Bl/6 mice and incubated with serially diluted recipient 
serum for 30 minutes at 4˚C. Antibodies bound to the thymocytes were detected by Cy5-
conjugated goat anti-mouse IgG (1:250 dilution, 1030-15, Southern Biotech) and Alexa Fluor 488-
conjugated goat anti-mouse IgM (1:250 dilution, 1020-30, Southern Biotech) for 30 minutes at 
4˚C and analyzed in a BD FACSCanto II (BD Biosciences, Franklin Lakes, NJ). The mean 
fluorescence intensities (MFI) in the APC-channel (measuring bound IgG) and FITC channel 
(measuring bound IgM) were determined with FlowJo 10 software (FlowJo, LLC, Ashland, OR). 
 
6.6.9 Immunohistochemistry for T cells 
To analyze T cell infiltration following into non-encapsulated or encapsulated ovarian allografts, 
paraffin-sectioned slides were stained to identify CD4 and CD8+ cells. First, sections were 
deparaffinized with Xylene and rehydrated. The slides were incubated in antigen retrieval buffer, 
pH9.0 (ab94681, Abcam) for 20 minutes at 97°C and additional 20 minutes at room temperature 
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to cool down. Next, the slides were incubated with KPL Universal Block (5560-0009, Sera-Care) 
to block non-specific binding sites for 30 minutes at room temperature. The sections were 
incubated at room temperature for 1 hour with primary antibodies: rabbit monoclonal anti-
mouse CD4 antibody (1:1000 dilution, ab183685, Abcam), rabbit polyclonal anti-mouse CD8 
antibody (1:500 dilution, ab203035, Abcam). The slides were subsequently incubated at room 
temperature with secondary antibodies: goat anti-rabbit Ig (1:100 dilution for 15 minutes, 4010-
05, Southern Biotech) for CD4 and goat anti-rabbit (1:50 dilution for 30 minutes, 4010-05, 
Southern Biotech) for CD8. Diaminobenzidine (BDB2004L, Betazoid DAB Chromogen kit, BioCare 
Medical) was used as a chromogen for 10 minutes at room temperature. Hematoxylin (220-102, 
Fischer Scientific) was used as a counterstain. For negative-controls, paraffin sections were 
incubated without the primary antibody. To assess presence or absence of CD8+ cells, 12 sections 
from the front, middle, and end of each specimen were examined, to represent the full thickness 
of the implant. 
 
6.6.10 Statistics 
Statistical analysis was performed using the R software version 3.1.2 (2014). Significance was 
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A common complication of life-saving chemo and radiotherapy treatments is premature ovarian 
insufficiency (POI) due to being gonadotoxic. POI can lead to a multitude of life long co-
morbidities and is particularly devastating in patients who experience it prior to puberty; possibly 
resulting in deleterious effects to bone health, cardiovascular health, cognition, and metabolic 
balance. The only available treatment for POI during puberty is hormone replacement therapy 
(HRT), which delivers non-physiological levels of estrogen, lacks other ovarian hormones and 
pulsatility, and is not responsive to feedback regulation. We have previous shown that the use of 
an immuno-isolating capsule can support allogeneic ovarian tissue, restoring ovarian endocrine 
function without causing an immune response in a murine model. Here, we report non-human 
primate ovarian tissue encapsulated in immune-isolating capsules survives and develops, 
restoring ovarian endocrine function without evoking an immune response in a syngeneic and 
allogeneic non-human primate model of POI. Ovariectomized monkeys implanted with 
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encapsulated either syngeneic and allogeneic ovarian tissue demonstrated pulsatile levels of 
estradiol (E1C) and progesterone (PdG) throughout the 4 and 5 month implantation period with 
levels rising to up to 50 and 70ng/mg Cr, respectively. Healthy developed follicles up the antral 
stage were observed following explantation of the capsule. Importantly, a minimal immune 
response was provoked by the encapsulated allogeneic tissue as a low percentage of recipient 
CD4+ and CD8+ cells divided when exposed to the allogeneic donor cells. This demonstrates the 
immuno-isolating capsule can support the large volumetric expansion present during NHP 
folliculogenesis without compromising its immuno-isolating capabilities, leading to long term 
graft survival and restoration of ovarian endocrine function. This is the first report to 
demonstrate an immuno-isolating capsule can be used to allow for ovarian tissue allo-
transplantation, restoring ovarian endocrine function and preventing an immune response in an 




Over the past decades, childhood cancer survival rates have increased substantially reaching over 
85% due to advances in cancer therapies. However, the same cancer therapies can potentially 
lead to a myriad of health complications in childhood cancer survivors [8,24,46,47,163,165]. One 
of the most common complications for female cancer survivors is premature ovarian insufficiency 
(POI) as the treatments are gonadotoxic. POI leads to depletion of the follicular pool, resulting in 
infertility and disruption of ovarian endocrine function. POI is particularly detrimental in children 
that experience it prior to undergoing puberty, as the puberty is one of the most important 
physiological events in a female’s life and the effects are irreversible. Changes occurring during 
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puberty promote the physical and psychologic development into adulthood determining height, 
bone health, insulin responsiveness, lipid metabolism, cardiovascular health and cognition [9-
11]. These changes are initiated before puberty and orchestrated by the pulsatile secretion of 
gonadotropin releasing hormone (GnRH) and growth hormone (GH) from the hypothalamus, 
which regulates the release of gonadotropins, luteinizing (LH) and follicle-stimulating (FSH) 
hormones from the pituitary. FSH and LH stimulate the ovaries to produce ovarian hormones and 
peptides including estradiol, androstenedione, progesterone, inhibins A and B, activin and 
follistatin. All of these hormones have a systemic effect in many organs and tissues downstream. 
This process is extremely regulated and ovarian hormones create a negative feedback loopy by 
inhibiting the production of GnRH and FSH in the brain and pituitary [12-14]. This creates a 
dynamic and pulsatile system known as the hypothalamic-pituitary-gonadal (HPG) axis, and the 
correct regulation of this axis is crucial for the development of reproductive, musculoskeletal, 
cardiovascular, and immune systems [15-16]. In young patients with POI, the HPG axis and the 
negative feedback is disrupted due to deficiencies in ovarian hormones, which leads to 
imbalances throughout the endocrine system resulting in comorbidities such as irregular bone 
development, metabolic changes, and abnormal fat deposition [19-21].  
The only clinically available option to treat POI in adolescent girls and initiate puberty is hormone 
replacement therapy (HRT), HRT is the exogeneous delivery of hormones, specifically low levels 
of estrogen followed by progesterone replacement [44,45,167]. HRT was originally designed to 
treat postmenopausal systems in women and the impact on children using this methodology for 
a span of decades is not known [44]. Additionally, HRT delivers only a fraction of ovarian 
hormones in a non-pulsatile manner which does not mimic physiological puberty due to the 
 136 
complexity of the HPG axis. In turn, HRT induced puberty in girls with POI can lead to premature 
closure of bone growth plates, cessation of bone growth, and metabolic imbalances [44,46-48]. 
Another experimental option to induce puberty in girls with POI is cryopreservation of ovarian 
tissue prior to anti-cancer treatments followed by auto-transplantation. This option could 
potentially restore both fertility and endocrine function and has led to more than 100 babies 
born to identical twin sisters and cancer survivors who cryopreserved their ovaries [29-35]; 
however; this option is associated with the risk of re-introducing malignant cells harbored in the 
stroma of ovarian tissue, particularly in patients with hematological malignancies which is 
common in childhood cancers [38-40]. There has been no universal protocol established to 
screen ovarian tissue for cancer cells and deem it as safe, which adds to the risk of re-implanting 
cryopreserved autologous ovarian tissue. Further, auto-transplantation cannot be performed if 
the patient did not cryopreserve their tissue prior to treatment, which is the most common case 
[180,197].  
To provide physiological delivery of hormones and mitigate the risk of cancer re-implantation, 
we hypothesize an option for these patients is allo-transplantation from a donor. To avoid the 
use of immunosuppressive treatments, which have complications of their own, the concept of 
immuno-isolation must be utilized. Immuno-isolation is the use of a semi-permeable membrane 
to encapsulate allogeneic cells/tissue, which allows for free diffusion of necessary metabolites 
and nutrients but does not allow the infiltration of host immune cells preventing rejection. 
Previously, we have developed a novel synthetic poly(ethylene glycol) (PEG) hydrogel that 
sustains survival and function of allogeneic mouse ovarian tissue while preventing rejection. The 
proteolytically degradable core of the capsule provides a supportive environment for the 
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encapsulated and implanted tissue, while the non-degradable shell allows for diffusion of oxygen 
and nutrients, but physically prevents immune cell infiltration. Our earlier studies in mice have 
demonstrated that ovarian follicles and tissue encapsulated in the Dual PEG capsule develop and 
undergo the process of folliculogenesis, producing ovarian hormones in a regulated physiological 
manner, restoring ovarian endocrine function in a POI model [146, 172]. Additionally, we 
demonstrated the Dual PEG capsule was able to isolate the encapsulated allogeneic mouse 
ovarian tissue from the host immune environment preventing immune-mediated rejection by 
allo-specific antibodies and cellular infiltration [173]. However, to date, these studies have been 
conducted using a mouse model, which ovarian follicles grow to approximately 300 µm in size at 
the antral stage. Larger animals such as non-human primate and human follicles grow to greater 
than 500 microns and 2 centimeters, respectively. The objective of this study was to demonstrate 
Dual PEG can support non-human primate ovarian tissue restoring ovarian endocrine function in 
an ovariectomized syngeneic and allogeneic model. Previous groups have investigated the ability 
of ovarian tissue to restore fertility and normal hormone function in ovariectomized monkeys 
[200,201]; however, this study used autologous ovarian tissue so no encapsulation was needed 
as an immune response was not a factor. Here, we investigated whether the Dual PEG capsule 
can withstand the large volumetric expansion of monkey ovarian tissue present during 
folliculogenesis restoring ovarian endocrine function, while maintaining immuno-isolating 
capability in an allogeneic non-human primate model.  
 
7.4 Results 
7.4.1 Ovarian Tissue Encapsulated in PEG Capsules Develops and Restores Endocrine Function 
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We evaluated restoration of ovarian endocrine function by measuring levels of estradiol (E!C) 
and progesterone (PdG) in the urine daily.  E1C and PdG levels were normalized to creatine levels 
in the urine. Additionally, any signs of menstruation were observed. After implantation of 
autologous tissue encapsulated in immuno-isolating capsules, the monkey demonstrated cyclic 
levels of progesterone and estradiol throughout the initial five-month implantation period. 
Estradiol and progesterone levels fluctuated from 12 to 69 ng/mg Cr and 8 to 55 ng/mg Cr (Figure 
7.2A), respectively indicating the encapsulated tissue was producing ovarian hormones in a 
regulated, pulsatile manner. Levels would reach a depression and peak approximately every 7 
days . After the other monkey in the first round of implantations received allogeneic ovarian 
tissue from the other monkey encapsulated in immuno-isolating capsules, pulsatile levels of E1C 
and PdG were observed as they fluctuated from 10 to 35 ng/mg Cr and 15 to 55 ng/mg Cr, 
fluctuating approximately every five days (Figure 7.2C). No signs of menstruation were observed 







Figure 7.2: Estradiol (E1C) and PdG levels in urine of monkeys that received (A) encapsulated 
autologous tissue for 5 months, (B) encapsulated autologous tissue for 4 months, (C) 
encapsulated allogeneic tissue for 5 months and (D,E) encapsulated allogeneic tissue for 4 




After 5 months implanted subcutaneously, the capsules encapsulating autologous tissue were 
removed from one of the monkeys. No capsules in the monkey receiving encapsulated allogeneic 
tissues could be found or retrieved after 5 months. To evaluate the follicular development of the 
implanted ovarian tissue we analyzed tissue sections explanted after implantation by histological 
analysis. We observed the presence of healthy developing follicles indicating the process of 
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folliculogeneis was supported. All stages of follicles ranging from primordial to antral were 
observed (Figure 7.3B,C).   
After explantation of the initial capsules, one of the monkeys from the initial implantation period 
was implanted with allogeneic ovarian tissue encapsulated in Dual PEG for 4 months. Similar to 
the initial implantation period, fluctuating E1C and PdG were observed for the entirety of the 4 
months, although the E1C window of fluctuation was generally tighter and demonstrated more 
frequent pulsatility. E1C and PdG levels fluctuated from 10 to 59 ng/mg Cr and 5 to 50 ng/mg Cr, 
respectively, pulsing approximately every 4 days (Figure 7.2D). The second monkey was 
implanted with allogeneic ovarian tissue from another monkey encapsulated in Dual PEG for 4 
months. During this time, this monkey demonstrated E1C and PdG levels ranging from 8 to 37 
ng/mg Cr and 9 to 67 ng/mg Cr, respectively, pulsing approximately every 7 days (Figure 7.2E). 
When the capsules were removed, we observed the presence of ovarian tissue containing 
primordial and primary follicles (Figure 7.3D,E). Once the additional monkey was ovariectomized, 
it received its own tissue encapsulated in immuno-isolating capsules for 4 months. E1C and PdG 
pulsed from 10 to 40 ng/mg Cr and 11 to 68 ng/mg Cr, respectively with 3 very distinct peaks at 
Day 43, 62, and 89 (Figure 7.2B). Between the distinct peaks, the ovarian hormone levels were 
pulsatile but at a lower amplitude. When the capsules were extracted and sectioned and stained 





















Figure 7.3: Histological analysis of (A) non-human primate ovarian tissue at time of implantation, 
(B,C) autologous NHP ovarian tissue encapsulated in immuno-isolating capsules for 5 months, 
and (D,E) allogeneic NHP ovarian tissue encapsulated in immune-isolating capsules for 4 months. 
Scale bars: 500μm(C), 200μm  (D), 100μm (A,B),  50μm (E). 
 
7.4.2 Ovarian Tissue Encapsulated in PEG Capsules Elicit Minimal Immune Response 
 
To assess whether animals mounted an immune response against the encapsulated tissue, mixed 





autologous cells (negative control) or to cells from the donor of the ovarian allograft. Through 
the entirety of the four-month implantation time, we observed no significant spike in active CD4+ 
T cells, with the transient peak being 1.0% of CD4+ cells dividing when cells from a recipient were 
exposed to cells from an allogeneic donor, which was not significantly higher than negative 
controls (Figure 7.4A). Similarly, there was no significant spike in dividing CD8+ cells in any of the 
animals when implanted with allogeneic or autologous ovarian tissue; the division was 
comparable with that seen after mixing responder cells with irrelevant, non-donor stimulators. 
The peak value observed was 1.5% of CD8+ dividing from a monkey receiving encapsulated 
allogeneic tissue during the first implantation, which is not significantly different than negative 
controls. When cells from one of the recipient monkeys were reacted with cells from an 
allogeneic donor, 0% of CD8+ cells were dividing 4 months after implantation even though 
allogeneic tissue was encapsulated and present in the recipient (Figure 7.4B).  
 
Figure 7.4: Mixed lymphocyte culture of recipient cells reacted with donor cells quantifying 






In this study we investigated the ability of a PEG based capsule to support follicular development 
and protect ovarian allografts from a host immune response, restoring ovarian endocrine 
function in an ovariectomized syngeneic and allogeneic non-human primate model. Previously, 
we have developed the Dual PEG capsule to contain a proteolytically degradable PEG core with 
a non-degradable photo-polymerized PEG shell [173,174]. Day et al demonstrated that the Dual 
capsule can support folliculogenesis, while protecting encapsulated ovarian allografts from a host 
immune response [accepted for publication,Scientific reports]. The core cross-linked with 
protease sensitive peptides supports the growth and development of murine primordial follicles 
[146, 172]), while the non-degradable shell acts as an immune-protective barrier that elicits a 
minimal inflammatory response [173]. Here, our results show that the Dual PEG capsule can 
support non-human primate ovarian allografts, restoring ovarian endocrine function in 
ovariectomized rhesus monkeys.  
While we have previously shown that the Dual PEG capsule can support murine follicular 
development and protect ovarian allografts from immune rejection, the question remained 
whether the capsule can support the large volumetric expansion present in non-human primate 
folliculogenesis while not compromising the capsule’s immuno-isolating ability. To measure 
restoration of endocrine function in a non-human primate POI model, E1C and PdG levels were 
measured in the urine. Once the monkeys were ovariectomized and implanted with ovarian 
tissue encapsulated in the respective capsules, they presented with cyclic pulsatile levels of E1C 
and PdG throughout the entirety of the implantation period. Prior to ovariectomy E1C and 
progesterone levels were peaking at 65 and 51 ng/mg Cr, respectively. During the implantation 
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period, E1C levels exceeded 50 ng/mg Cr indicating the HPG axis was restored and ovarian 
hormones were being produced from the encapsulated ovarian grafts. The presence of cyclic PdG 
confirmed that ovulation was occurring, although, interestingly, none of the monkeys showed 
evidence of menstruation upon observation but this may due to the age of the animals. Following 
transplantation, the presence of pulsatile ovarian hormones could be due to the activation of the 
implanted follicles and recruitment into the growing pool with pulse. To confirm whether the 
PEG capsules could support non-human primate folliculogenesis, histological analysis was 
performed to evaluate tissue morphology. Healthy follicles were consistently present in the 
histological analysis of the encapsulated ovarian implants in all monkeys. We observed the 
presence of all stages of follicles (up to the antral stage), indicating non-human primate 
folliculogenesis can be supported by PEG capsules. The fact that we observed antral follicles 
indicates that non-human primate ovarian tissue can undergo the massive volumetric expansion 
during folliculogeneis without being restricted by the Dual PEG capsule. We hypothesize this is 
due to the viscoelastic properties of the PEG matrix; allowing for a dynamic volumetric change 
without impacting the network.  Upon macroscopic evaluation when explanting the capsules, 
there also appeared to be minimal inflammation around the implantation site, demonstrating 
the Dual PEG capsule elicits a minimal foreign body reaction, similar to previous findings 
[172,173].  
Additionally, the presence of ovarian hormones in the transplanted animals and healthy ovarian 
follicles in the encapsulated ovarian grafts, even in an allogeneic transplantation, indicates the 
Dual PEG capsule protected encapsulated ovarian allografts from a host immune response. To 
measure whether implanted monkeys have mounted an immune response against the 
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encapsulated allografts, mixed lymphocyte cultures were performed. We observed that when 
cells from any of the monkeys were exposed to cells from the monkey of the respective implanted 
allograft, a minimal reaction took place (compared to positive controls), indicated by the low 
percentage of CD4+ and CD8+ that divided upon exposure. In turn, this demonstrates the 
monkeys were not sensitized to the allo-antigens and the PEG capsules immune-isolated the 
encapsulated non-human primate ovarian allografts. Importantly, the PEG capsules were able to 
support folliculogenesis and protect the encapsulated tissue from an immune response, 
indicating the capsule is able to withstand the 10-fold volumetric change present during non-
human primate folliculogenesis without compromising the immuno-isolating capability.   
Lee et al have reported the restoration of ovarian endocrine function in ovariectomized non-
human primates; however, this study was exclusively in a syngeneic model, necessitating a 
heterotopic implantation and negating the use of an immune-isolating capsule [201]. This report 
is the first to demonstrate the use of an immune-isolating Dual PEG capsule can support non-
human primate folliculogenesis while protecting the ovarian allograft from an immune response, 
restoring ovarian endocrine function in an allogeneic model.  
In summary, the approach of hydrogel-based immune-isolation presents a minimally invasive and 
a robust way to restore hormonal balance in non-human primates. We have shown that the Dual 
PEG capsule can support non-human primate folliculogenesis in an allogeneic model. Further 
studies testing the ability of the Dual PEG capsule to support human ovarian tissue and promote 
corpus luteum formation must be conducted. Further capsule modification may be required to 
promote vasculature formation and greater diffusion of necessary metabolites and nutrients 
without the risk of immune rejection. Because this cell-based approach delivers hormones in a 
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pulsatile self-regulating manner, adverse side effects and long-term comorbidities associated 





7.6 Materials and Methods 
7.6.1 Experimental Design 
We performed two rounds of subcutaneous implantations of encapsulated autologous and 
allogeneic ovarian fragments. In the first round, two animals received 20 encapsulated ovarian 
fragments (N=1 autologous and N=1 allogeneic). The implants were retrieved after 5 months.  In 
the second round three animals received 20 encapsulated ovarian fragments (N=1 autologous 
and N=2 allogeneic) (Figure 7.1). The implants were retrieved after 4 months.  All animal 
procedures conformed to the requirements of the Animal Welfare Act and protocols were 
approved prior to implementation by the Institutional Animal Care and Use Committee (IACUC) 
at the University of California, Davis. Activities related to animal care (diet, housing) were 
performed per IACUC approved California National Primate Research Center standard operating 
procedures (SOPs).  Physical signs were monitored daily and body weights assessed each time 






Figure 7.1: Experimental design of encapsulated autologous and allogeneic non-human primate 
tissue implanted into non-human primates (n=3). 
 
 
7.6.2 Ovariectomies in Recipient Non-human Primates 
Animals were sedated with ketamine (10 mg/kg; IM) and prepared for bilateral ovariectomy 
according to established protocols. Briefly, atropine was administered (0.04 mg/kg) and the 
animals intubated and placed on intravenous (IV) fluids and inhaled isoflurane. A small incision 
was made, and the ovaries exposed and removed individually and placed in a sterile culture dish 
for processing. During processing the incision was closed according to surgical SOPs. Ovarian 
tissue from Animal A was encapsulated in hydrogel under aseptic conditions in both Animal A 
and Animal B. Ovarian tissue from Animal B was processed then cryopreserved using a controlled-
rate cryopreservation protocol. Once the encapsulated tissue was ready for Animal A, a small 
incision (~0.5 cm) was made between the scapulae (right and left). The encapsulated tissue was 
gently inserted under aseptic conditions then the incisions sutured closed and skin glue added.  
Animal B received encapsulated tissue from Animal A with insertion and closure as described.  
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Blood and urine samples were collected regularly as described below.  All animals were 
monitored post-surgery per SOP and administered analgesics post-operatively. 
 
At approximately five months post-surgery all animals were prepared for surgery as described 
above. The third monkey was ovariectomized and received autologous tissue (right ovary). The 
initial hydrogels were removed from the initial two animals, and then received encapsulated 
tissue from the third monkey. At approximately four months post-implantation the encapsulated 
tissue was collected for analysis. 
 
7.6.3 Collection of Donor Ovaries 
Ovaries from rhesus monkeys were collected following ovariectomy and transferred to Leibovitz 
L-15 media (Sigma-Aldrich, USA). The ovaries were dissected into approximately 60 1X1mm 
pieces and transferred into maintenance media (α-MEM, Gibco, USA) for encapsulation.  
 
7.6.4 PEG Hydrogel Preparation and Ovarian Tissue Encapsulation 
To prepare MT PEG hydrogels, 8-arm PEG-VS (40kDa, Jenkem Technology, Beijing, China) was 
cross-linked with a plasmin sensitive tri-functional peptide sequence (Ac-GCYK↓NSGCYK↓NSCG, 
MW 1525.69 g/mol, >90% Purity, CelTek, ↓ indicates the cleavage site of the peptide). Dual PEG 
hydrogels were prepared using 4-arm PEG-VS 20kDa, Jenkem Technology) with Irgacure 2959 
(Ciba, Switzerland, MW=224.3) and 0.1% N-vinyl-2-pyrrolidone (Sigma-Aldrich, St. Louis, USA). 
The detailed protocol is described in Day et al. [172] for encapsulation in the MT PEG, the ovarian 
tissue was transferred into a 10 µL droplet of the plasmin sensitive tri-functional peptide and 
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PEG-VS precursors’ solution. The droplet was allowed to crosslink for 5 minutes and then was 
quenched in maintenance media. For Dual PEG hydrogel encapsulation, the tissue was first 
encapsulated in an 8 µL MT PEG hydrogel and was then placed in the center of a 20 µL bead of 
PEG-VS precursor solution (5% w/v PEG-VS, .4% Irgacure 2959, 0.1% NVP) and exposed to UV 
light for 6 minutes.   
 
7.6.5 Subcutaneous Implantation  
Two small incisions were made on the dorsal side of the anesthetized monkey and the 
immunoisolators (MT PEG, Dual PEG) with the ovarian tissue were implanted subcutaneously. 
The skin was closed using 5/0 absorbable sutures.  
 
7.6.6 Urine Hormone analysis 
Urine samples were collected daily from cage pans according to SOP starting one month prior to 
surgery and through the post-implantation period. Collected samples were centrifuged at 1,500 
g for 10 minutes then supernatant (~2-3 ml) transferred to a cryogenic vial (Caplugs Evergreen, 
Buffalo, NY) and stored at ≤-20˚C until processed. Urinary estrone conjugates (E1C) and 
pregnanediol-3-glucuronide (PdG) were determined according to established protocols 
[202,203]. Urine was not collected and analyzed from day 98 to day 145 in the first four-month 
implantation.  
 
7.6.7 Histological analysis of the retrieved devices and the encapsulated ovarian tissue 
Following sacrifice, the immuno-isolating devices were retrieved from monkeys, fixed in 4% 
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paraformaldehyde at 4°C overnight, transferred and stored in 70% ethanol at 4°C. After 
processing, samples were embedded in paraffin, serially sectioned at 5 μm thickness, and stained 
with hematoxylin and eosin.  
 
7.6.8 Mixed Lymphocyte Culture 
PBMC were isolated by centrifugation onto a step gradient of Lymphocyte Separation Medium 
(LSM; MP Biomedicals, LLC, Solon, OH). Stimulator cells were treated with 40 µg/ml mitomycin C 
(Sigma) at 37 C for 30 min. CFSE-labeled responder cells were stimulated with an equal number 
of unlabeled stimulator cells or with plate-bound anti-CD3 antibody (positive control; clone SP34-
2). Cells were harvested after 4-6 days of incubation, stained with fluorescently labeled 
antibodies including those specific for CD4 and CD8 (clones L200 and 3B5, respectively); 




Statistical analysis was performed using the R software version 3.1.2 (2014). Significance was 




















8.1 Summary of Findings 
 
The aim of the doctoral thesis presented here was to develop means to restore ovarian endocrine 
function using donor ovarian allogeneic tissue without immunosuppression. We hypothesized 
that encapsulation of ovarian tissue in immuno-isolating capsule that allows diffusion of nutrients 
and growth factors while preventing infiltration of immune cells from the host would restore 
ovarian endocrine function. This dissertation describes the process of identifying the materials, 
physical characterization of the hydrogels and animal studies to determine survival and function 
of the implanted grafts and the immuno-isolating abilities of the capsule. We hypothesized that 
PEG would be an appropriate material for immuno-isolation of ovarian tissue because it is 
viscoelastic, tunable, inert, robustly functionalized, and can form hydrogels in a physiologically 
appropriate environments. Variability of the functional end groups on PEG macromolecules 
supports crosslinking and gelation via a multitude of chemistries. First, we demonstrated that 
PEG-vinyl sulfone (PEG-VS) was most appropriate to create an immuno-isolating barrier for 
ovarian tissue in comparison to PEG-acrylate (PEG-Ac) and PEG-maleimide (PEG-Mal) as PEG-VS 
hydrogels form efficiently, have a network conducive to support ovarian tissue survival and 
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development, are hydrolytically and proteolytically stable, and elicit a minimal inflammatory 
response in mice. From here, we developed a Dual PEG hydrogel that is conducive for the 
dynamic volumetric expansion of ovarian tissue, while protecting the tissue from an immune 
response. The Dual PEG capsule contains a proteolytically degradable core that supports ovarian 
tissue growth and development and a non-degradable shell that acts as a protective barrier. We 
tested in a syngeneic mouse model whether the degradable, non-degradable, and Dual PEG 
capsules support folliculogenesis in a mouse model of POI. We demonstrated that when ovarian 
tissue was implanted in these immune-isolating capsules, ovarian endocrine function was 
restored as demonstrated by resumption of estrous activity, restoration of the HPG axis, and 
healthy developed follicles present in the graft post-implantation.  We next evaluated the Dual 
PEG capsule’s ability to protect encapsulated ovarian allografts in an allogeneic mouse model. 
We show that compared to controls, ovarian allografts encapsulated in Dual PEG elicit a non-
detectable allo-specific antibody response and the Dual PEG does not allow for cellular 
infiltration, promoting long-term graft survival and restoration of ovarian endocrine function.  
We then demonstrated that allogeneic ovarian tissue encapsulated in Dual PEG does not sensitize 
the host immune system. This was tested by consecutively implanting mice with non-
encapsulated ovarian allografts followed with ovarian tissue encapsulated in Dual PEG and vice 
versa. Ovarian tissue in Dual PEG does not sensitization the host, which would allow for 
consecutive implantations to restore ovarian endocrine function in a physiological manner. 
Additionally, the capsule being able to protect allogeneic ovarian tissue in an already sensitized 
host, enables us to possibly implant in humans as all humans have previously been exposed to 
allo-antigens are to some degree sensitized. Furthermore, additional tests and 
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immunophenotyping is required to investigate the underlying mechanism of tolerance induction 
by encapsulating ovarian tissue in degradable PEG. This can be done by conducting mixed 
lymphocyte cultures at different timepoints to assess the kinetics of exposure of allo-antigens to 
the immune environment and characterizing the surround immune environment by measuring 
elevated cytokine levels.  
Lastly, we tested whether the Dual PEG capsule can support non-human primate ovarian tissue 
in a syngeneic and allogeneic non-human primate model of POI. Non-human primates are the 
most appropriate model for female reproduction and puberty induction. We demonstrated that 
in both a syngeneic and allogeneic setting, monkeys implanted with ovarian tissue encapsulated 
in Dual PEG showed evidence of ovarian endocrine restoration with pulsatile levels of estradiol 
and progesterone and healthy developed follicles in the grafts post-implantation. Additionally, in 
the allogeneic model, monkeys implanted with encapsulated ovarian allografts demonstrated no 
increase in circulating CD4+ and CD8+ activity indicating the encapsulated tissue did not evoke 
an immune response. A challenge moving forward is to allow for maximum diffusion without 
compromising the immuno-isolating capabilities of the capsule. To do this the tissue must be in 
close proximity with vascular without being directly exposed to that blood flow which is where 
immune cells are transported from. A possible course of action is to promote vascular formation 
via the addition of a biological motif, such as RGD, on the outer shell of the capsule to minimize 
the distance of nutrient exchange. Additionally, the ability for the capsule to support corpus 
luteum formation must be investigated as this is essential to knowing whether ovulation is 
supported. The fact that there was cyclic progesterone in the NHP study indicates corpus luteum 
was supported, however, no evidence was observed via histological analysis.   
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The work presented in this dissertation addresses a clinical need to restore reproductive 
endocrine function in female cancer survivors who experience POI. Particularly for young female 
cancer survivors who experience POI prior to puberty, physiological puberty induction is vital for 
post-treatment quality of life as this process affects a multitude of factors including bone health, 
metabolism, cognition, cardiovascular health, and cognition. Non-physiological pubertal 
development may cause life-long comorbidities such as poor bone health, abnormal fat 
deposition, high risk of cardiovascular events, and impaired immune system and cognition. The 
development of an immuno-isolating capsule for donor ovarian tissue implantation fills a clinical 
gap in treatment for POI patients as the current options such as HRT and allo-transplantation are 
associated with limitations such as non-physiological and incomplete delivery of ovarian 
hormones and re-introduction of cancerous cells. By making allo-transplantation of ovarian tissue 
possible, females experiencing POI can possibly have their hormonal balance restored through 
transplantation of donor ovarian tissue; and the use of an immuno-isolating capsule allows 
implantation of donor ovarian tissue without the need for immunosuppressive therapies. 
Collectively, this work aims to close the gap to meet a clinical need for girls and women that 
experience POI due to anticancer treatments; allowing for allo-transplantation of donor ovarian 
tissue, which will lead to physiological restoration of ovarian endocrine function and a higher 
quality of life post-treatment. 
 
8.2 Future Directions 
To this point, we have tested the capability of the Dual PEG capsule to support and protect 
allogeneic ovarian tissue in murine and NHP models. Translation of this technology into the clinic 
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would require proven efficacy and safety with human tissue. In the near future we will test 
whether the Dual PEG capsule can support human ovarian tissue survival and development. 
Other groups have utilized biomaterials to promote growth and development of human ovarian 
follicles implanted in immune deficient mice [204,205]. Yet the application of immunoisolating 
capsule to support allogeneic applications has not been explored. The volumetric expansion 
during human folliculogenesis is massive with follicles reaching 2 centimeters in diameter. The 
first step is to test whether the capsule, as it exists right now, can withstand that large expansion 
without being mechanically compromised, which would impact its immuno-isolating capabilities. 
To do this, either fresh or frozen-thawed ovarian tissue will be encapsulated in the Dual PEG 
capsule and implanted subcutaneously in an immune compromised SCID mouse. To induce 
folliculogenesis, mice will be stimulated with FSH and hCG and the explant will be extracted and 
evaluated to see if the capsule can support tissue health and development. Preliminary studies 
have been conducted with promising results showing the presence of healthy human ovarian 
follicles present in the graft after 1 and 4 months transplantation in SCID mice. Further 
improvements in the capsule design will allow facilitated diffusion of the nutrients to improve 
follicle health, accommodation of larger fragments to extend the duration of the graft function, 
improved immunoisolating and stealth properties to allow xenograft transplantation without 
evoking the innate immune response and the possibly to load and reconstitute the capsule 
multiple time without compromising its integrity and immunoisolating action.  
Additionally, capsule modification and mass manufacturing may be conducted by using 3D 
printing, which can possibly minimize the thickness of the immuno-isolating barrier, decreasing 
the distance of diffusion for nutrients and metabolites, without compromising immuno-isolation. 
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Additionally, by decreasing the distance to vasculature, corpus luteum formation may be 
enhanced which is essential for production of progesterone. The use of 3D printers to 
manufacture the capsule and streamline the process will help in clinical translation of this 
technology and mass production. To this end, we are preparing a pre-IND packet for the Food 
and Drug Administration, including standards and protocols, such as materials used, quality 
control of tissue, and manufacturing processes. If accepted, this clinical trial encapsulating 
human ovarian tissue in Dual PEG would be the first to attempt to restore ovarian endocrine 
function using allo-transplantation and would be a crucial step for allowing female cancer 
survivors with POI to receive donor ovarian tissue to either induce puberty or restore 



















Customer Discovery and Development of a Business Plan for the 
Technology that Aims to Restore Ovarian Endocrine Function in Adolescent Girls 
with Premature Ovarian Insufficiency 
 
The National Science Foundation (NSF) I-Corps program prepares scientists and engineers to 
extend their focus beyond the university laboratory and accelerates the economic and societal 
benefits of NSF-funded, basic-research projects that are ready to move toward 
commercialization. Through I-Corps, NSF grantees learn to identify valuable product 
opportunities that can emerge from academic research, and gain skills in entrepreneurship 
through training in customer discovery and guidance from established entrepreneurs. As a part 
of translating our technology to the clinic our team participated in a 3-month long national I-
CORPs course.   
Currently young girls suffering from premature ovarian insufficiency (POI) as a result of 
anticancer treatments have limited and inadequate options to undergo puberty and start their 
transition into adult life. The existing hormone replacement therapy (HRT) applied to induce 
puberty in girls with POI leads to long-term morbidities, such as decreased bone density, 
predisposition to obesity and diabetes. We developed a technology that allows the restoration 
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of ovarian endocrine function in prepubescent girls and has the potential to become a central 
mainstream treatment for POI, which would result in significant improvement of the short and 
long-term health and eliminate long-term morbidities associated with premature ovarian failure. 
The proposed treatment will significantly lower health costs associated with obesity, diabetes 
and osteoporosis and translate to positive health economics.  
The pre-clinical work in the past 4 years demonstrated that an immuno-isolating capsule can 
protect encapsulated allogeneic ovarian tissue from an immune response, allowing the allograft 
to produce ovarian hormones in a physiological regulated manner, restoring ovarian endocrine 
function. To date, we have demonstrated the feasibility of this application in murine and non-
human primate models. The next step is to translate the developed technology towards the clinic, 
which requires a clear understanding of the existing clinical gap. Many of the academic 
entrepreneurs assume what they perceive as true about the market and never learn what the 
customers care about. To avoid making false assumptions, we applied for the National Science 
Foundation Innovation Corps (NSF I-Corps) to perform customer discovery, determine the 
customer segments and investigate the current clinical treatments available and how the 
proposed technology might fill the clinical need. NFS I-Corps entailed a 7-week program, where 
our team of three, called OvaArt, were tasked to interview more than 100 potential customers 
and stakeholders to create a business plan using the Business Model Canvas (BMC) from 
“Business Model Generation” by Alexander Osterwalder and Yves Pigneur (Figure A1).  
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Figure A1: Final iteration of business model canvas after 7-week NSF I-Corps program and 
interviewing 118 customers.  
We reached out and interviewed potential users, payers, and influencers regarding our 
technology and learned what they value and what the current weaknesses and gaps in the field 
were; As a result we developed a business plan,  value proposition, customer segments, channels, 
customer relationships, revenue streams, key activities, key resources, key partners, and cost 
structure after talking to over 100 potential customers about these pillars.  
An important aspect of our target patient population is the ecosystem and customer segments 
surrounding the girls and women that experience POI due to anti-cancer treatments. We 
hypothesized that pediatric oncologists  diagnose and treat the disease, , and years later pediatric 
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endocrinologists treat the adolescent girls if they experience POI with hormone replacement 
therapy (HRT). We assumed that the ecosystem for these patients was linear with only 3 main 
segments. Within the first week of “getting out of the building” and talking to pediatric clinicians, 
patients and their families, we learned that the ecosystem was more complex, disorganized, 
disconnected and convoluted than previously hypothesized. We learned that additional 
segments of the ecosystem would be impacted by OvaArt and the potential application, such as 
the patient, family of the patient, pediatric oncologists, pediatric endocrinologists, directors of 
survivorship clinics, nurse case manager, OBGYN and reproduction specialists. We investigated 
what was important for each segment in terms of ease of use, safety, and advantages over 
current treatments, and after combining our findings we develops a new value proposition. The 
value proposition for OvaArt, is that it would provide an implantable capsule that delivers a 
constant source of ovarian hormones in a physiological controlled manner, restoring ovarian 
endocrine function in pediatric patients experiencing POI and allowing them to go through 
puberty correctly. The pediatric endocrinologists we interviewed confirmed our value proposition 
regarding the limitations of HRT treatments. While most pediatric endocrinologists stated that 
certain milestones such as secondary sexual characteristics could be achieved with HRT, they also 
recognized limitations of HRT. Namely, compliance was a huge concern as multiple 
endocrinologists estimated “50-75% of patients don’t use HRT as prescribed”. This is due to the 
mode of administration and application being complicated, as patients often have to divide 
estrogen patches (which originally were developed for post-menopausal women) into eighths to 
deliver an appropriate dose, the patches would often fall off, children are self-conscious about 
looking different than peers, and patches would often cause irritation and rashes. Additionally, 
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we found that fear was a factor in parents avoiding HRT, mostly because of the side effects and 
increased long term risks for developing cancer.  We heard testaments regarding the limitations 
of HRT as “a one size fits all system” when in reality, treatment and hormone production should 
be tailored for each patient for appropriate development and regulation. Overall, most 
endocrinologists from multiple hospital systems (OHSU, Johns Hopkins, UPMC, Childrens Hospital 
of Pennsylvania, St. Jude’s Childrens Hospital) acknowledged the shortcomings of HRT therapy 
and expressed the importance of appropriate endocrine health during pubertal development and 
thereafter. When asked whether HRT meets the standards of naturally produced hormones from 
the ovary, the overwhelming answer was “nature is always better” and HRT does completely 
mimic the hormonal milieu. By talking to these experts all over the country, we were about to 
confirm our value proposition of delivering physiological controlled hormones.  
Reimbursement for the treatment was another important aspect for us to consider as the 
technology moves towards the clinic and what needs to be done to maintain a self-sustaining 
business. We interviewed healthcare consultants, distributors, leaders of biotech companies, 
insurance companies, and other healthcare providers and determined that an implantable 
capsule containing a cellular component would be introduced to the clinic through indirect sales 
and paid for via reimbursement.  We learned a common model for an implantable device is the 
sale of the product to a distributor, in our case a specialty pharmacy company such as Cardinal 
Health, and the distributor would send the device to the clinic once prescribed by the clinician. 
The payment for the procedure and capsule would initially be paid for upfront by the 
family/patient but would then be reimbursed by the respective insurance company (Figure A2).  
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Figure A2: Revenue flow model from manufacturing of the capsule to the patient. 
 
For pricing, consultants and biotech leaders emphasized the importance of value based pricing 
and “what value we are adding” . This includes potentially decreasing co-morbidities associated 
with absent puberty and abnormal hormonal balance. From this and comparing to similar spaces 
such as islet cell transplantation, we initially placed the price of the capsule and procedure at 
$25,000 for this exercise with the patient having to receive a capsule once per year. Additionally, 







Figure A3: Market size analysis of OvaArt. The target market (smallest circle) consists of 75,000 
patients experiencing POI due to anticancer treatments, multiplied by $25,000 per capsule 
gives a potential market of $1.9 billion. 
We estimated that our initial market of pediatric patients who experience POI due to anticancer 
patients being $1.9 billion/year with potential to apply this technology to larger markets such as 
all women experiencing POI.  
NSF I-Corps program encouraged the team to layout the major steps and milestones that the 
technology needs to reach the clinic. We have performed pre-clinical studies in murine and non-
human primate models and have demonstrated feasibility towards the application of restoring 
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ovarian endocrine function using ovarian allografts. Through talking to consultants and leaders 
of biotech companies, we determined that the next key step is to contact the Food and Drug 
Administration (FDA) (business model canvas) after completing gap analysis and compiling a pre-
IND submission package. We anticipate to learn from the FDA what additional tests are needed 
to move towards a first-in-human clinical trial. Additionally, through mapping out the key 
milestones that must be made prior to being implemented in humans, we were able to identify 
certain quality control tests that must be done such as cryopreservation of the capsule and 
human tissue characterization to make sure the product is within our established tolerances and 
does not cause harm.  
In summary, the NSF I-Corps program was instrumental to bridge the gap between conducting 
pre-clinical studies and developing a product that will fill a clinical need through talking to 
potential customers. To gain knowledge about our customer segments, potential business model, 
and future steps the OvaArt team “got out of the building” and talked to 118 potential customers 
during a 7-week period (and much more since the program). This entailed talking to experts in 
multiple hospital systems all over the country including OHSU in Portland, Michigan Medicine in 
Ann Arbor, St Jude’s Children’s Hospital in Memphis, UPMC in Pittsburgh, Children’s Hospital of 
Pennsylvania in Philadelphia, and Johns Hopkins Hospital in Baltimore. We confirmed that the 
current treatment of HRT is associated with limitations, patients care about “feeling normal”, and 
clinicians wish there was a better option than HRT for patients experiencing POI. These findings 
contributed to our value proposition that the capsule can provide physiological delivery of all 
ovarian hormones to childhood cancer patients experiencing POI, allowing them to go through 
puberty correctly and avoid long-term co-morbidities. We were also able to map out the 
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ecosystem and identify all customer segments that would be influential towards implementing 
OvaArt into the clinic.  Additionally, we were able to develop a minimal viable product and 
develop a business plan by using the Business Model Canvas. Through the BMC, we mapped out 
the potential revenue stream of this product, the mode of reimbursement for the patients, what 
partnerships are vital for the production of this technology, and the major milestones still 
remaining. From this process we have expanded our knowledge of what it takes to get a product 
from the bench-side to the clinic. Although the OvaArt team is very early in this process, going 
through these exercises was crucial to understanding the potential of a developed technology to 
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